Epithelial remodelling of the conjunctiva in ocular allergy. by Georgakarakos, ND
1 
 
 
 
 
 
Epithelial remodelling of the conjunctiva in ocular allergy 
 
 
 
A Thesis submitted for the degree of the Doctor of Medicine (by Research) 
 
Nikolaos D. Georgakarakos 
 
Institute of Ophthalmology, 
University College London,  
London UK 
 
and 
 
Moorfields Eye Hospital NHS Foundation Trust,  
City Road, London UK.  
 
 
 
 
 
 
2 
 
ABSTRACT 
Background: The spectrum of ocular allergy includes reversible conditions 
(seasonal, perennial and giant papillary conjunctivitis) and irreversible chronic severe 
forms of disease involving the cornea (vernal and atopic keratoconjunctivitis). 
Conjunctival remodelling may play a role in the pathogenesis of chronic allergic eye 
disease (CAED).  Based on findings on asthmatic airway epithelia, it is suggested in 
chronic asthma that activation of the epithelial-mesenchymal trophic unit (EMTU 
hypothesis) and EGFR may participate in disease development and account for 
chronicity, severity and poor response to steroid treatment. This thesis investigates 
the potential application of the EMTU hypothesis to CAED.  
 
Aims and Methods: Conjunctival biopsies of healthy subjects, SAC, GPC (controls 
group) were compared to VKC and AKC (CAED group) and conjunctival tissues of 
active and treated OCP. Expression of EGFR, TGFα and CD44 was assessed by 
means of immunohistochemistry.  Cells of two human epithelial conjunctival cell lines 
(IOBA-NHC & CHwK) received single and multiple cytokine treatments (PMA, IL-17A, 
TNFα/IL-1β) and secretion of EGFR, VEGF, CD44, TGFα and p21waf of harvested 
supernatants were assessed by means of ELISA.  Statistical analysis was performed 
using Mann-Whitney test for the immunohistochemistry and t-test for the ELISA 
results.  
 
Results: Immunohistochemistry studies revealed that there was increased 
expression of all EMTU remodelling markers in the CAED group compared to 
Controls (p<0.01). OCP conjunctival biopsies showed no expression for EGFR and 
TGFα. There was increased secretion of the remodelling molecules by both cell lines 
after single/multiple cytokine treatments.  
 
Conclusions: Epithelial conjunctival remodelling may be responsible for disease 
severity in CAED as shown in chronic asthma. Epithelial cell EGFR-mediated 
remodelling parallels the observations made in chronic asthmatic epithelia and the 
results are in agreement with previous studies in biopsies and tears of VKC patients. 
Finally suggestions for new treatment strategies are proposed to prevent or inhibit 
disease perpetuation.   
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CHAPTER 1 
 
 
 
INTRODUCTION 
 
The role of the epithelium in inflammation and remodelling in asthma and 
ocular allergy 
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1.1 Overview  
 
Allergic conjunctivitis is a group of inflammatory diseases of the ocular surface which 
can be acute or chronic, mild or severe and it includes acute disorders, seasonal 
(SAC) and perennial allergic conjunctivitis (PAC) as well as chronic or persistent 
forms of disease, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC) 
and giant papillary conjunctivitis (GPC). Common to these diseases are a papillary 
conjunctivitis and a type I IgE mediated hypersensitivity reaction (except GPC), 
although each disease category has unique immunopathogenic features.  
Seasonal and perennial allergic conjunctivitis represent the commonest forms of 
ocular allergy which are mild, resolve either spontaneously or due to treatment and 
are not sight threatening.  VKC and AKC are rarer but more severe with corneal 
involvement which can cause sight impairment. GPC is usually seen in contact lens 
users and patients with ocular prosthetic implants. At the moment we accept that 
there is an overlap between the phenotypes of the severe forms of ocular allergy and 
rely on clinical features to make the diagnosis and decisions on treatment. 
The conjunctiva being a mucosal membrane shares common structural and 
functional features with the mucosal lining of other systems such as the respiratory 
tract. It has been suggested by Prof Stephen Holgate and his team in Southampton, 
UK that an abnormal epithelial-mesenchymal communication (the EMTU hypothesis) 
may explain the disease severity in chronic asthma.  
In the course of Chapter 1 an account is given of the basic known structural and 
functional properties of the epithelial cells as part of mucosal membranes. 
Hingorani’s work on the central role of the epithelium in ocular allergy pathogenesis 
provides stronger insight and forms the basis for future work on its 
immunopathogenesis and treatment. It was suggested that it has pro-inflammatory 
roles in chronic allergic eye disease with involvement in leucocyte recruitment and 
cytokines upregulation promoting eosinophilia. Its role in allergic inflammation will be 
presented, focusing on allergic eye disease and asthma. 
Prof Holgate’s hypothesis on asthma pathogenesis will be presented along with a 
discussion about the role of remodelling markers. The EMTU hypothesis for the 
21 
 
pathogenesis of asthma will be adapted for application to allergic conjunctivitis. A 
claim of this study is that since the respiratory tract and conjunctiva are both mucosal 
membranes sharing common structural and functional characteristics, a similar 
hypothesis may apply to VKC and AKC. The role of remodelling in conjunctival 
inflammatory disease will be presented together with the concept of epithelial-
mesenchymal interaction in mucosal inflammatory diseases based on asthma as 
proposed by Prof Stephen Holgate and his team.  
Furthermore in Chapter 1, a detailed presentation of the clinical features and 
classification of ocular allergy is given highlighting the overlap of features and 
frequent similarities in clinical presentation as well as the need to achieve disease 
control. The study continues with an inquiry into the adequacy of the classification 
systems available to date.  
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1.2 Epithelial Cell biology  
Epithelial cells form the major constituent of various tissues in the body lining the 
surface of organs or internal cavities and tracts and are arranged in cell sheets with 
the help of intercellular adhesive cell junctions. Basement membranes separate the 
epithelial layer from the underlying tissues and depend on metabolite and oxygen 
diffusion from supporting tissues. Therefore they are involved in a great variety of 
processes such as the regulation of secretion and adsorption in organs such as the 
skin, gut, and lungs, and the protection of the sub-epithelial tissue components from 
pathogenic microbes, toxic factors and physical trauma to which they are directly 
exposed.  
 
In the lung the respiratory tract consists of an epithelial layer, basement membrane, 
lamina propria and cartilages.  The epithelial layer is mainly composed of 
pseudostratified columnar ciliated epithelial cells and separated from the lamina 
propria by a basement membrane.  The lamina propria contains fibrous tissue with 
blood and lymphatic vessels as well as smooth muscle cell fibres. The epithelium 
together with the basement membrane and the lamina propria form a mucosa.  
 
The epithelium acts a physical barrier between the external environment and the 
respiratory system responsible for gas exchange.  Additionally it has immunological 
and metabolic properties. In asthma it is known that epithelial damage causes 
increased permeability and easier access of antigens and allergens to the 
subepithelial components. In atopic conditions such as asthma and dermatitis the 
epithelium is dysregulated leading to increased permeability and access to airborne 
allergens (1-2).  
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1.2.1 Epithelium classification  
Epithelia are classified based on the number of cell layers, the shape of the cells and 
the presence of associated features at the surface such as cilia or keratin. More 
specifically they can be a simple cell monolayer or stratified in two or more layers. 
The whole body has an epithelial covering, the skin. Furthermore the gastrointestinal 
tract, respiratory tract, urinary tract all have epithelial cell linings facing the lumen.  
Glandular and exocrine secretions occur via an epithelial duct. The conjunctiva as its 
original definition suggests, is a continuous mucosal translucent thin membrane 
joining the eyeball to the lids and, consists of a superficial epithelial layer and 
connective tissue stroma. It forms a mechanical barrier on surfaces exposed to the 
external environment but can be also specialized to perform specific functions such 
as removing inhaled debris with cilia in the respiratory tract, nutrients’ absorption 
from the gastrointestinal tract, or mucin production and fluid for  lubrication and 
transport in ducts. 
Types of epithelia are described below and illustrated in Figure 1.1:  
a)  Squamous epithelium: cells at the surface have smaller nuclei and greater 
amounts of keratin and form a multi-layered structure. If the mucosal 
membrane is involved in significant “wear and tear” it is covered by a thick 
layer of acellular keratin (e.g. skin), otherwise it is non-keratizining squamous 
epithelium (e.g. cervix).  
b) Columnar epithelium: the cells are taller along a basal lamina, typically line 
glandular ducts, produce mucin and can be ciliated (e.g. colon). 
c) Pseudostratified columnar epithelium: in this type of epithelium not all the cells 
along the basal lamina reach the lumenal surface, but all contact the basal 
lamina e.g. respiratory tract from the nasopharynx down into the bronchioles 
of the lung; ciliated. Illustrated in Figures 1.2 and 1.3.  
d) Cuboidal epithelium: the cells have a rounder shape and typically lines ducts 
draining glands and found in renal tubules. The small ducts of sweat glands 
(including breast, a modified sweat gland) can pile up to a stratified cuboidal 
appearance in larger ducts.  
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Figure 1.1: The structures of various types of epithelia. (a) simple cuboidal 
epithelium e.g. small collecting ducts in salivary glands, kidney, pancreas (b) simple 
columnar epithelium: typically found in highly absorptive surfaces (c) simple ciliated 
columnar epithelium: not common except in the female reproductive tract (d) 
stratified squamous epithelium: found on lining surfaces subject to mechanical 
abrasion and kept moist by glandular secretion (3).  
 
 
(a) (b) 
(c) (d) 
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Figure 1.2: Scanning electron microscopy of the surface of the tracheal epithelium 
demonstrating the numerous cilia with goblet cells (black arrow); (magnification 
x2000) (4). 
 
 
                    
Figures 1.3 (a&b):  Micrographs of the primary bronchus showing the epithelium (E) 
facing the lumen over the lamina propria (LP); Magnifications (a) x150 and (b) x900, 
(3).  
 
 
 
 
(a) 
(b) 
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The epithelium lies on a basement membrane that separates the epithelial cells from 
the underlying connective tissue stroma. Integrins in the epithelial cells extend into 
the basement membrane and attach to laminin which in turn attaches to type IV 
collagen and to fibronectin in the basal lamina. There are anchoring fibrils made of 
type VII collagen. Therefore the basal lamina acts as an anchoring point for the 
epithelium and forms a meshwork that acts as a barrier to trap or exclude molecules. 
The lamina reticularis of the basement membrane interfaces with the underlying 
connective tissue. 
1.2.2 The conjunctival epithelium: cellular biology  
The epithelial cells are attached with desmosomes across highly interdigitating 
borders and the basal region of the cells attaches to the basal lamina by 
hemidesmosomes via intermediate filaments (Figure 1.4). The cell density reduces 
with age (Figure 1.5). The superficial cells are joined by continuous anterior borders 
of junctional complexes that seal the intercellular spaces, which obstruct the 
passage of water soluble molecules and makes the conjunctiva a semipermeable 
membrane. The apical cytoplasm of the cells at the surface outermost layer contains 
numerous vesicles containing mucoprotein and is also known that their number is 
increased in allergic conditions.  
                            
Figure 1.4: Transmission electron microscopy of fornical conjunctival epithelium in a 
45 year old, showing columnar cells with apical microvilli (magnification x2500) (4).  
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Additionally throughout the conjunctival tissue the epithelium contains Goblet cells 
with highest population at the plica semilunaris at epithelial crypts most dense 
nasally. The goblet cells are the main cellular production of mucin which is a 
component of the tears moistening the ocular surface. 
   
Figures 1.5: (a) scanning electron micrograph of the conjuncival epithelial surface 
form a 30 year old showing small polygonal cells and interspread goblet cells – black 
arrow (b) scanning electron micrograph of the conjunctival epithelial surface in a 77 
year old showing pleomorphic cells and absence of goblet cells (4).  
  
The conjunctiva being a semi-transparent mucosal membrane shares common 
features with the respiratory tract mucosa in health and asthmatic disease. It 
consists of an epithelial layer and a connective tissue stroma with a subepithelial 
mesenchymal cell layer, as shown in Figure 1.6 below.  
 
In the embryo, it is known that the mesenchymal cells (also known as the embryonic 
fibroblasts) make the embryonic tissue and will differentiate later to fibroblasts, blood 
and blood-related organs (eg spleen). Some will remain in a “dormant” state below 
the epithelial layer and will be activated later in life, should the need arise e.g. tissue 
response to injury.  
(a) (b) 
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Figure 1.6: Histology of conjunctival tissue section showing the basic anatomical 
features of the mucosal membrane. 
 
The mucosal membrane is well known to participate in the regulation of inflammation 
and leucocytes. More specifically the epithelium of the conjunctiva is thought to have 
a role in the pathogenesis of ocular allergy via cytokines and pro-inflammatory 
mediators as well as inflammatory cell regulation.  Similar evidence exists for the 
respiratory mucosal epithelium in asthma.  
 
This section aims to describe these roles and provide a detailed account of the 
evidence so far. Furthermore, the role of cytokines will be described and, finally the 
role of remodelling molecules.  
 
 
 
 
 
 
 
Stroma 
connective 
tissue  
Epithelium   
Mesenchymal cells  
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1.2.3 Epithelial integrity, cellular adhesion and barrier actions  
The integrity of the epithelium depends on the epithelial adhesion eg CD44, e-
cadherin promoted by junctional and non-junctional cell adhesion molecules and the 
cytoskeleton eg keratins. The epithelial integrity is reduced and permeability is 
increased after allergen challenge (5). The epithelial tight junctions were previously 
found to be altered in inflammatory bowel disease (6) and asthma (7). Expression of 
epithelial cell adhesion and cytoskeleton proteins were found to be reduced in out of 
season SAC compared to normal subjects and normal expression of e-cadherin is 
important for the maintenance of tight junctions and epithelial barrier function (8).  
Protease activated receptor 2 (PAR-2) was found to be increased in SAC by means 
of immunohistochemistry (9). Increased PAR-2 expression is known to be related to 
increased epithelial permeability. In the same study the expression of adhesion 
molecules ICAM-1, VCAM-1 was assessed and was found that there was poor 
epithelial expression in both normal and “out of season” conjunctival tissues and 
ICAM-1 was found to have increased expression (though not statistically significant) 
in SAC. Therefore there are structural changes of the epithelium in allergic disease 
that alter the barrier properties and may relate to alterations in function as the 
epithelium becomes structurally weaker and more permeable.  
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1.3. Allergic inflammation of the airway and conjunctival mucosa  
 
The role of the conjunctival epithelium is crucial in allergic inflammation and there 
are similarities with its role in atopy and the asthmatic lung. Asthma and rhinitis, may 
be associated with allergic conjunctivitis.  The conjunctiva has been described as a 
representation of the upper extremity of the respiratory system which maintains a 
drainage system into the nose via the nasolacrimal duct (10). This can be 
demonstrated by the reduction of rhinitis symptoms by instillation of topical eye drops 
(11,12).  
 
Allergic conjunctivitis can be reversed either spontaneously or with treatment, 
depending on disease severity. The diagnosis is a clinical one and in the absence of 
a standardized definition it is not possible to make clear evidence based 
management recommendations. The same applies to asthma where central to all 
definitions is presence of symptoms and of variable airway obstruction that can 
resolve spontaneously or due to treatment (13). 
 
Seasonal and perennial allergic conjunctivitis involve a type 1 hypersensitivity 
reaction similar to the asthmatic subjects experiencing seasonal reversible disease. 
In the chronic forms of allergic conjunctivitis where corneal involvement is present, 
disease severity is greater and involves a Th2 cell mediated response, as seen in 
airway dysfunction in asthma (14). The most detailed investigation is that of the 
respiratory epithelium.  Nasal and bronchial mucosa are able to express ICAM-1 and 
its levels correlate to disease severity (15-17) and similar properties were shown in 
the conjunctiva in ocular allergy as described above (18). Similarly HLA-DR is 
expressed by airway epithelial cells and is increased in asthma (15). Human nasal 
and bronchial epithelial cells express various cytokines with proinflammatory 
properties e.g. IL-1, IL-3, IL-6, IL-8, TNFα, RANTES, GM-CSF which are increased 
in allergic disorders (19,20) and decreased after anti-allergic treatment (21-23).  
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1.3.1. T cell derived cytokines and allergic asthma  
 
It is well established that asthma can been considered mainly as a Th2 driven 
disease with IL-4, IL-5, and IL-13 participating in the immunopathogenesis of allergic 
inflammation associated with an Ig-E – dependent Type I hypersensitivity reaction 
and mast cells. Increased levels of Th2 cytokines, Ig-E levels, eosinophils and mast 
cells are reported in asthmatic lungs relative to controls (24,25). Atopic patients 
suffering from asthma had a Th2 type of airway inflammation with increase levels of 
IL-4+ and IL-5+ cells as well as increased eosinophils, and raised IgE levels in 
bronchial biopsies (26). On the other hand non-atopic asthmatics did not have 
evidence of Th2 inflammation but had raised levels of IL-8 and neutrophils without 
elevation of serum IgE. Increased mast cells numbers were observed in both non-
atopic and atopic asthmatics regardless of IgE levels. Additionally the same group 
reported structural differences: there was greater epithelial damage in the atopic 
asthmatics (26). The diversity of symptoms in asthma has lead investigators to 
classify asthma into atopic and non-atopic as well as eosinophilic/non-neutrophilic/ 
steroid sensitive and non-eosinophilic/ neutrophilic/ non-Th2-type asthma. Allergic or 
atopic asthma is considered as a Th2 driven disease with accumulation of 
eosinophils and mast cells. 
 
There is good evidence that IL-17 may participate in the development of 
inflammation in asthma.  IL-17 mRNA was found to be increased in the lungs and 
serum of asthmatics and the levels of IL-17 correlated to disease severity (27). IL-17 
leads to epithelial and smooth muscle cells activation and potentiation of bronchial 
fibroblasts (28). IL-17 enhances ICAM-1, IL-8 (neutrophil chemoattractant) and GC- 
CSF (important for neutrophil development) (29,30) levels secreted by epithelial 
cells. IL-17 mediated inflammatory mediators do not seem to contribute to Th2-
mediated eosinophil driven allergic asthma development. There are further reports 
suggesting that IL-17 may contribute to the pathogenesis of non-atopic, non 
eosinophilic, neutrophil dominant, non-Th2 driven asthma (31,32). However there is 
evidence that IL-17 may participate in the Th2 cytokines mediated mouse asthma by 
acting in two phases: in the sensitization phase by promoting allergen specific T 
helper cells and in the induction phase and by inhibiting the local allergic response 
(33). 
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 1.3.2. The roles of fibroblasts  
 
Conjunctival fibrobasts are capable of promoting local inflammation by expressing 
eotaxin-1 in response to IL-4, IL-13 and TNFα (34). It has been shown that 
conjunctival fibroblasts cultured from VKC biopsies prolonged the survival of 
eosinophils in culture up to 5 weeks and suggested that they produce survival factors 
e.g. GM-CSF that reinforce eosinophilic persistence in the tissue (35,36).  
 
TGFβ along with Th2 cytokines (IL-4) stimulated the expression of VEGF protein and 
mRNA in human conjunctival fibroblasts (by means of PCR analysis) (37). Similarly 
IL-13 caused an increase in VEGF levels but was not statistically significant at the 
mRNA level. Other pro-inflammatory cytokines including IFNγ (Th1 cytokines) 
induced less VEGF production leading to the conclusion that VEGF production was 
more dependent on Th2 cytokine-mediated inflammation (37). Furthermore 
fibroblasts’ biosynthetic capabilities are amplified by eotaxin and VEGF resulting in 
remodeling and perpetuation of the disease process. TGFβ treatment of asthmatic 
fibroblasts in vitro resulted in increased expression of both eotaxin and VEGF (38). 
However, very little is known about the role(s) of VEGF in epithelial remodelling in 
ocular allergy.  
 
Histamine treatment of conjunctival fibroblasts for 24 hours induced expression of 
proinflammatory cytokines, IL-1, IL-6, IL-8, and production of pro-collagen I (39). 
Additionally histamine reduced apoptosis of fibroblasts caused by serum deprivation. 
These data suggest that the role of fibroblasts extends from structural stromal 
functions and matrix production to effector cells of allergic inflammation (40).  
 
The fibroblast being a major collagen production cell is also known to participate in 
remodeling. Matrix metalloproteinases (MMPs) are produced by connective tissue 
cells and macrophages and are inhibited by their natural inhibitors (Tissue Inhibitors 
Matrix Metalloproteinases- TIMPs). These enzymes participate in many pathological 
processes: wound healing, inflammation, cancer and angiogenesis (41). The balance 
between MMPs and TIMPs determines proteolysis, degradation of all components of 
the extracellular matrix and tissue invasion. It is known that MMP-1 degrades 
collagen I, III and V (major collagens found in conjunctiva and cornea) and MMP-9 
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degrades the basement membrane component collagen IV as well as participation in 
eosinophil migration (42). 
 
In chronic allergic eye disease there is significant fibroblast activation and collagen 
deposition compared to acute reversible forms of ocular allergy with maximal cellular 
infiltration in the subepithelial area. Remodelling and scarring lead to the 
development of clinical signs, dry eye and corneal involvement.  More specifically 
collagen deposition, mainly type I and III, occurs at the subepithelial space and forms 
a fibrovascular structure that sustains the giant papillae as seen in VKC. This 
remodelling effect suggests abnormal extracellular matrix homeostasis resulting in 
increased collagen production. Conjunctival remodelling involves degradation of 
extracellular matrix and simultaneous synthesis and deposition of new matrix (43). In 
the same study the authors reported increased expression of MMP-1 and MMP-9 in 
the tears of VKC patients compared to normal subjects. More specifically the higher 
levels of MMP-9 to MMP-1 also correlated with disease activity indicated by corneal 
involvement, giant papillae formation, signs and symptoms and the authors proposed 
that the origin of the MMP-9 may be the eosinophils. Eosinophil cell counts 
correlated with pro-MMP-9 tear levels and MMP-9 activity. Furthermore it was 
suggested that the corneal shield ulcers in VKC are mainly limited to the superficial 
stroma due to the TIMPs action and the re-epithelialization of ulcers could be due to 
raised levels of MMP (43).  
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1.4 Tissue remodelling  
 
Tissue remodelling is an adaptive physiological phenomenon due to physical or 
hormonal stimuli featuring inflammation, cellular hypertrophy, proliferation, apoptosis, 
and extracellular matrix changes. The prolonged remodelling process causes 
pathological changes eg fibrosis in asthma, and ocular allergy. Tissue fibrosis is 
mediated by growth factors via transcription factor activations. Remodelling is a 
collective term that includes the changes in the amount and organization of the 
cellular and molecular components of the tissues, and is known to have deleterious 
irreversible effects contributing to disease severity. Its role in airway disease such as 
asthma and COPD has been described and the potential for therapeutic reversibility 
or prevention have also been suggested yet not completely understood. Similarly, in 
allergic conjunctivitis there are environmental insults as well as genetic susceptibility 
predisposing and leading to development of remodelling of the conjunctiva. 
However, the full impact of various remodelling mechanisms, on the conjunctival 
tissues is not completely understood.  
 
The process of remodelling involves structural changes such as alterations in the 
composition, size, and organisation of the cellular and molecular components of the 
tissue.  The attempted repair process follows multiple episodes of injury due to 
chronic inflammation.  The structural changes of normal cytological architecture lead 
to alterations in function, clinical signs and symptoms.  For example in airway 
remodelling,  features include epithelial abnormalities, basement membrane 
thickening, extracellular  matrix abnormalities, thickening of the smooth muscle cell 
layer, increased vascularity, hypersecretion and hypertrophy of the mucous glands 
and thickening of the airway wall (44).  
 
More specifically in asthma, the epithelium is fragile, the basement membrane 
thickened , the smooth muscle cells enlarged and in chronic obstructive pulmonary 
disease (COPD) there is airway fibrosis and alveolar destruction leading to 
emphysema (45).  Therefore there maybe overlapping of remodelling features 
despite asthma and COPD being pathologically distinct diseases (46,47).  
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Patients with asthma and COPD and non-symptomatic smokers show epithelial 
injury and repair, with denuded epithelial areas and squamous metaplasia (45). 
Wound healing is a process that involves multiple cellular and molecular events 
characterised by the participation of platelets, neutrophils, macrophages and T 
lymphocytes that interact with the tissues and release growth factors, cytokines and 
fibrin to repair the wounded tissue. In the conjunctiva similar features have been 
reported in chronic conjunctival allergic and cicatrizing disease.   
It is known that epidermal growth factor receptor (EGFR), as a marker of epithelial 
activation, is increased in the respiratory epithelium in severe asthma (48) and, in 
turn, leads to increased expression of pro-angiogenic and growth factors e.g. TGF-β, 
VEGF. TGFβ activates the mesenchymal subepithelial cells to produce matrix and 
enhances proliferation and may promote epithelial-mesenchymal transition (49).  In 
addition there is extracellular matrix deposition (ECM). Fibrosis and remodelling lead 
to irreversible structural changes and reduction in function. Fibroblasts are affected 
by inflammatory mediators produced by mast cells and eosinophils as seen in 
idiopathic pulmonary fibrosis, scleroderma and Crohn’s disease. The following table 
1.1 summarises the structural and functional changes in airway remodelling. 
Structural changes in airway remodelling  Pathophysiological changes  
Epithelial injury  
Basement membrane thickening 
Goblet cell hyperplasia  
Matrix deposition  
Mucus metaplasia  
Subepithelial fibrosis  
Increased smooth muscle  
Vascular dilation and angiogenesis  
Vascular remodelling  
Increased symptomatology  
Disease perpetuation  
Decreased lung function 
Airway hyperresponsiveness  
Mucous hypresecretion 
Oedema  
Irreversibility of airway obstruction  
Death  
 
Table 1.1: Features of airway remodelling (Modified by Figure 3 of reference 49)  
 
 
 
36 
 
1.4.1 Growth factors and soluble mediators in tissue remodelling  
 
It has been reported, by means of in vitro experiments, that the concept of damaged 
bronchial epithelial cells production of PDGF, βFGF, and TGFβ-1 reinforce fibroblast 
proliferation (50). Further to this conclusion it has been suggested that conjunctival 
epithelial cells and fibroblasts communicate through active growth factors and 
cytokines production leading to regulation of epithelial differentiation, wound healing 
and angiogenesis (51,52). The role of fibroblasts and collagen deposition has been 
investigated in inflamed conjunctival tissue and tears from patients with ocular 
allergy.  
 
Less is known regarding the participation of potential remodelling candidates (e.g 
EGFR and its ligands, VEGF) in various forms of ocular allergy, particularly in 
epithelial remodelling in CAED compared to reversible forms. VKC is the form most 
studied to date and mainly by means of immunohistochemistry. Investigators have 
described the distribution and expression of epithelial and stromal molecules in VKC 
conjunctival biopsies.  The mechanisms of giant papillae formation are still not fully 
understood and are thought to participate in corneal involvement in the chronic forms 
of ocular allergy. Previous studies investigated the cellular and cytokine participation 
in conjunctival remodelling mainly in VKC but very few have concentrated on the 
study of epithelial remodelling markers. In addition no proposal has been made as to 
what promotes the remodelling processes in severe forms of ocular allergy. On the 
contrary the bronchial mucosa and epithelium have been studied extensively and it 
has been proposed that modified epithelial function promotes tissue remodelling and 
sustain persistent inflammatory responses as seen in chronic asthma.  
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1.4.2 Eosinophils and remodelling  
 
 It has been shown in the asthmatic bronchial mucosa, by means of 
immunohistochemistry, that there are increased numbers of VEGF positive 
eosinophils and macrophages contributing to increased airway thickness. 
Eosinophils produce important angiogenic mediators to include VEGF, TGFβ, TNFα, 
IL-6 and IL-8 and it has been suggested that eosinophils induce angiogenesis in vitro 
and ex vivo providing evidence for a possible role of remodelling (53). Th2 cytokines 
(IL-13) and TGFβ synergistically increase eotaxin expression in human airway 
fibroblasts suggesting that fibroblasts may participate in the exacerbation of allergic 
inflammation (54). Antigenic stimulation induces VEGF expression in bronchial 
mucosal epithelial cells (55). Eosinophils express TGFβ and therefore may 
participate in tissue remodelling (56).  
 
Eosinophils and IL-5 were shown to affect TGFβ and remodelling. More specifically, 
in the remodelled airways of IL-5 deficient mice, TGFβ was reduced (57). Similarly 
eosinophil TGFβ expression contributes to airway remodelling in anti-IL-5 mAb -
treated asthmatic subjects since it was observed that TGFβ levels and TGFβ positive 
eosinophils were reduced (58). Furthermore PDGF, FGFβ and TGF-β1 induce 
fibroblast proliferation and extracellular matrix production in pulmonary fibrosis (59).  
 
1.4.3 The role of MMPs in remodelling  
 
The distribution of MMP- 1, -3, -9, -13 and TIMP-1 in VKC, asthma and nasal polyps 
by means of immunohistochemistry was studied, aiming to show  the potential 
contribution of MMPs to remodelling in different organs. In this comparative study, 
there were differences in collagen and MMP expression in the three different tissues. 
The differences in collagens’ expressions reflects the obvious differences of the 
anatomical structures and the differences in MMPs expression may be a feature of 
different tissues undergoing similar processes in allergic inflammation (60).  More 
specifically there was intense expression of collagen I in VKC giant papillae and 
nasal polyps which are fibrovascular outgrowths rather than just mucosal thickening 
as seen in asthma. Collagen III was increased in asthma and VKC suggesting that 
the remodelling processes may differ in tissues. It was also shown that there was 
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increased MMP-13 expression in the epithelium and moderate expression of MMP-3 
and MMP-9 (60). Collagen I and III are those most involved in remodelling 
processes. Regarding MMPs, MMP-1, MMP-3, MMP-9 and MMP-13 were expressed 
in VKC, MMP-1 and -9 nasal polyps and MMP-13 was overexpressed in bronchial 
epithelium. MMPs are known to be increased in the bronchial mucosa in asthma 
especially during exacerbations (61) and increased tear levels and activity of MMP-1 
and 9 were found to reflect clinical signs in VKC suggesting a strong role in allergic 
inflammation and remodelling (43,62). MMP-9 has been shown to be involved in 
eosinophil migration (63) and increased levels of MMP-9 and TIMP-1 were reported 
in bronchoalverolar lavage and sputum in asthma patients (64). MMPs interact with 
cytokines known to play a crucial role in allergic inflammation. More specifically 
MMP-9 is shown to catalyze the activation of IL-1β (65) and TNFα (66) and hence 
have pro-inflammatory roles. Additionally MMP-9 can potentiate IL-8 (67) and 
process chemokines (68).  
 
It has been suggested that in asthma there is also an altered expression pattern of 
extracellular matrix degrading enzymes. Asthmatic fibroblasts produce less MMP-3 
(69) and MMP-2 (72). However MMP-9 was reported to be increased in asthmatic 
subjects which may account for the decreased expression of collagen IV in the 
basement membrane of asthmatic subjects (70).  
 
The interactions of MMPs also induce mast cell activation. In fact MMP-1 was 
reported to be involved in mast cell infiltration and activation (71). The study reported 
that collagenase-1 was expressed by human mast cell cultures and by mast cells in 
normal and inflamed tissues. EGF receptor activation and VEFG are overexpressed 
together with a variety of other fibrogenic factors, resulting in production of collagens 
leading to epithelial-mediated remodelling (123). The levels of expression of different 
MMPs in VKC conjunctiva, nasal polyps and asthmatic airway have been 
investigated. These different tissues express at different levels of various MMPs 
whilst undergoing similar disease processes. There was increased MMP-13 
expression in the epithelium and modulate expression of MMP-3 and MMP-9 (60).  
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1.5 Asthma and the Epithelial Mesenchymal Trophic Unit (EMTU) hypothesis 
 
Atopy is a key characteristic of asthma pathogenesis and T-helper cell (Th2) airway 
inflammation participates in airway dysfunction.  T cells, mast cells, and eosinophils 
are features of the Th2 response leading to an inflammatory response.  The T-helper 
cell type-2 paradigm for asthma provides a link with atopy. Mast cells, eosinophils, 
and basophils coordinated by T cell antigen presenting cells have an important role 
in mediating inflammation in asthma. Atopy is an important risk factor for asthma but 
it accounts only for <40% of the attributable risk for having the disease (73).  
Corticostreroids administered via inhalation are shown to be efficacious by 
suppressing Th2 cytokines which mediate eosinophil and other immune system cells 
responses (74). 
 
 In chronic asthma there may be persistence of airway dysfunction despite high dose 
inhaled corticosteroids. This may be partially overcome with the addition of long 
acting inhaled β2 adrenoceptor agonists providing relaxation of the smooth muscle 
cells and the corticosteroids suppress inflammation. Therefore in chronic asthma 
some disease components may not respond successfully to steroid treatment (75). 
This in turn leads to the conclusion that “there may be two mechanisms running in 
parallel that are essential to convert the disease from mild to severe and chronic:  
i) a susceptible airway linked to altered structure and function (remodelling), 
and  
ii) a microenvironment capable of sustaining a chronic inflammatory 
response due to an imbalance of EGF and TGFβ signalling pathways 
e.g. mast cell population of airway smooth muscle cells correlating with variable 
airflow obstruction (76)  and BHR and eosinophils in airway lumen correlating 
with asthma exacerbations (77)” (78).  
 
It is suggested that an additional series of events is required to provide a better 
explanation for the disease chronicity and severity. This is based on the evidence 
that the altered epithelium communicates with the underlying mesenchyme to create 
a trophic unit that induces and reinforces remodelling from the epithelium. This is 
achieved with the participation of Th2 cytokines which maintain inflammation and 
drive remodelling (79).  
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1.5.1. Chronic asthma: altered response to injury and epithelial-mesenchymal 
communication  
 
On its own the Th2 mediated inflammation is insufficient to cause asthma. The 
model of the chronic wound with production of growth factors involving activation of 
the epithelial-mesenchymal trophic unit (EMTU) has been proposed which provides 
the essential stimuli for altered airway wall structure and function (80). More 
specifically Holgate’s suggestion states that the asthmatic state from a combination 
of increased susceptibility of the bronchial epithelium to injury and prolonged tissue 
repair involves an imbalance in responses to tyrosine kinase receptor ligands (EGF, 
TGFβ) and Th2 cytokines. These in turn alter the cell-cell communication between 
the epithelium and the subepithelial mesenchymal cell layer leading to activation of 
the EMTU. The abnormal EMTU activation causes structural airway changes 
promoting chronic inflammation.  
 
Communication between the epithelium and the underlying sub-epithelial fibroblast 
layer is reminiscent of the process that promotes branching morphogenesis in the 
foetus where the epithelium and mesenchyme function as a trophic unit (EMTU) 
(78). The EMTU plays an important role in pulmonary embryogenesis and its 
reactivation leads to pathologic remodelling in chronic asthma. It is established that 
during morphogenesis EGFR activation increases expression of MMP enzymes to 
degrade the extracellular matrix and induce epithelial proliferation. On the other hand 
TGFβ expression reduces MMP levels and matrix degradation leading to inhibition of 
epithelial proliferation. The intermittent changes of EGF/TGFβ balance produces 
alternating linear and branching of the developing airways (81).  
 
Therefore this imbalance leads to the activation and function of tyrosine kinase 
receptor ligands involving epidermal growth factor (EGF) and transforming growth 
factor beta (TGFβ). These molecules interfere and change the cell communication 
between the epithelium and the subepithelial mesenchymal cells. Epidermal growth 
factor receptor (EGFR) family members are upregulated as a normal response to 
epithelial injury aiming to promote proliferation and repair. In asthma EGFR 
expression is upregulated and correlates with disease severity irrespectively of the 
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inhaled corticosteroid treatment of the patient. Immunohistochemistry studies have 
shown that EGFR’s expression is increased in the epithelium in asthma but not in the 
normal epithelium (82,83). This is illustrated in Figure 1.7 below:  
 
                            
Figure 1.7: Activation of the epithelial-mesenchymal trophic unit in chronic asthma: 
injured epithelium and underlying fibroblasts induce mesenchymal cell proliferation 
leading to remodelling. Th2 cytokines (IL-4, IL-13) interact with the EMTU to 
enhance remodelling (78).  
 
The authors propose this alternative paradigm to explain the rising trends and 
prevalence of the disease: changes in the environment may have exposed a pre-
existing susceptibility involving local factors (78,84). In the case of chronic asthma it 
is proposed that in genetically susceptible individuals exposure to environmental 
factors closely associated to asthma (as opposed to atopy) causes a continuous 
activation of the EMTU leading to remodelling and chronic disease (78,84,85). These 
environmental factors may include exposure to environmental tobacco smoke, air 
pollutants, a diet low in antioxidants high in fat and proteins, pre- and perinatal 
exposure to oxidants (e.g. paracetamol) and respiratory virus infections (85). TGFβ 
produced by the epithelium seems to play a role as well by differentiating airway 
mesenchymal cells into myofibroblasts which have contractile and secretory actions 
and provide a continuous source of precursor cells to generate smooth muscle cells 
(86,87). TGF-β2 participates in airway wall thickening by inducing collagen secretion 
and promotes VEGF release (88,89).  
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1.5.2. Th1 and Th2 participation: essential but not enough to account for 
disease severity.  
 
Based on the evidence described in the previous sections, cellular and molecular 
mechanisms of chronic and severe asthma are different from those of mild forms of 
the disease. The severe and chronic asthma requires early activation of epithelial-
mesenchymal communication. On the contrary the mild forms of the disease are 
more dependent on a Th2 inflammatory response alone (78). Th2 cytokines IL-4 and 
IL-13 promote equally TGFβ release in epithelial cells and in asthmatic fibroblasts 
they promote production of eotaxin, GM-CSF which might provide an explanation for 
the recruitment of eosinophils (38). Additionally IL-4 and IL-13 have been shown to 
increase TGFα production form the epithelium in asthmatic epithelial cell lines in vitro 
(90).  
 
The trophic response leads to a chronic wound state and remodelling. In the 
remodeled airway mediators, cytokines and matrix agents promote an ideal 
microenvironment for perpetuation of chronic inflammation (91) adapting an 
additional Th1 pattern that involves participation of neutrophils and pleiotrophic 
cytokines e.g. TNFα, IFNγ which induce further tissue damage (92). It is also 
reported that Th1 cytokines participate in the development of childhood asthma 
(93,94). Th2 cytokines such as IL-4, IL-13, IL-9, GM-CSF have been localized and 
favored by the EMTU and maintain inflammation as well as driving remodelling 
processes (95,96).  These interactions are illustrated in Figure 1.8 overleaf.  More 
specifically, a parallel model for asthma pathogenesis in which inherited or acquired 
epithelial susceptibility to environmental agents leads to induction of stress-injury 
and repair. Growth arrest and prolonged repair enhances cell-cell communication in 
the EMTU leading to propagation of remodelling responses. As shown in figure 1.8 
at each level the Th2 cytokines interact with the EMTU to amplify these responses 
(82). 
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Figure 1.8: The interaction between Th2 mediated inflammation and EMTU in 
asthma pathogenesis (84) 
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1.5.3. Mechanisms of epithelial damage in asthma: epithelial-mesenchymal 
communication.  
 
1.5.3.1 The role of growth factors and the EMTU hypothesis   
 
EGFR is a glycoprotein (130kDa protein and 40kDa sugar chain) made of four 
domains: the glycosylated extracellular domain is the binding site for EGF and TGFα, 
a transmembrane lipophilic segment, tyrosine kinase domain and a phosphorylation 
domain. The binding of EGF or TGFα to the receptor causes DNA synthesis and cell 
proliferation/hypertrophy. The complete mechanism of the signal transduction is 
unclear and it is assumed that it involves tyrosine autophosphorylation and 
phosphorylation of interacting proteins. It becomes activated due to homo- or 
heterodimerization which is mediated either by ligand binding or by high receptor 
density due to overexpression. It is expressed by epithelial tissues and epithelium-
derived tumours. It is reported that there is an asthma related increase in epithelial 
EGFR with remodelling suggesting a link between with subepithelial fibrosis and 
epithelial damage/activation (97). The EGFR expression levels are increased in 
asthma and correlate with disease severity (48). This overexpression is due to tissue 
response to injury but not proven to induce cell proliferation in asthma (98). The 
EGFR is known to be expressed in the basal surface of the epithelium of upper and 
lower airways as well as in bronchial epithelial derived cell lines (e.g. H292 and 
16HBE14o) (99,100). 
 
Members of the EGF family include TGFα, heparin binding EGF-like growth factor 
(HB-EGF), amphiregulin and epiregulin and are important regulators of epithelial 
population due to their ability to stimulate cell migration, proliferation, differentiation 
and survival (48). The EGF family of growth factors exerts its effects by binding and 
activating the EGFR. EGFR signaling was shown to be an intrinsic component of the 
response to injury and EGFR activation occurs rapidly after tissue damage and is 
independent of exogenous ligands (48). Epithelial EGFR expression occurs at areas 
of damage in asthmatic bronchial biopsies and more specifically there is disease-
related increase in its expression. Corticosteroid treatment did not decrease the 
expression of EGFR in intact bronchial epithelium despite that corticosteroids are 
known to promote epithelial repair in vivo. This suggests a steroid non-
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responsiveness element that may participate in severe chronic disease leading to 
the conclusion that increased EGFR expression blocks the epithelium into a repair 
mode which promotes inflammation and remodelling by provision of pro-
inflammatory mediators, cytokines and fibrogenic growth factors (48). There is no 
similar evidence published so far for the severe forms of allergic conjunctivitis where 
steroids may also not be enough to achieve disease control.  
 
EGF promotes mitosis of human bronchial epithelial cells and in vitro studies have 
shown that EGFR activation plays a significant role in airway epithelial repair after 
injury (98). However despite the increased EGFR expression in asthma, there is no 
increased epithelial cell proliferation to replace the lost columnar cells (98,101). 
Further studies attempted to provide an explanation and investigated the role of 
p21waf, a cyclin dependent kinase inhibitor that was reported to be overexpressed in 
epithelial cells in patients with severe asthma (98). 
 
 
TGFα shares a 33% homology with EGF and binds to the EGFR inducing activation 
of tyrosine phosphorylation and cell proliferation. TGFα is shown to be released at 
higher levels in asthmatic epithelial cells in response to pro-inflammatory cytokines 
e.g. TNFα, IL-4, IL-13 and allergen (90). It is expressed mainly by epithelial cells, 
macrophages and eosinophils. The bronchial epithelial cell line 16HBE14o 
expresses TGFα in addition to HB-EGF and it is proposed that these ligands are 
responsible for EGFR activation (48). In nasal biopsy specimens of normal 
volunteers exposed to ozone for two hours there was significant increase in the 
expression of EGFR, EGF, and TGFα with a positive correlation of EGFR epithelial 
expression and increase in neutrophil numbers. More specifically, EGFR expression 
was significantly increased in vitro 6 hours after exposure of the cells in TNFα and in 
vivo there was increased EGFR expression in nasal biopsies 8 hours after ozone 
exposure.  
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1.5.3.2 The role CD44 in enhancing EGFR signalling 
 
CD44 is expressed by a variety of cells: T and B lymphocytes, monocytes, 
erythrocytes, epithelial cells, granulocytes, fibroblasts and mast cells. It is a 
glycoprotein transmembrane adhesion molecule (90kDa) which acts as a cell surface 
receptor for hyaluronate suggesting role in cell regulation and migration. CD44 is 
known to be upregulated in the respiratory epithelium in asthma and associated with 
epithelial injury (102,103) and its expression can be regulated by pro-inflammatory 
cytokines (104). CD44 has a physiological role in epithelial repair in airway 
epithelium derived cells (105). Cytokines including IFNγ increased cell adhesion via 
CD44 without increasing CD44 expression. Additionally CD44 mediated cell 
migration is involved in the response of airway epithelial cells to damage and 
promoted the epithelial cell repair process. High levels of CD44 expression were also 
observed on the cells close to the damaged are where epithelial migration takes 
place (104). It was suggested that CD44 may have an important function in localizing 
chemokine and growth factors to the disrupted epithelium (106). 
 
There are four EGF receptor subtypes which are activated upon ligand crosslinking 
of two of these receptors (cerb B1 or B2) on cell surface. This activates tyrosine 
kinase which phosphorylates the opposite chain and leads to a cellular signal 
generation which has two directions:  
1) into the nucleus via STAT-1/STAT-3 protein activation (signal transducer and 
activator of transcription) to produce cell proliferation  
2) activation of  alternative cell pathways involved in cell mobility linking to the 
actin cytoskeleton and turning an epithelial cell into a mobile mesenchymal 
cell (227). 
In vitro investigations for the role of EGFR in damaged bronchial epithelial repair 
have shown that it becomes rapidly phosphorylated and the repair rate is 
accelerated by the addition of exogenous EGF (48). CD44 is suggested to play an 
interesting role in this mechanism which is illustrated below in Figure 1.9.  
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Figure 1.9: The role of CD44 enhancing EGFR mediated signalling and epithelial 
cell migration (106).  
 
The epithelial 3v CD44 isoform selectively binds heparin binding EGF and when 
overexpressed in damaged or wounded epithelium it captures available EGF and 
presents it more efficiently to the cell surface EGFR. This in turn activates the kinase 
and promotes the epithelial repair. Additionally CD44 helps ezrin connect to moesin 
which is linked to the cytoskeleton and leads to cell movement as part of the repair 
process. The EGFR is overexpressed in injured epithelium and this has been 
reported to occur in the bronchial epithelium of patients with mild and severe asthma 
(100). The level of EGFR epithelial expression is disproportionate to the level of 
epithelial cell proliferation. Therefore in asthma increased EGFR expression does 
not lead necessarily to a repair response and a normal epithelium, as shown in vitro 
in primary bronchial epithelial cell cultures (16HBE 14-o-cells). 
 
TGFβ is also expressed at wound sites of the bronchial biopsy similar to EGFR but is 
independent to EGFR activation. This may suggest that there are parallel 
mechanisms taking place in the epithelium (48).  
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1.5.3.3 The roles of Transforming Growth Factor-β (TGF-β) and the TGF-β – 
EGF axis 
  
There are three TGFβ isoforms: β1, β2, β3 and is secreted from inflammatory cells, 
epithelium, myofibroblasts, fibroblasts and can promote remodelling by inducing 
production of extracellular matrix components. TGFβ participates in the homeostasis 
of lung immunity, lung development and extracellular matrix deposition. It mediates 
intracellular signalling via the Smad proteins (serine phosphorylated by the type I 
receptor after ligand activation) leading to transcription of target genes as shown in 
Figure 1.10 below. It is anti-inflammatory (107) and promotes cellular migration 
(108). On the contrary an excess of TGFβ can inhibit epithelial proliferation that is 
essential for wound healing. In asthma it is shown that its expression is increased 
and which can account for the changes seen in airway remodelling.  
 
                    
 
Figure 1.10: TGFβ signalling via Smads resulting in transcription of genes e.g 
promotes fibronectin synthesis, collagen proteins (260). 
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TGF-β1 regulates the migratory phase of epithelial repair (109). More specifically it 
can increase the migration of damaged bronchial epithelial cell monolayers (110). 
Additionally it has been shown to inhibit cell proliferation of epithelial cells (111) with 
upregulation of cyclin dependent kinase inhibitors (e.g. p21waf) (112).  
 
In the bronchial fibroblasts TGFβ can exert a number of effects. TGFβ promotes the 
transformation from fibroblast to myofibroblast (via Smad mediated adhesion 
independent and dependent signaling pathways) (113) and promotes their survival 
by inhibiting apoptosis mediated by IL-1β (164). Myofibroblasts are transient in vivo 
and have more synthetic capabilities than fibroblasts, predominate in granulation 
tissue and play an important role in fibroproliferative disease when upregulated. It 
has been proposed that TGFβ induces transformation of the myofibroblast to smooth 
muscle cells and in asthma the smooth muscle cell layer is hyperplastic (114).  
 
Th2 cytokines (IL-4, IL-13) are shown to exert myofibroblast transformation indirectly 
via TGF-β2 release (38). Additionally, TGFβ was reported to upregulate fibroblast 
proliferation (115,116). Integrin mediated TGFβ activation in EMTU was reported in 
foetal tracheal epithelial cells (117). It was suggested that this mechanism could 
result in delayed epithelial repair and stimulation of sub-epithelial matrix deposition 
and participation in airway remodelling.  
 
TGFβ and EGF promote various cellular events including growth, migration and lung 
embryogenesis. TGFβ antagonizes EGF-induced attachment of cells on a fibronectin 
matrix (118). Additionally TGFβ inhibits EGF- induced bronchial epithelial cell 
migration (119). Both molecules participate in lung morphogenesis: TGFβ inhibits 
growth of the developing airways (120,121) whereas EGF promotes elongation of 
the bronchial tube (122). From the above we can conclude that TGFβ can affect EGF 
signaling and vice versa and the outcome is determined by the relative balance 
between the two molecules. The balance between EGF-mediated proliferation and 
TGFβ mediated fibroblast differentiation is of particular importance in the 
pathogenesis of airway remodelling.  
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1.5.3.4 Regulation of epithelial cell population: The role of p21waf cyclin 
dependent kinase inhibitor  
 
As mentioned earlier, the increased expression of EGFR in the asthmatic airway 
epithelium is not associated with increased epithelial cell proliferation. The bronchial 
epithelium acts as a physical barrier and serves in airways defense. Cell 
homeostasis is controlled by a balance between proliferation, inhibition of growth and 
apoptosis. Cell cycle inhibitors control cell proliferation. During the cell cycle entry 
into S phase is controlled by the cyclin dependent kinases (CDK). One example of 
CDK inhibitor is the antiapoptotic factor p21waf which blocks G1 to S phase transition 
by inhibiting the phosphorylation of retinoblastoma protein (124). p21waf can be 
induced by cytokines with antiproliferative properties TGFβ, IFNγ, by corticosteroids 
and by injury (125).  
 
p21waf expression has been mainly localized at the epithelium and has been found to 
be greater in asthmatic subjects and unaffected by corticosteroid treatment. p21waf 
was induced in vitro by TGFβ or H2O2 but not dexamethasone. The increased 
expression of p21waf in asthmatic bronchial epithelium may reflect its inability to 
proliferate leading to an imbalance between proliferation and apoptosis and may 
contribute to persistent inflammation and remodelling in asthma (98). Furthermore 
fibroblasts’ biosynthetic capabilities are amplified by eotaxin and VEGF resulting in 
remodelling and perpetuation of the disease process. TGFβ treatment of asthmatic 
fibroblasts in vitro resulted in increased expression of both eotaxin and VEGF. 
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1.5.3.5. EGFR and growth factors in chronic allergic eye disease 
 
The normal epithelium in the conjunctiva may show weak immunoreactivity of VEGF 
and EGFR but not for TGFβ, PDGF, β FGF (123). The conjunctival epithelium 
overexpresses EGFR and VEGF as shown in Figures 1.11 and 1.12 (126). The 
increased immunoreactivity of EGFR is shown to be more intense in the deeper 
epithelial levels and VEGF in all levels (biopsies from 16 VKC patients with severe 
active disease in King Abdul-Aziz University Hospital, Saudi Arabia) but some 
variations were also noted. More specifically EGFR positive inflammatory cells were 
observed in 8 out of 16 biopsies and VEGF positive inflammatory cells were 
observed in 9 out of 16 biopsies. Additionally inflammatory cells (eosinophils, 
macrophages, monocytes) expressing TGFβ, EGFR, VEGF, β-FGF, PDGF were 
located in the stroma (126).  
 
   
Figure 1.11: EGFR expression in              Figure 1.12: The epithelial expression of 
VKC is stronger in the deeper                        VEGF in VKC (126)  
Epithelial layers (126)  
                                
Expression of integrins α3 and α6 was found increased in the basal and sub-basal 
epithelial areas in VKC.  Growth factors can modulate the level of expression of 
integrins. Integrins have been documented to participate in the maintenance of 
epithelial cell populations, in epithelial wound healing and remodelling (127-129). 
These results suggest a possible role of growth factors in remodelling in the 
pathogenesis of VKC by means of immunohistochemistry studies.  
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Fibroblast proliferation or fibrosis occurs in chronic inflammatory disease and in 
chronic ocular allergic diseases. The giant papillae in VKC form the pathological 
construction of fibroblast activation and tissue remodelling. Collagens I, III, VII and 
fibronectin were highly expressed in the sub-epithelial area in VKC with collagen I 
being the major element in VKC compared to controls (130). There is increased 
diffuse epithelial expression of fibrogenic growth factors TGFβ, PDGF, and FGF in 
association with increased deposition of collagen in the giant papillae of VKC (130). 
Collagen VII expression is considered an indication of increased epithelial growth 
and conjunctival area and collagen I seemed to be the major connective tissue 
component in VKC. The epithelium in VKC subjects was intensely positive for PDGF, 
FGFβ, and TGF-β1 suggesting that they are produced by the epithelium or they have 
been accumulated there from tears or other sources. Additionally it was suggested 
that these factors may be involved in the chemoattraction of mast cells.  
 
TGFβ is an important regulator of extracellular matrix deposition by controlling 
collagen and protease inhibitors expression (131,132). It is involved in the regulation 
of allergic inflammation and remodelling. Intracellular signalling by TGFβ members is 
mediated via binding to a heteromeric receptor complex (130,131,133) causing 
phosphorylation of its intracellular receptors (Sma- and Mad- related protetin (Smad) 
family of signal transducers (131,132,134). TGF-β1 and -β2 levels were significantly 
increased in association with Smads (131).  
 
There is no published data to date regarding the roles of CD44 in ocular allergy, as 
an enhancer of EGFR signalling, and TGFα as a major ligand binding the EGFR. 
Similarly there is no published data on the roles of p21, an anti-apoptotic molecule, 
in ocular allergy. Its overexpression in the epithelium may indicate an imbalance 
between proliferation and apoptosis and may contribute to persistent inflammation 
and remodelling in chronic allergic eye disease, as reported in chronic asthma. 
Although there is some data on the detection of growth factors participating in 
remodelling in VKC most studies concentrated on the roles of fibroblasts and there is 
no suggestion as to why it occurs in chronic allergic eye disease which could 
account for disease severity.  
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1.6 The role of the conjunctival epithelium in ocular allergy  
 
1.6.1 Cellular participation and cytokines  
 
Various cells participate in the immune response involving cytokine production, 
further chemotaxis and hypersensitivity. In VKC there is a massive involvement of T 
cells, macrophages, eosinophils and neutrophils which differentiates it from SAC or 
PAC as shown in Table 1.2 below that illustrates the various cells participating in the 
pathogenesis of each form of ocular allergy (135).  
 
 
Table 1.2: Overview of the cells and mechanisms in ocular allergy.  
 
Mast cells contribute to the immunopathogenesis of allergic eye disease and are 
able to store produce and secrete several factors such as histamine, TNFα, IL-4, IL-
6, IL-8 contributing to the inflammatory response by the recruitment of eosinophils 
and neutrophils. Two forms of mast cells are present: the tryptase and chymase 
(MC-TC) and tryptase only (MC-T) found in mucosal membranes which increases in 
ocular allergy and is present in all epithelial layers. The conjunctival mast cell is 
central in the allergic cascades in ocular allergy.  In the late phase of the allergic 
response after mast cell activation, the conjunctiva is infiltrated by inflammatory cells 
(neutrophils, lymphocytes, basophils, eosinophils). They are the principal 
inflammatory cells in SAC with eosinophilic recruitment capabilities. So far it is 
recognized that in addition to T-cells, mast cells, eosinophils and epithelial cells are 
significant sources of cytokines in allergic inflammation. There are different cytokine 
profiles, T cells and eosinophils in the epithelium of the conjunctiva in different forms 
of ocular allergy (18).  
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1.6.2 The pro-inflammatory roles and antigen presentation capabilities of the 
conjunctival epithelium  
 
The conjunctival epithelium is a non-keratinized, 2-6 thick cell layer and plays an 
important role in the immunopathogenesis of ocular allergic disease. It contains 
goblets cells secreting mucin and it has the ability to express co-stimulatory 
molecules. However, so far the most detailed investigation of epithelial cells is that of 
the airway epithelium. The most important role of the epithelium of the conjunctiva, in 
ocular surface defense and inflammation, has long been thought to be its barrier 
function and stabilizing the tear film (136,137). The airway mucosa and the 
conjunctival epithelium, express adhesion molecules, surface antigens and pro-
inflammatory cytokine mediators (138). So far there are reports on the cytokine 
profiles in allergic eye disease in relation to the role of the epithelium assessed by 
means of immunohistochemistry, flow cytometry and cell line cultures. It is known 
that the conjunctival epithelium plays a crucial pro-inflammatory role in the 
immunopathogenesis of chronic allergic ocular disease (139).  
 
In SAC the predominant mediator is histamine produced via a type I hypersensitivity 
reaction with symptomatology reflecting allergen exposure. Immunohistological 
evidence in SAC conjunctival bulbar and tarsal biopsies showed increased 
expression of ICAM-1 and E-selectin compared to controls only during the pollen 
season (140). In VKC and AKC the mechanisms are more complex and in addition to 
the eosinophils, mast and epithelial cells, involve Th2 T cells.  
 
Further immunohistochemistry studies on conjunctival biopsies from AKC, VKC, 
GPC patients revealed that the epithelial cells are capable of ICAM-1 adhesion 
molecule expression for leucocyte migration, MHC class II (HLA-DR in human) 
expression important in antigen presentation and T cell activation and synthesis of 
prostaglandins and leukotrienes essential for leukocyte activation and attraction (65). 
ICAM-1 interacts with LFA-1 to promote the migration, recruitment and retention of 
leukocytes. HLA-DR expression is also increased in chronic inflammatory conditions 
of the conjunctival epithelium which is required for antigen presentation to T cells 
with class II MHC (139). Its expression was increased in AKC and VKC more than 
GPC where there is no corneal involvement. Interestingly GPC is not considered a 
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true allergic conjunctival disease. It is caused by repeated mechanical irritation (e.g. 
contact lens use) and can be reversible upon removal of the cause. T cell infiltration 
is also seen in this form of chronic allergic eye disease. It is not associated with 
atopy.  
 
The apical side of the epithelial layer is exposed to the environment and allergen 
directly whereas the basolateral surface appears to be the site of CD4+ T cell 
recruitment via a not well understood mechanism (141). T cell infiltration appears to 
be in all forms of chronic allergic eye disease: GPC, AKC, VKC (142). It has been 
reported that there are Th2 cytokine producing cells in the sub-epithelial layer in 
GPC, AKC and VKC. More specifically in AKC conjunctival T cell lines produce 
increased IFNγ, IL-10, IL-13 and little IL-4 and IL-5. (143)  In VKC conjunctival cell 
lines produce IL-5 and IL-13 (141).  Table 1.3 below summarizes the various 
cytokines known to participate in various forms of ocular allergic disease in relation 
to the various types of inflammatory cells involved (135). However, there has been 
no study to date to suggest the potential involvement of growth factors /or relate their 
detection to the severe forms of disease as opposed to the reversible IgE mediated 
types (SAC, PAC). 
 
 
Table 1.3: Tear mediators, cytokines and cells detected in active ocular allergies 
(135).  
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It has been proposed that due to their expression of co-stimulatory molecules and 
secretion of pro-inflammatory cytokines, these cells could present and process 
antigen. Additionally it was found that in chronic allergic eye disease there is an 
upregulation of various cytokines in the conjunctival epithelium: RANTES, GM-CSF, 
IL-3, IL-8, TNFα. There are different cytokine profiles in epithelial cells in different 
clinical disorders.   
 
VKC is a Th2 driven disease with a Th2 cytokine profile: increased levels of IL-3, IL-
4, IL-5 and IL-13. Th2 lymphocytes induce IgE hyperproduction (IL-4, IL-9, IL-13), 
recruitment of mast cells (IL-3) and eosinophils (IL-5) (141). The IgE mediated 
hypersensitivity reaction alone is not enough to explain the complete spectrum of 
progression and severity (144-146). So far it is known that the conjunctival infiltration 
of inflammatory cells leads to the release of toxic mediators (eosinophil neurotoxin, 
eosinophil peroxidase, matrix metalloproteinases 2, 9 which in turn causes corneal 
epithelial damage (147-151). In the epithelial cells TNFα, IL-1β induce increased 
expression of ICAM-1 and IL-1β is a more potent stimulator releasing IL-8 than 
TNFα. RANTES production requires IFNγ and TNFα treatment and is one of the 
most potent eosinophilic chemoattractants with effects to T cells and macrophages 
(152). 
 
Dendritic cells, are potent initiators of primary immune responses, stimulate naïve T 
cells and participate in maintaining and initiating the Th2 response. They express the 
high affinity IgE receptor (FcεRI) that enables antigen presentation to T cells. In 
conjunctival biopsies from non-atopic and VKC patients it was reported that the 
FcεRI on dendritic cells is increased, which could enable antigen presentation and 
development of ocular symptoms. These cells had greater populations located in the 
epithelium (153).  
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1.6.3 The roles of eosinophils in ocular allergy  
 
Levels of eosinophilic activation, and not total cell number are greater in those forms 
of ocular allergy with corneal involvement than without. There are also differences in 
the cytokine profile which may be attributed to the T cell subsets. It seems that the 
eosinophils have an important role and these may be either secondary to the actions 
of the various T cell subtypes or a cause affecting T cell responses (154). The 
enhanced activation of eosinophils in AKC and VKC suggested that these cells 
release their cytokines and could play a role in disease perpetuation (154).In AKC, 
there is increased eosinophil expression of IL-4, IL-8 and GM-CSF. IL-4 is a B cell 
stimulator and influences the development of T cells, whereas IL-8 is mainly a 
neutrophil chemoattractant (154). Other studies confirm that in VKC there is 
expression of IL-3, IL-5, IL-6, GM-CSF which are pro-inflammatory and 
chemoattractant for cells such as mast cells and B cells (155-157).  
 
These immunohistochemistry studies enable the eosinophil cytokines to be studied 
because like mast cells eosinophils contain a significant amount of stored cytokines 
which are secreted upon activation. On the contrary, T cell cytokines studies require 
in situ hybridization since T cell cytokines are released almost immediately from the 
cells following activation.  
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1.6.4 The roles of T cell subsets 
 
Mast cells numbers are increased in chronic allergic eye disease but the major 
cellular participants are mainly CD4+, CD8+ T cells and eosinophils and are found in 
increased numbers in the subepithelial areas of the conjunctiva. Epithelial cell-
derived cytokines are detected in the conjunctiva in chronic ocular allergic diseases 
with different cytokine profiles in each form of disease (158). Studies have shown 
that in VKC there are increased number of activated T cells mainly located in the 
sub-epithelial layer and increased HLA-DR expression (159). T lymphocytes play an 
important role in mediating the immunopathology seen in the chronic allergic 
response in the skin and the lungs. The prevalence of T cells and their subsets in 
different chronic allergic eye conditions by means of immunohistochemistry has been 
investigated and it has been reported that there are significantly increased numbers 
of CD4+, CD45RO+, and HLA-DR+ T cells in the conjunctiva of patients with atopic 
and vernal keratoconjunctivitis and giant papillary conjunctivitis, compared to non-
inflamed controls, with a corresponding upregulation of markers present on antigen 
presenting cells (158). 
The cytokine profile of T cells in different clinical groups of subjects with chronic 
allergic eye disease (AKC, VKC, GPC) and normal control subjects was investigated 
by means of in situ hybridization to identify cytokine messenger RNA (mRNA), and 
two-colour immunohistochemical analysis. Allergic tissue expressed increased levels 
of mRNA for IL-3, IL-4, and IL-5 when compared with normal tissue (160). There was 
significantly greater IL-2 mRNA expression in subjects with AKC than in those with 
VKC and GPC. Immunoreactivity for T-cell IL-5 was present more frequently in 
subjects with VKC, AKC and GPC compared to normal conjunctival biopsies (159). 
However, T-cell associated IFNγ protein expression was greater in subjects with 
AKC than in subjects with VKC and normal individuals suggesting a Th2 T-cell 
cytokine array in subjects with VKC and GPC but a shift in cytokine profile toward a 
Th1 pattern, potentially because of differences in chronicity of the disorders, in 
subjects with AKC. These important functional T-cell variations in chronic allergic eye 
conditions are likely to be important in understanding differences in clinical 
characteristics and therapeutic responses (159).  
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T cells infiltrate the conjunctiva in AKC and VKC. The role of the Th1/Th2 paradigm 
was described in previous section. Further to this concept, there is growing evidence 
that other T cell subsets exist which might participate in allergic inflammation but little 
is known about their potential roles in ocular allergic disease. The identification of 
novel T helper cell subsets i.e. Th17,Th9, Th22 and regulatory T cells (Treg) resulted 
into a more detailed insight of the immunopathogenesis of autoimmune diseases and 
immune responses. Furthermore, these developments have led to a new approach 
and revision of the previously described Th1/Th2 paradigm, which provides the basic 
understanding the molecular immunopathogenic mechanisms of disease 
development. Figure 1.13 shows an up to date summary of IL-17 activities (164) 
 
             
 
            Figure 1.13: The effects of IL-17 on various types of cells (164)  
 
IL-17 mRNA was found to be increased in the lungs and serum of asthmatics and 
the levels of IL-17 correlated to disease severity (162). IL-17 leads to epithelial and 
smooth muscle cell activation and potentiates fibroblasts. IL-17 enhances ICAM-1, 
IL-8 levels, G-CSF, CXCL-1 levels by epithelial cells. IL-17 mediated inflammatory 
mediators do not seem to contribute to Th2-mediated eosinophil driven allergic 
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asthma development. Allergic or atopic asthma is considered as a Th2 driven 
disease with accumulation of eosinophils and mast cells. There are further reports 
that support the fact that IL-17 may contribute to the pathogenesis of non-atopic, non 
eosinophilic, neutrophil dominant, non-Th2 driven asthma. To conclude, the main 
effector cytokine produced by Th17 cells is IL-17 which has six members (A-F) and 
is known to induce the production of IL-1β and TNFα which have pro-inflammatory 
roles in the immunopathogenesis of allergic inflammation (162).  
 
There is no published evidence for an important role of IL-17 in ocular allergic 
disease (163). On the contrary it seems that IL-17 plays an important role in 
experimental induced dry eye in mice (EDE) (163). In a recent study using an acute 
form of experimental allergic conjunctivitis - EAC (induced by ragweed pollen in 
Balb/c mice), severity of the disease did not differ in the naïve wild type or the IL-17 
knockout mice suggesting that IL-17 is not important in acute allergic conjunctivitis. 
In the latter model, EAC developed due to increased expression of Th1 and Th2 
cytokines (164).  
 
Unfortunately there are no models of chronic allergic conjunctivitis currently available 
to address the role of different cytokines including IL-17, in chronic forms of 
conjunctivitis. Nevertheless it has been found in other experimental models eg 
experimental autoimmune uveitis, that blocking one or even two cytokines results in 
disease being mediated by other pro-inflammatory cytokines (165) suggesting these 
are compensatory mechanisms and disease can be mediated by several pro-
inflammatory cytokines. In Experimental Dry Eye (EDE) when IL-17 was neutralized 
with anti-IL-17 antibody, the clinical signs were significantly reduced compared to 
controls (166). There is significant evidence that IL-17 contributes to ocular surface 
inflammation and tissue damage in EDE (166,167). The full spectrum of its roles in 
chronic allergic eye disease is yet to be determined. Similarly there is no data to date 
to suggest potential roles of IL-17 in tissue remodelling in ocular allergy.  
 
 
 
 
 
61 
 
1.7 The immunopathogenesis of ocular allergy  
 
1.7.1 T cell roles  
 
Historically it is known that the ratio of Th1/Th2 type cytokines plays an important 
role in the allergic inflammation development. The Th2 cell type, CD4+ T cells and 
Th2 cell cytokines predominate in VKC and these findings have been described 
since 1990s (168-171).  On the contrary Th1 type lymphocytes protect against 
allergic disease by dampening the activity of Th2 by inhibiting the development and 
proliferation of Th2 cells. Additionally, IFNγ a typical Th1 cytokine, inhibits IgE 
synthesis (172-174).  
 
Th2 T-cell lymphocytes are suggested to play a crucial role in the pathogenesis of 
allergic disorders by producing regulatory and pro-inflammatory cytokines (IL-4, IL-5, 
IL-13). Various studies provide evidence that increased levels of activated 
eosinophils are found in the tears and conjunctiva of patients with VKC and AKC and 
release pro-inflammatory and epitheliotoxic mediators after recruitment and 
activation by Th2 cytokines and chemokines (151,175-179). 
 
On the other side the Th1 profile cytokines seem to be participating in AKC 
(168,170,171,180-182) but it is not clear if IFNγ plays a downregulating role or 
participates in the pathogenesis of allergic disease of the conjunctiva (183). IFNγ 
measured in the tears of patients with AKC and VKC was found to be increased in 
those with corneal damage and significantly correlated with the corneal score (183). 
This can suggest that increased expression of IFNγ, a pro-inflammatory cytokine, 
might be related to the development of disease severity of allergic inflammation. 
IFNγ upregulated ICAM-1 expression and production of IL-6, IL-8 (pro-inflammatory 
cytokines) suggesting that IFNγ may play an important role in inflammatory cell 
recruitment, attachment and activation. IFNγ may participate in the active phase of 
the disease of severe ocular allergy and IFNγ secreting cells may participate in the 
perpetuation of chronic inflammation since this cytokine up-regulated the expression 
of adhesion molecules, chemokines and co-stimulatory factors produced by 
conjunctival and corneal epithelial cells.  
 
62 
 
Using the mouse model (Brown Norway rats) it was shown that IFNγ downregulated 
the development of allergic conjunctivitis during the induction phase in the 
experimental model (184). IFNγ may have a downregulatory role in the induction 
phase of experimental conjunctivitis but in another study of experimental 
conjunctivitis in IFNγ knockout mice it promotes its development during the active 
phase (185,186).  
 
Another factor affecting the Th1/Th2 balance is the expression of intracellular 
regulatory signals. The suppressor of cytokines SOCS3 and SOCS5 are expressed 
in Th2 and Th1 cells respectively and reciprocally inhibit the Th1 and Th2 cell 
differentiation. SOCS3 is expressed in the allergic conjunctiva and its inhibition 
reduces the severity of experimental allergic conjunctivitis (183).   
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1.7.2 Pathogenesis of IgE – mediated diseases: seasonal and perennial allergic 
conjunctivitis.  
 
It occurs in sensitized individuals and the major pathogenic mechanism involves a 
type 1 hypersensitivity reaction initiated by allergen causing cross-linkage of the 
membrane bound IgE leading to mast cell degranulation causing the production of 
various cytokines and inflammatory mediators. There are two phases of the Ig-E 
Type 1 reaction: an early immediate phase which occurs minutes after activation and 
is caused by the degranulation of the mast cells releasing mediators as described 
above and a late phase occurring 4-6 hours due to chemoattraction of T cells and 
eosinophils. Histamine is one of the major molecules participating in the early 
development of symptoms. The activation of mast cells leads to the release of 
inflammatory mediators as well as de novo synthesis of cytokines, and eicosanoids. 
This response lasts 20-30 minutes and induces increased tear levels of histamine, 
tryptase, prostaglandins, leukotrienes (151). Phospholipase A2 (PLA2) is important 
in allergic conjunctivitis since it hydrolyses the acyl-ester bond and generates 
arachidonic acid which is then converted to prostaglandins and leukotrienes (187).  
 
In SAC the symptoms occur in spring and autumn whereas in PAC they can occur all 
year round. SAC is more common and associated with pollen. PAC is related to 
animal dander, house dust mite or other allergens present throughout the year. 
Various pro-inflammatory cytokines are present with variable immune-mediated 
effects e.g. TNFα, IL-1β, IFNγ after conjunctival epithelium activation and lead to 
increased production of ICAM-1 and RANTES..  
 
The late phase of conjunctival allergic response occurs a few hours after the first 
mast cell activation. There is infiltration of inflammatory cells eg neutrophils, 
lymphocytes, eosinophils, basophils and an increased expression of adhesion 
molecules eg ICAM-1 and E-selectin. The adhesion molecules are found to be 
downregulated in the conjunctiva of patients with SAC out of season suggesting that 
the epithelium may be capable of self-protection that affects allergic disease 
progression (188).  
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Conjunctival mast cells are tryptase and chymase positive and produce IL-4 which 
promotes T-cell growth, Ig-E production from B-cells, upregulating adhesion 
molecules and regulating Th2 cell differentiation (189). IL-4 also induces eotaxin 
expression from conjunctival fibroblasts and keratocytes but not from the epithelium 
(190). The mast cells and their products participate in the pathogenesis of SAC and 
during the disease their numbers are increased (191).  
 
In PAC there is also a Type I Hypersensitivity reaction but since the allergens are 
present continuously there is a more chronic inflammation. Mast cells are also 
increased in the conjunctiva in patients with PAC (192). Additionally neutrophils, 
eosinophils and T cells are also detected suggesting that other cell mediated 
mechanisms, though not clear to date, are involved. The changes in PAC are more 
pronounced than in SAC since there is prolonged exposure to allergens. In SAC and 
PAC there is no corneal involvement and the inflammation may resolve once the 
allergens are removed.   
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1.7.3 Current understanding of the immunopathogenesis of Atopic and Vernal 
keratoconjunctivitis.  
 
More complex mechanisms are responsible for the development of these chronic 
forms of the disease and there is a persistent T cell infiltrate. In both diseases the T 
cell is considered the primary effector cell. The pathogenesis involves production of 
various cytokines by effector cells whose immunopathogenic roles are still under 
investigation.  
 
Various cytokine profiles and immune cell types lead to inflammatory cell 
participation by production of mediators which in turn promote disease progression. 
The initiating mechanism in the chronic forms of ocular allergic diseases (AKC/VKC) 
is not yet fully understood. The major effector cells in AKC are the mast cells, T cells, 
eosinophils and conjunctival epithelial cells (193,194) and there is a Th1 cell 
response (168). A Th2 response is also contributing but to a lesser degree. The Th1 
component involves a delayed hypersensitivity reaction and cell mediated 
cytotoxicity via a variety of cytokines including IL-2, IFNγ and IL-12. Additionally IL-8 
and RANTES are also expressed in the epithelium leading to T cell, eosinophil and 
neutrophil chemoattraction (194).  
 
However different patterns of T cell cytokines are observed in each disease. In VKC 
there is increased IL-5 and a Th2 cell profile. Eosinophils, fibroblasts and Th2 T 
lymphocytes contribute to this immune mediated allergic response. Th2 T-cells 
produce IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13 and regulate IgE production, and 
induce significant antibody responses and eosinophil activation or differentiation 
(168). The role or the conjunctival epithelium is thought to play an important role in 
the immunopathogenesis of ocular allergic disease.  
 
It has been shown that there are functional variations and differences in the cytokine 
production profile in both T cells and eosinophils in the different forms of chronic 
allergic eye disease, which may determine the development of corneal involvement.  
 
 
66 
 
GPC is histologically similar to AKC and VKC but there is no corneal involvement 
and no known etiology. It is not characterized as a “true” allergic disease as the other 
forms of ocular allergy and is thought to be triggered by persistent mechanical 
irritation (e.g. from the contact lens, ocular prosthetic implant, sutures in contact with 
the conjunctiva) and augmented by associated allergy. It can occur with any type of 
contact lens and the lens coating and trauma to the conjunctiva are probably the 
triggering factors. T cells do not seem to participate in its pathogenesis since T cell 
lines from GPC produced only small amounts of cytokines. Eosinophils are known to 
be involved but eotaxin is not participating significantly in its pathogenesis. 
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1.7.4 Giant papillary conjunctivitis: Non-IgE mediated “allergic” disease  
 
GPC is suggested to be an inflammatory disorder that typically leads to giant papillae 
development on the superior tarsal conjunctiva. There is an immune response 
directed against the protein residues on the lenses rather than the lens polymers or 
lens systems care or bacteria. Interestingly, although the inflammation is similar to 
VKC the recent literature differentiates its pathogenesis from GPC. A continuous 
mechanical stimulus and an abnormal immunological response are mainly 
responsible for this disease (135). Contact lenses, ocular prostheses, exposed 
sutures, elevated corneal deposits and extruded scleral buckles are able to induce 
conjunctival micro-trauma and corneal irritation leading to inflammatory mediators 
release. It is suggested that released IL-8 leads to dendritic cell recruitment and 
enhances antigen presentation to T cells (195,196). Furthermore, altered tear 
clearance leads to conjunctival epithelial changes and concentration of inflammatory 
mediators with antigen adhesion (197). Histological and cytological features may be 
similar with VKC. Mast cells and lymphocytes are increased but eotaxin eosinophil 
recruitment and activation does not seem to have a major role in GPC 
immunopathogenesis (198-200) since eotaxin levels do not seem to be increased in 
GPC patients. Despite the similar histological features with VKC, there are 
differences in the tear profiles. However, IL-6 and MMP-2 were the only two factors 
significantly increased both in VKC and GPC compared to normal tears and it is 
suggested that they may participate in papillae formation (199).  
 
In the conjunctival area of allergic inflammation, using in situ hybridization, it was 
reported an increase in mRNA expression of IL-3 and IL-4 in T cells, reflecting a Th2 
pattern in GPC (159). T cell lines from contact lens induced GPC produce low levels 
of cytokines compared to VKC and AKC (198). Additionally IL-5 was reported to be 
localized to eosinophils in GPC conjunctival biopsies with antigen expression and 
cytokine production in chronic allergic diseases of the eye (154). Another study 
showed that IL-6, IL-8, RANTES and TNFα were expressed in the conjunctival 
epithelium and IL-8, which chemoattracts neutrophils and eosinophils, was increased 
in GPC (160).  
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There are histopathological similarities with VKC (202,203). More specifically the 
conjunctival epithelium appears thickened and irregular overlying the giant papillae 
with invaginations into the stroma. The papillae contain epithelial cells, goblet cells, 
mucus granules, leucocytes, mast cells, lymphocytes, eosinophils, basophils, 
neutrophils and newly formed vessels among fibrosis (200,203-205). Normal 
individuals do not have mast cells in their conjunctival epithelium and the presence 
of these cells as well as eosinophils, basophils in the epithelium or the stroma reflect 
the allergic inflammatory reaction in GPC (206). The reversible nature of this 
condition upon removal of the biomaterials inducing the pathological changes may 
suggest that remodelling is not as severe as seen in VKC, or AKC. No study to date 
investigated the expression of remodelling markers in GPC and compared them to 
the other forms of chronic ocular allergy. 
 
Eosinophil infiltration is pathognomonic for ocular allergic diseases. In previous 
studies eosinophils were detected in the conjunctiva in biopsies from contact lens 
induced GPC (203,204) and ocular prosthesis GPC (204,205).It has been reported 
that there is a significant eosinophil infiltrate in GPC tissues which was even higher 
than VKC or AKC (154). Eosinophils were recruited mainly in the stroma rather than 
the epithelium but there was no correlation between the cellular response of 
cytokines and degree of symptoms (208). T cells were also found to be increased. 
Lymphocytes are found in the normal conjunctiva but reported to be increased (both 
CD4+ and CD8+ T cells) in GPC by means of immunohistochemistry studies 
(154,209). 
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1.8 Classification of Ocular Allergic Diseases  
 
Two major classification systems provide a useful framework to differentiate between 
the various forms of ocular allergic disease. They are based on the clinical features, 
immunopathogenesis and duration of disease. Therefore classification systems can 
be dependent on new evidence and the advances in the understanding of aspects 
that are being looked up meaning that there is a dynamic situation where criteria can 
change. Multiple mediators, cytokines, receptors, growth factors and possibly other 
not yet known processes lead to the development of different clinical signs and 
symptoms and are differently expressed in the various forms of ocular allergy.  
Ocular allergy forms range in severity from mild to severe which may lead to visual 
impairment. In SAC or PAC the cornea is not involved whereas in AKC or VKC there 
is corneal involvement and structural as well as functional conjunctival changes 
related to the inflammatory effects of the cellular and biochemical mechanisms 
involved.  
The European Academy of Asthma, Allergiology and Clinical Immunology 
(EAACI) Classification (210). 
Based on this classification an immunopathological approach is suggested for 
allergic conjunctivitis which divides it into two broad categories: IgE medicated and 
non-IgE mediated conjunctivitis (see later section on pathogenesis for detailed 
description). IgE mediated conjunctivitis can be divided into intermittent and 
persistent allergic conjunctivitis and persistent allergic conjunctivitis into AKC and 
VKC. This system has some limitations: GPC is a non-IgE mediated form of ocular 
allergy and does share some common features with VKC.  However, this 
classification system does not consider all types of allergy.  
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The International Ocular Inflammation Society (IOIS) Classification 2006 (211).  
This is more comprehensive approach and proposed that allergic conjunctivitis refers 
to a collection of hypersensitivity disorders that affect the lid, conjunctiva and/or 
cornea. More specifically, it proposes that allergic conjunctivitis is non- infectious 
immune mediated and can be IgE or non-IgE mediated. Various forms are included 
based on the traditional classification of ocular allergy: SAC, PAC, VKC, AKC, GPC 
and drug-induced dermatoconjunctivitis. The external eye represents an ideal site of 
immediate hypersensitivity reactions because of the high number of mast cells in the 
conjunctiva and the potential for local IgE production. The diseases range in severity 
from mild to severe forms and all can potentially interfere with the quality of life and 
lead to visual impairment.  
In the 1980s it was initially thought that all types (SAC, PAC, VKC and AKC) are IgE 
medicated. A grading system for VKC was proposed in 2007 and suggested 
treatment options for each grade based on clinical signs and symptoms of ocular 
surface inflammation. This study was the first to describe a new grading system of 
vernal keratoconjunctivitis that may help clinicians and researchers to classify 
disease activity and to establish a common agreement for treatments (212). Similarly 
a grading system for AKC was also proposed that was based on clinical severity 
taking into account symptoms and signs (213). An overview of the classification is 
shown in Table 1.4. This thesis will attempt to make new suggestions based on the 
results in chapters 3 and 4 and enhance our understanding of the 
immunopathogenesis of the severe forms of ocular allergy and the possible role of 
growth factors and epithelial remodelling in disease re-classification.  
 
 IgE MEDIATED IgE and 
non-IgE 
MEDIATED 
Non-IgE MEDIATED 
INTERMITTENT       
   
 
 
PERSISTENT         GPG 
    
CHRONIC      CDC 
 
         Table 1.4: Types of Ocular Allergic disease and their classification (132). 
71 
 
1.9. Clinical Characteristics and forms of ocular allergy  
 
1.9.1 Seasonal and Perennial Allergic conjunctivitis  
 
SAC is the most common allergic ocular condition and is usually caused by pollen 
and the symptomatology is limited to the season (commonest in spring and autumn). 
The classic symptom of allergy is itching. Vasodilation leads to an erythematous 
appearance and chemosis may be present (Figure 1.14). The vasodilation is more 
superficial and pink rather than deeper and red. The chemosis may be subtle and 
thus only visible on slit lamp examination. The lids may also be swollen which peaks 
at 15-30 minutes after exposure and dissipates slowly (10).  
 
There may be eyelid swelling and it could be transient. The intensity of the 
symptoms is proportionate of the allergen exposure. Clinical history may include 
atopy, allergic rhinitis and asthma. Allergens drain to the nose and may contribute to 
nasal involvement. Evidence for this eye to nose drainage pathway is described in 
the conjunctival allergen challenge model (10,214-215). This is also confirmed by the 
reduction of nasal symptoms after instillation of ocular therapy (214,215). These 
disorders may resolve either spontaneously upon removal of the allergen or due to 
treatment. They are self-limiting and not associated with corneal involvement or 
visual impairment. PAC is caused by more persistent allergens such as cat dander 
and dust mites leading to a more chronic form of inflammation. The symptoms are 
similar to SAC and have a significant effect on the patient’s quality of life, health and 
comfort.   
                                    
    Figure 1.14: Seasonal allergic conjunctivitis with chemosis (arrow) (216).  
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1.9.2. Vernal Keratoconjunctivitis  
 
VKC is a chronic allergic disease with seasonal exacerbations and characterized by 
severe itching, tearing, mucous secretions, foreign body sensation and photophobia. 
(10,217,218).This is a rarer (less than 1% affected) sight threatening disease in 
patient with an atopic history and an onset before the age of 10 years (218-220). It 
can resolve during puberty and can last for up to 10 years although in some cases it 
may still be present in adult age (10,217,218,221).  
 
Usually it affects young males in dry warm climates e.g. Mediterranean countries, 
West Africa. 75% of patients have a family history of atopy and patients can have a 
significant history of atopic diseases e.g. eczema, asthma. Clinical features may be 
asymmetrical and not always bilateral and include superior cobblestone papillae 
(Figure 1.15), limbal gelatinous nodules, Trantas limbal dots and a Shield ulcer. 
There could be corneal involvement from superficial punctate keratitis to ulceration 
and shield formation leading to scarring and visual impairment (10,221,222). Other 
features may include keratoconus, astigmatism, neovascularization and steroid 
induced complications such as cataract and glaucoma (10,222). There a chronic low-
level inflammation all year round with a seasonal worsening. The intervals between 
intense symptoms’ periods and symptom-free periods are variable which makes the 
management of the disease challenging and needs adjustment in each patient 
individually.  
 
                                   
                                 Figure 1.15: Giant papillae in VKC (223) 
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The clinical diagnosis of VKC is based on history and clinical examination. Important 
points in history include: (1) the age of the patient, (2) positive atopic family history, 
(3) association with allergic conditions in the present and the past. It rarely presents 
before the 3rd year or after the 25th year of life. It was observed that the mean age of 
the patients was 11+/- 6 years (range 2-32) (218). Positive family atopic history was 
present in 48.7% with asthma being the most common atopic disease present.  VKC 
was the only manifestation in 58% (218). 
 
Negative prognostic clinical factors include: (1) the size of giant papillae which are 
related to the persistence of the disease or worsening of symptoms in the long-term 
period. (2) the bulbar form of the disease which is worse long-term than the tarsal 
form (224). Corneal ulcers appear in 10% of cases and steroid induced cataract and 
glaucoma in 2% (224). The reasons for mysterious spontaneous resolution of the 
disease after puberty are still not fully understood but it is thought that hormonal 
changes may play a role.  
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1.9.3. Atopic keratoconjunctivitis  
 
This form of chronic ocular allergic disease affects usually males and females aged 
30-50 years. There could be a family history of allergy, asthma, atopy, eczema, 
urticaria. Typically patients have atopy and either atopic dermatitis or asthma. 3% of 
the population has atopic dermatitis and approximately 15-40% of those will develop 
ocular disease. Symptoms include bilateral severe itching, tearing, burning and 
photophobia. Currently there is no agreement about the diagnostic criteria for AKC. 
Unlike VKC, AKC is bilateral and symmetrical.  
 
Eyelids can be involved and may be swollen with a scaly appearance and patients 
may suffer from lid eczema. Blepharitis, meibomian gland dysfunction and dry eyes 
may also be present (atopic blepharoconjunctivitis) leading to a thickened lid margin. 
The conjunctiva is hyperaemic and chemotic with tarsal conjunctival papillae seen 
usually in the early years of the disease. Later in the course of the disease the 
papillae may be replaced by sheet scarring with or without shortening of the fornices. 
Gelatinous nodules may be present with or without Trantas dots which occur usually 
during exacerbations due to limbal tissue hypertrophy. Corneal involvement in the 
form of filamentary keratitis and punctate erosions may progress to frank corneal 
erosions and Shield ulcer with a mucous plaque development within 24 hours. These 
changes may lead to scarring, corneal thinning, corneal vascularization, perforation 
and sight impairment. Atopic keratoconus and cataract can also be seen in these 
patients. Posterior subcapsular cataract and glaucoma may also develop secondarily 
to the prolonged steroid use. S. aureus may complicate further the picture causing 
bacterial conjunctivitis and keratitis as well as herpes simplex virus making difficult to 
differentiate between acute herpetic and acute atopic disease causing a corneal 
plaque.  
 
As mentioned above there is no agreed definition for AKC to date. There have been 
attempts but either did not take into account that patients may not suffer from atopic 
dermatitis but be positive for other atopic diseases or ignore the corneal involvement. 
A recent proposal attempted to define the disease is as follows:  
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“A chronic ocular surface noninfectious inflammatory condition with the following 
features:  
(1) Always associated with atopic conditions (typically atopic dermatitis, 
periocular eczema, or asthma) 
(2) Occurring at any time point in the course of the associated atopic disease and 
independent of its degree of severity  
(3) With evidence of corneal involvement at some time in the course of the 
disease”. (225) 
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1.9.4 Giant papillary conjunctivitis  
 
GPC is a chronic hypersensitivity inflammation of the conjunctiva with the formation 
of giant papillae (> 0.3 mm) on the tarsal conjunctiva due to mechanical trauma in 
the presence of predisposition to allergy (Figure 1.16). More specifically it is 
associated with contact lenses, ocular prosthetic implants, scleral buckles or sutures 
in contact with the conjunctiva. Prolonged contact lens wear eg patients who sleep 
with disposable lenses are three times more likely to develop GPC. Clinical features 
include, itching, tearing, mucous secretions, foreign body sensation, lens intolerance 
which may necessitate discontinuation and blurred vision. The disease can occur 
with any type of contact lens material. In contrast to VKC and AKC, the disease is 
completely reversible upon removal of the foreign body and the cornea is not 
affected.  
 
                              
 
           Figure 1.16: Upper tarsal conjunctival giant papillae in GPC (10).  
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1.9.5 Treatment strategies in Ocular allergy  
 
Initially, patients are advised to avoid allergen exposure. They can also be advised 
that cold compresses may be helpful in symptom relief and the use of lubricants may 
help in diluting the allergens-antigens in the ocular surface. Topical antihistamines 
such as pheniramine (first generation) are available over the counter combined with 
vasoconstrictors. Second generation selective H1 antagonists such as levocabastine 
are more effective and shown to reduce itching in SAC and PAC but their benefits 
are short term (226).Systemic antihistamines are commonly used to control allergic 
rhinoconjunctivitis but also in more severe cases such as AKC and VKC, as an 
adjuvant therapy to anti-inflammatories. Mast cell stabilizers (sodium chromoglycate, 
lodoxamide) have an unclear mechanism of action but lead to decreased histamine 
degranulation. Therefore they may need a few days before their effect takes place 
and they can be combined with other drugs if an immediate symptomatic relief is 
required. Dual-acting agents combine mast cell stabilizers and antihistamines and 
form the first-line drug for many patients.  
 
Non-steroidal Anti-inflammatory drugs such as ketorolac can be used to alleviate 
ocular pruritus but is not as effective as antihistamines (226). Topical steroids are 
very effective but may cause significant side effects such as cataract and raised 
intraocular pressure. Therefore it is recommended that topical steroids are used in 
short term periods during acute flare-ups. Preservative free dexamethasone 0.1% or 
prednisolone 1% are preferred and are equally potent. Fluorometholone has poor 
intraocular penetration and is therefore is a good option for ocular surface 
inflammatory disease but is less efficacious. Steroid superior tarsal injections can be 
also used in cases with corneal or limbal involvement not responding conventional 
therapy. Giant papillary conjunctivitis can resolve upon removal of the biomaterial 
and symptomatic control can be achieved with artificial tears and control of the 
inflammatory response with topical steroids.  
 
Topical cyclosporine A (2%) has been shown to be effective in the management of 
AKC and VKC (227) especially as a steroid sparing agent to prevent their long term 
use side effects. it was recommended that the minimum dose for the management of 
shield ulcers is 1% (227). Because T cells are central in the pathogenesis of these 
78 
 
diseases, as described above, use of topical cyclosporin A can offer beneficial 
effects with important changes in the conjunctival immune cell profile. The in vitro 
effects of cyclosporine A translate into a reduction of T cells and decrease of T cell 
activation as well as T cell cytokine expression (228). This is described in greater 
detail in the following section on the role of the epithelium in allergic eye disease. 
There are also a small number of papers advocating the oral administration of 
cyclosporin A in severe AKC (229).  
 
Finally, surgical options include excision or cryotherapy of giant papillae may help in 
resolution of epitheliopathy or corneal ulcer but papillae can regrow. Surgical 
debridement of the ulcer may be required if resistant to medical treatment and 
amniotic membrane transplantation is an option in the case of persistent epithelial 
defects. In steroid induced glaucoma the patient may require trabeculectomy 
surgery.  
 
Once remodelling is established with permanent tissue structural, functional 
changes, disease perpetuation and exacerbations, achieving disease control is 
harder. Similar observations are seen in chronic asthma. As explained before a re-
classification of ocular allergic disease and consensus are required based on the 
clinical signs to decide therapy. Proactive management is often advised before 
seasonal exacerbations with environmental modifications and systemic medications. 
Therefore the need of new therapeutic strategies aiming to offer better symptomatic 
relief and arrest of the remodelling changes at the molecular and cellular level, are 
suggested as new therapeutic options to explore.  
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1.9.6 Chronic “autoimmune” conjunctival inflammatory disease: ocular 
cicatricial pemphigoid 
 
Ocular cicatricial pemphigoid (OCP) (now referred to as ocular mucus membrane 
pemphigoid) is a systemic autoimmune vesiculobullous disease directed against 
mucosal basement membrane, affecting mucous membranes, oro-pharyngeal 
mucosa (85% of cases), the skin (25% of cases) and the conjunctiva (65% of cases) 
(230). Vesiculobullous eruptions occur with a chronic course and acute inflammatory 
episodes. The lesions heal with scarring and the mucosal inflammation leads to 
cicatrisation. Chronic progressive inflammation of the conjunctiva leads to 
subepithelial fibrosis, symblepharon, lid abnormalities, sicca syndrome and 
districhiasis. Corneal involvement may occur from direct epithelial damage and 
abnormal tear film production. The conjunctiva shortens due to fibrosis following 
episodes of inflammation. In OCP, most patients have a progressive form of bilateral 
conjunctival disease and some may develop blindness within months from disease 
onset.  
 
The autoimmune nature of OCP involves immunoglobulins and complement at the 
conjunctival basement membrane, autoantibodies in serum, T cell cytokine 
dysregulation and response to immunosuppression. OCP is probably an 
autoimmune disease (“autoimmune conjunctivitis”) with a chronic progression and 
can lead to blindness. Its severe chronic nature with fibrosis and corneal involvement 
may suggest that remodelling plays a role in its pathogenesis. Approximately 75% of 
patients require systemic immunosuppression (231) and 45% require continuing 
systemic treatment to avoid reactivations (232). Most patients present during the 
fibrotic stage of the disease and cicatrisation may progress despite 
immunosuppressive treatment (233). Various immunosuppressants are used 
including mycophenolate mofetil which seems to be effective and well tolerated for 
moderately active OCP (230). Others used include, dapsone, azathioprine, 
methotrexate and cyclophosphamide with prednisolone. Over the last decade 
significant advances have been aiming to improve our understanding of the 
pathological mechanisms involved in the fibrosis in pemphigoid disease affecting 
various tissues. However the conjunctival fibrosis in OCP has not been studied in 
similar depth yet.   
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1.10 Summary  
 
Allergic ocular disease is common with increasing prevalence and affects more than 
ten million patients in the UK. The spectrum of ocular allergy spans across the mild 
and reversible forms to the other end of irreversible and chronic sight-threatening 
diseases. The conjunctival mucosal membrane plays a crucial role in the 
immunopathology of ocular allergy and it has been proposed that its structural and 
functional alterations in allergic disease may contribute to disease severity and 
progression. Although previously the majority of research work was based on the 
fibroblast and subepithelial areas of the conjunctiva, recently there has been more 
attention drawn to the roles of the epithelium.  
Over the last 8 years there has been more progress in understanding the 
immunopathogenesis and clinical behaviour of allergic eye disease based on direct 
clinical evaluation, histological assessment and in vitro studies. It has been 
suggested that IgE hypersensitivity, cytokines and T cells on their own may not be 
enough to account for disease severity and perpetuation. Other local factors have 
been thought to co-participate such as remodelling of the conjunctival tissue. 
Remodelling of the epithelial cells leads to permanent changes in the local 
cytological architecture and functional deficiencies. VKC has been the form of ocular 
allergic disease mostly studied. Drs Leonardi and Bonini from Italy, have 
demonstrated that remodelling markers can be overexpressed in VKC and have 
attempted to produce diagnostic and treatment recommendations for this disease. 
Similarly Dr Calogne’s team in Spain suggested a grading system for AKC. However, 
the need of a general consensus for an improved classification system of ocular 
allergy, based on clinical signs and therapeutic decisions, remains a major task to be 
achieved.  
So far there is published work that investigated the distribution of collagens and 
growth factors mainly in VKC but no reason has been proposed as to why this 
occurs making AKC and VKC different to the other forms. An important claim of this 
study is that remodelling constitutes an important immunopathological feature that 
distinguishes the reversible from the persistent and chronic forms of allergic 
conjunctivitis. 
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 In addition no much is known about the role of remodelling in the immunopathology 
of GPC. There is no study to date to compare the detection of epithelial remodelling 
markers in GPC and the other chronic or persistent forms of allergic conjunctivitis.  
The presence of eosinophils and T cells in the conjunctival tissue, as seen in VKC 
and AKC, in biopsies of patients with GPC may suggest that remodelling molecules 
may be detected. Given the reversible nature of the condition one could expect that 
the expression of remodelling molecules, if any, would not be at the levels seen in 
the severe forms of ocular allergy.  
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1.11 Aims and Hypothesis 
 
The conjunctiva being a mucosal membrane shares many common features with the 
respiratory tract where the mucosa is also directly exposed to environmental factors.  
Based on the recent epithelial-mesenchymal trophic unit hypothesis in asthma it is 
suggested that a similar hypothesis may be applied in the chronic forms of ocular 
allergy. The central aim of this thesis is to investigate potential candidate remodelling 
epithelial molecules of the conjunctiva, involved in the EMTU hypothesis, in 
reversible and irreversible forms of ocular allergy.  
 
Chronic inflammation is a feature of chronic or persistent ocular allergic disease but 
can also be seen in other disease such as ocular cicatricial pemphigoid, also known 
as “autoimmune conjunctivitis”. Therefore the following question is set: Can epithelial 
remodelling markers of the EMTU hypothesis be detected in other forms of chronic 
conjunctival inflammation of immunological origin? The line of argumentation hinges 
on the claim that the EMTU hypothesis may be applied to chronic mucosal 
inflammatory epitheliopathy of allergic immunopathological nature rather than 
autoimmune as seen in OCP. 
 
As seen in chronic asthma, Th1 and Th2 cytokine participation is not enough to 
account for disease severity. It is thus hypothesised that increased conjunctival 
epithelial growth factors related to remodelling contribute to abnormal epithelial 
repair in the chronic forms of disease as opposed to reversible forms without corneal 
involvement. The methodology in Chapter 2 of the thesis consists of an initial 
investigation to look for evidence of remodelling markers associated to the EMTU 
hypothesis in conjunctival tissues from patients with ocular allergy, and further in 
vitro experiments to explore the behavior of the conjunctival epithelial cells under 
inflammatory conditions in relation to those remodelling markers.  Employing 
immunohistochemistry, in vitro cell line cultures, cell viability assessments and 
ELISA assays, my studies were designed to investigate the following:  
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1)  The expression patterns of EGFR, its ligand TGFα, and CD44 in chronic forms of 
ocular allergic disease (AKC/VKC) compared to reversible forms of ocular allergy 
(SAC/GPC and normal non-inflamed subjects) by means of immunohistochemistry.  
2) The detection, if any, of EMTU associated molecules in other types of chronic 
inflammatory conjunctival disease. To address this, conjunctival biopsies of chronic 
uninflamed and actively inflamed ocular cicatricial pemphigoid are used. 
3) The in vitro secretion of EGFR, TGFα, sCD44, p21waf and VEGF-A by conjunctival 
epithelial cells in response to treatment with various cytokines. It is aimed that 
human conjunctival epithelial cell lines can be used to develop an in vitro model of 
epithelial remodelling molecules in ocular inflammation.  
4)  T cells are known to participate in the immunopathogenesis of chronic ocular 
allergic disease and given the recent identification of the new subset of Th response 
Th-17, and the suggested role of IL-17E (or IL-25) in remodelling in asthma, this 
thesis will also investigate the effect of IL-17A and IL-25 on remodelling conjunctival 
epithelial markers.  
5) Finally, an attempt is made to apply the results of the study aiming to enhance our 
understanding of the immunopathogenesis, classification and new therapeutic 
strategies of ocular allergic disease.  
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CHAPTER 2 
 
 
 
MATERIALS & TECHNIQUES 
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2.1  Conjunctival biopsies  
 
Conjunctival biopsy tissue sections used throughout this study were obtained from 
our Tissue Bank, as part of our immunological studies in conjunctival allergic 
mechanisms.  
 
2.1.1. Biopsy of non-inflamed subjects 
 
The conjunctival biopsy specimens were originally harvested prior to the 
commencement of cataract or strabismus surgery from non-atopic individuals, non-
age matched. Patients undergoing elective surgery were asked to participate in the 
study and if fulfilling any of the following criteria were excluded (Research & 
Development Ethics Approval Reference number: LIGS1012, M Hingorani’s MD 
Thesis, University of London, 2000): 
 
1. Age <18 years 
2. External eye disease 
3. Concurrent systemic treatment that may influence the immunological 
response (e.g. leukemia, steroids)  
4. Concurrent topical ocular treatment (steroids within 1 month)  
5. AIDS/ Hepatitis B.  
 
2.1.2 SAC biopsies.  
 
The specimens were originally harvested prior to the commencement of a 
randomized trial and sections prepared for immune studies. For the SAC group, two 
biopsies were included in the group of controls. The SAC patients were challenged 
with allergen 24 hours before biopsy procedure. Timothy plus rye grass combination 
was used and a reported positive response was documented prior inclusion. Patients 
with a history of SAC were challenged as part of a phase II clinical trial (Reference 
number CAT-213-0203) and were all consented to donate tissue biopsies with Ethics 
approval.  
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2.1.3 Biopsies of patients with GPC, VKC, AKC: 
 
Conjunctival biopsies were obtained by consented patients according to the 
regulations of the Research and Ethics Committee of Moorfields Eye Hospital 
(Research & Development Reference Number LIGS1012). They were subsequently 
stored -80oC and used exclusively for research purposes.  
 
Patients with active disease and symptoms were recruited from the External eye 
disease clinics of Moorfields Eye Hospital and any of the following features excluded 
them from the study (M Hingorani’s MD thesis, University of London, 2000): 
  
1. Age <18 years, except in the case of VKC giant papillae between 11-18 which 
might have been biopsied with the child’s and parents’ informed consent.  
2. Other external eye diseases  
3. Concurrent topical ocular therapy (steroids within 4 weeks prior to biopsy and 
sodium chromoglycate within 7 days prior to biopsy)  
4. Concurrent systemic disease or therapy that might have influenced the 
immunological response (e.g. leukemia or steroids)  
5. AIDS/Hepatitis B.  
 
The diagnoses were made clinically and all AKC patients also suffered from atopic 
dermatitis. All AKC and VKC patients had current or previous corneal involvement. 
The age of the VKC patients was higher than expected since ethical approval of this 
study required patients to be over 16 years old.  
 
 
2.1.4   Biopsies from OCP patients.  
 
Initially approval by Research and Ethics Committee of Moorfields Eye Hospital was 
obtained (Reference number 05/Q1604/126) and patients with chronic uninflamed 
OCP, actively inflamed OCP and nomal uninflamed subjects were consented to 
donate conjunctival biopsies for research purposes (Dr V Saw PhD Thesis, 
University of London, 2009).  
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2.1.5 Antibody optimization studies  
 
Initially preliminary immunohistochemistry studies took place to determine suitable 
antibody concentrations for the study for EGFR, its ligand TGFα and CD44 acting as 
a positive control. Initially sections of tissue were selected for the purpose of titrating 
each antibody, to determine the optimal dilution for staining. The final dilution 
selected was then used throughout the study. Optimal conditions and dilutions of all 
antibodies were determined in the initial experiments with various dilutions and 
variable antibody incubation times.  
 
Cytokeratin18 antibody, a known epithelial cell marker, was used with the antibodies 
under investigation for overnight double staining immunohistochemistry under 
various antibody dilutions to assess similarities and differences in the cell expression 
and distribution. Cytokeratins (CKs) are a heterogeneous class of approximately 30 
structurally related polypeptides that comprise the intermediate filament system 
characteristic of epithelial cells. The expression of cytokeratins in the normal human 
conjunctiva has been investigated (228). Cytokeratin 18 is known to be detected in 
epithelia and has been chosen for this preliminary study in an attempt to localise the 
conjunctival epithelium and assess if the remodelling epithelial markers can be co-
expressed in similar epithelial regions of the tissue (228). 
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Initially random biopsies from different subjects from the controls and the CAED 
groups were selected, stained and analysed for various antibody concentrations and 
graded by a masked observer. Single antibody overnight staining was used for the 
following antibodies shown in Table 2.1 (for results see chapter 3).  
 
 
 
 
 
 
 
 
Table 2.1: Antibodies used for optimization study  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Monoclonal mouse, anti human TGFα Clone MF9+TG86  Abcam, UK 
Monoclonal mouse, anti human CD44 Clone DF1485 Dako, Denmark 
Monoclonal mouse, anti human EGFR Clone E30 Dako, Denmark  
Monoclonal mouse, anti human 
Cytokeratin 18 
Clone CY-90 Sigma, USA.  
Monoclonal goat Control IgG  R&D systems, UK.  
Polyclonal Rabbit  F(ab)2 (1:200)  Dako, Denmark  
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2.1.6 Ocular allergy and OCP groups participating in study  
 
As described above, conjunctival biopsy specimens from a tissue bank maintained at 
the Institute of Ophthalmology were obtained from normal conjunctival tissue, 
seasonal allergic conjunctivitis (SAC), Giant papillary conjunctivitis (GPC), vernal 
and atopic keratoconjunctivitis (VKC, AKC) were divided into 2 groups. VKC and 
AKC are severe and chronic forms of ocular allergy that may involve the cornea 
whereas SAC and GPC not.  
 
Controls group: consisting of normal non-inflammatory subjects (n =6) GPC (n=3), 
SAC (n=2) biopsies. All patients had active disease without corneal involvement. 
GPC and SAC are reversible forms of ocular allergy.  
 
Chronic Allergic Eye Disease Group (CAED): severe and chronic disease group 
consisting of VKC biopsies (n=4) and AKC (n=4) biopsies (total n=8).  
 
Ocular Cicatricial Pemphigoid (OCP) Biopsies:  
Group1:  chronic uninflammed (n=6) 
Group 2:  active inflammation (n=9) 
Group 3:  normal conjunctival biopsies (n=7)  
 
Details of all ocular allergy and OCP patients who participated in the study can be 
found in Appendix 1 and the final antibody dilutions used in the study are shown 
below in Table 2.2:  
 
Table 2.2: Final antibody dilutions in the study.  
 
 
Monoclonal mouse, anti human TGFα Clone MF9+TG86, Abcam, UK 1:100 
Monoclonal mouse, anti human CD44 Clone DF1485,  Dako, Denmark 1:200 
Monoclonal mouse, anti human EGFR Clone E30, Dako, Denmark  1:200 
Monoclonal goat Control IgG R&D systems, UK 1:100 
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2.1.7 Immunohistochemistry principles and techniques  
 
Immunoperoxidase procedures allow visualization of cell components in frozen 
tissue sections. These methods involve the use of antibodies and the enzyme 
peroxidase and utilize an enzyme-substrate reaction to convert colourless 
chromogens into coloured products. A commonly used enzyme is horseradish 
peroxidase (HRP) which is small in size and does not interfere with the blinding of 
antibodies to adjacent sites. It forms a complex with the substrate hydrogen peroxide 
(H2O2) which then oxidizes an electron donor to produce the end product of the 
reaction which is a coloured molecule and water. 3 amino-9-ehtylcarbazole (AEC) is 
a chromogen or electron donor which can be oxidized to become coloured end 
product (forms a red product upon oxidation). The end product is alcohol soluble and 
therefore must not be stored immersed in alcoholic solutions. Instead an aqueous 
counterstain and mounting medium are used.  
 
The staining method utilizes an avidin or streptavidin biotin-peroxidase complex 
(ABC method) which is a more sensitive method than the direct, indirect and 
PAP/APAAP procedures. The ABC technique utilizes the high affinity avidin 
glycoprotein to the vitamin biotin where a complex of peroxidase conjugated biotin 
and avidin is formed. The free sites of the avidin molecule allow binding to biotin 
present on a secondary biotinylated antibody which links the complex to the primary 
antigen-specific antibody.The biotinylated antibody does not have to be added in 
excess since free F(ab)' sites are not required for binding. The strong affinity of 
avidin and streptavidin for biotin and a mild biotinylation process of the secondary 
antibody make these methods more sensitive. 
 
Background staining is a common problem in immunohistochemistry. The 
commonest reason is the nonspecific linking of the antibody to collagen of the 
connective tissue. In order to avoid this problem, an innocuous protein (non-immune 
serum from the same animal species) is added before applying the antibody. 
Additionally endogenous peroxidase present in the specimens may also contribute to 
background staining. A common method to suppress peroxidase activity is section 
incubation in 3% H2O2 or a mixture of sodium azide and H2O2. Finally the liability of 
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Fc receptor proteins present on macrophages and granulocytes may also contribute 
to non- specific staining. The use of F(ab)2 fragments may help avoid this problem.  
 
2.1.8 Preparation of Biopsies 
 
Specimens were previously obtained from the upper tarsal conjunctiva anaesthetized 
with amethocaine 1% and lignocaine 2% with adrenaline. A 3 mm trephine was used 
to obtain a sample from the central third of the upper tarsal conjunctiva which is the 
site of maximal inflammatory involvement (168). Where giant papillae were present 
one or occasionally two were shaved from the surface instead. In addition a small 
snip of bulbar conjunctiva was taken from the superior fornix.  
 
The specimens were immediately placed in the ice-cooled acetone containing 
protease inhibitors iodoacetamide (20mM) and phenylmethylsulfonylfluoride (2mM) 
and stored overnight at -20oC. The specimens were then processed for and 
embedded in glycerol methacrylate resin.  
 
Cleaned slides were placed into racks and immersed into a freshly prepared solution 
2% of APES (3-amino propyl tri-ethoxy silane) adhesive in 99% industrial methylated 
spirit for 10 seconds. This was followed by a wash in 99% methylated spirit and 
distilled water for 5 minutes each. Then the slides were left to dry overnight at 37C.  
 
6  m thick sections were cut using a cryostat (600 Cryotome, Angla Scientific) at       
-20  C. Correct orientation was ensured using 0.1  toluidine blue-immersed sections 
checked under a light microscope and re-orientated if required. Correctly orientated 
sections were cut and left to air-dry at room temperature for 1-2 hours before storage 
at -20C for immunohistochemistry studies.  
 
Plastic embedding media (epoxy resins and methacrylate) provide an attractive 
alternative to frozen and paraffin-embedded tissue sections. The epoxy resins 
polymerise evenly and preserve structure details but interact with tissue during this 
polymerization process and are therefore not suitable for immunohistochemistry 
studies. Methacrylates do not polymerise with the tissue and prevent alterations of 
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the antigens. Therefore they are more suitable for immunohistochemistry studies but 
may cause shrinkage of the tissue specimen and poor morphology.  
 
Prefixation of biopsies was carried out in acetone plus protease inhibitors since it 
was thought that mucosal biopsies contain proteolytic enzymes which may lead to 
tissue digestion according to the ModAMex method (modified cold acetone fixation 
with subsequent methylbenzoate and xylene treatment) 
 
2.1.9 Single antibody Immunohistochemistry  
 
An ultramicrotome was used to cut 2 µm sections which were acetone fixed for 20 
minutes and allowed to air dry. Peroxidase block was added for 10 mins and then 
rinsed in PBS 0.05% 3 times. Foetal Calf Serum (FCS) 10% 150 µl was added for 
each group for 30 minutes and then wiped out without rinsing. This was followed by 
addition of 150 µl of antibody in the concentrations stated above. Following addition 
of the antibodies slides were incubated in humidified chamber in room temperature 
overnight.  
 
The slides were washed 3 times for 5 mins each with PBS. F(ab)2 biotin (diluted 
1:200 in PBS) was added in each slide and was incubated for 2 hours in room 
temperature. Furthermore the slides were rinsed in PBS 3 times for 5 minutes each. 
SA peroxidase diluted 1:300 in PBS was added to the sections and incubated for 2 
hours in room temperature and PBS rinsed as described in the step above and 
further developed for 25 mins with 50 µl amino ethyl carbazole (AEC).  
Following this, the sections were rinsed with H2O in running tap for 5 minutes. For 
cell counts and background staining of the tissue, the slides were put through into 
Mayer’s haematoxylin for 1 minute and then rinsed with tap water running through 
the blue. The slides were then covered and mount in glycergel. After 
immunohistochemistry the cells staining positively for the antibody identification 
markers were identified by a red deposition of the AEC reaction product.  
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2.1.10 Immunostaining: grading and analysis  
 
Microscopy examination and quantitative grading assessment was carried out with 
four x40 adjacent fields per section per antibody which were examined by a masked 
observer to include both epithelial layer and stroma with an MOTIC BA400 
microscope. The intensity of the antibody uptake was graded for each field which 
was scored separately for the epithelium and the stroma. Then an average score 
was taken for the four fields of each section for the epithelium and stroma and finally 
the scores were grouped for each antibody and disease group.  
 
In order to quantify staining a simple scoring system was used as illustrated in Table 
2.3 below as used in similar studies (127,128). Dot plots of the data were developed 
and were analyzed using Mann-Whitney U-test (two-tailed) non-parametric statistical 
analysis to compare the grading scales. A p value <0.001 was taken as highly 
statistically significant. Examples of the degree of staining expected for each score 
are shown below using randomized conjunctival biopsies and shown overleaf in 
Figures 2.1-2.4. The localization of the staining was also recorded, either within the 
epithelium or the stromal areas in each section.  Where a small cluster or isolated 
cells expressed the antibody, this was graded as 0.5+. 
 
 
Score Antibody detection grade 
0 no staining 
1+ mild uptake (few cells positive per field) 
2+ moderate uptake (pink uniform staining) 
3+ intense uptake (intense red uniform staining)  
 
                      Table 2.3: Grading system for biopsy sections 
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Figure 2.1: Negative control showing background staining of the epithelium.  
 
Figure 2.2: Example of epithelial mild (1+) antibody staining (arrow). 
 
Figure 2.3 Example of epithelial moderate (2+) of antibody staining. 
 
Figure 2.4: Example of epithelial intense (3+) antibody staining.  
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2.2 In vitro studies 
 
2.2.1 Conjunctival Epithelial cell lines  
Two different human conjunctival epithelial cell line cultures were used to develop an 
in vitro model to investigate the secretion profiles of EGFR, VEGF-A and sCD44 
secondary to treatment with various cytokines. IOBA-NHC (kindly donated by M 
Calonge from IOBA, University of Valladolid, Spain) and Wong-Kilbourne derivative 
of Chang conjunctiva ChWK (clone 1-5c-4 ECACC, Idminton, UK) were cultured as 
described below and assayed in various stimulatory conditions. The culture 
techniques were as previously described (189,228,229). 
These two cell lines were selected because they are the only two non-transfected 
cell lines and have been previously used to investigate the effects of preservatives, 
toxicity, allergic and cytokine responses (189, 230-236). Both cell lines share 
important morphological and functional characteristics compared to primary human 
conjunctival epithelial cells. To our knowledge no comparison or in vitro model of 
remodelling factors of both IOBA-NHC and CHwK has been performed. Therefore 
the purpose of this experiment is to determine whether both cell lines are suitable.  
 
2.2.1.1 In vitro culture of IOBA-NHC line  
Cell line cells were taken from frozen stock (maintained in liquid nitrogen) and 
incubated a 37  C, 5  CO2 in 5 ml medium with DMEM Nutrient mixture F-12 HAM 
(Sigma-Aldrich) with 10% heat inactivated foetal calf serum FCS (Bio Sera, UK), 
100U/ml Penicillin/streptomycin (Invitrogen UK), 2ng/ml mouse EGF (Sigma), 1µg/ml 
bovine insulin (Sigma-Aldrich), hydrocortisone (5 µg/ml) and 0.1µg/ml cholera toxin 
(Sigma-Aldrich) in a 25 cm2 tissue culture flask.  
Cells were plated in 24-well plates and grown until confluent (24-48 hours). Prior to 
assay, they were maintained for 24 hours in serum-free non-supplemented medium 
to rest. When confluence was reached cells were transferred to a 25 cm2 flask in 
10ml IOBA medium and incubated at 37  C, 5% CO2. Cells were split and fed when 
monolayers reached 70-80% confluency.  
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Furthermore cells were detached with trypsin-EDTA (Invitrogen) and incubated at 
37  C, 5  CO2 for 3 minutes and then centrifuged at 400rcf for 10 minutes. Detached 
cells were re-suspended and added to the appropriate plate and incubated at 37  C, 
5% CO2. Cells were counted using tryptan blue exclusion and 50,000 cells /ml plated 
into 24-well plate (1ml/well).  
The cells were grown in IOBA medium and, prior to cytokine treatment, the medium 
was replaced with serum-free supplemented medium for 24 hours before treating the 
cells with the cytokines of choice. Control cells received no treatments. After 
treatment the culture medium was collected, centrifuged and harvested cell-free 
supernatants were stored at -80oC until assayed. Details of the techniques are 
described below:  
 
2.2.1.2 Defrosting cells  
A solution containing 44.5ml culture medium, 100U/ml P/S and 5 ml FCS under hood 
is prepared. Cells were taken out of liquid nitrogen and buffered with FCS and 
DMSO (to maintain cell wall integrity). Cells (5 x 106/mL) were placed in the 
incubator for 1-2 minutes to thaw and then mixed immediately with 10 ml culture 
solution to dilute the toxic effects of the DMSO and centrifuged at 400 rcf for 10 
minutes. After centrifuging the cells were re-suspended and 10 ml culture solution 
added and placed in incubator 37oC, 5% CO2 for 48 hours.   
 
2.2.1.3 Passaging cells  
Upon reaching confluence, the culture medium prepared for the cells is placed in a 
water bath. Then the medium is removed from the flask and cells are adherent on 
plastic surface.  The flask was then washed with PBS to remove FCS and allow 
trypsin to mobilise cells from the adherent areas.  5 ml of trypsin was added to 45 ml 
of PBS and 4 ml of this solution was added into the flask and placed in the incubator 
for 3 minutes. The same amount of 4ml 10% FCS with culture medium of cell line 
was added and then centrifuged at 400 rcf for 10 minutes. Then 1 ml of culture 
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medium was added to re-suspend and a further 10-20 ml to mix within the pipette. 
Furthermore 10 ml was added in flasks.  
At a later stage the fluid was removed from the flasks using a 10ml pipette and 
cleaned with sterile PBS. 4ml trypsin was added in the flask and placed in the 
incubator for 3 minutes. 6 ml of medium was added in each flask and then placed in 
an empty tube and centrifuged at 400 rcf for 10 minutes. After this step the cells 
were re-suspended with 1 ml medium and 4 ml were added.  
 
2.2.1.4 Cell density calculations 
Cells were harvested in a known volume and 10 µL loaded to a haemocytometer and 
examined immediately under a microscope (x10 objective). Cells were counted in the 
central gridded square (1mm2) and multiplied by 104 to estimate the number of cells 
per mL. Cell viability was also assessed.1 mL of Tryptan blue 0.4% solution is added 
to 1 mL of cells. The number of blue stained cells and the total number of cells were 
counted in each field, counting at least 100 cells in total. 
 The viable cells % was calculated as follows:  
% viable cells = [1.0 – (number of blue stained cells /number of total cells)] x100 
To calculate the number of viable cells per mL of culture the following formula was 
used and corrected for the dilution factor:  
Number of viable cells x 104 x 2= cells/mL culture. The cell density is the adjusted to 
aim for 50,000cells/1ml. In every experiment, cell viability was at least 95% prior to 
use.  
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2.2.1.5 In vitro culture of ChWK line  
The cells were taken from frozen stock and maintained in Medium-199 (45ml) with L 
glutamine (2mM) and 10% FCS (5ml) supplemented with penicillin/streptomycin 
(100U/ml). As above, cells were seeded at a 50,000cells/1ml density in 24-well 
plates in culture medium and upon reaching pre-confluence (70-80%) the cells were 
detached using trypsin-EDTA, centrifuged at 400rcf and split into flasks.  
Cells were routinely used between passage #6 and #9 for experiments for both cell 
lines to ensure there were no changes in function when cells were multiply 
passaged.  
 
2.2.2 Cytokine treatments of conjunctival epithelial cells.  
The epithelial cells were detached as before and centrifuged at 400rcf for 10 
minutes. Cells were then re-suspended and plated out in a 24-well plate at 1x105 
cells/ml and incubated at 5% CO2, 37  C. hen the cells had reached pre-confluence 
(70-80%), supernatant was removed and replaced with fresh medium in the 
presence or absence of various cytokines.  
The following Table 2.4 below, shows the types and concentrations of cytokines 
used to treat the cells at variable time points. The cells were then treated for the time 
periods as described below. After incubation the supernatants were removed and 
centrifuged. The cell debris was then removed and cell-free supernatants were 
frozen at aliquots at -70  C ready for ELISA assay according to the manufacturer’s 
instructions: BenderMedsystems (sCD44) and R&D (p21, VEGF-A, EGFR, TGFα) 
protocols.  
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Cytokines Final concentrations 
TNFα (Peprotech)  25 ng/ml 
IL-1β (R&D systems)  10 ng/ml 
LPS (Sigma-Aldrich) 5 µg/ml 
PolyI:C (Sigma- 
Aldrich) 
50 µg/ml 
Grass pollen extract 
(Sigma-Aldrich) 
10 µg/ml 
PMA (Sigma- Aldrich) 1.0 ng/ml 
IL-17A (Peprotech) 10 ng/ml 
Zymosan (Peprotech) 20 µg/ml 
IL-25 (Peprotech) 
titrations  
1000ng/ml, 100ng/ml, 
10ng/ml, 1ng/ml 
 
     Table 2.4: Recombinant Cytokine concentrations used to treat cells.  
 
The doses of the stimulatory cytokines used were based on previous work (189). 
Dose and time response curves were also performed (237). TNFα, IL-1β, IL-17A, IL-
25 are all human recombinant cytokines reported to be expressed in inflammatory 
responses (237).  
Supernatants were taken at various time intervals as specified below. In the steroid 
treatment study 1µM Dexamethasone was added 30 minutes prior to cytokine 
treatments. All experiments were repeated at least twice and mean values calculated 
per sample. When combinations of stimulants were selected the concentrations of 
each were added together.  
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More specifically fresh culture medium was prepared using the agents described 
before for each cell line. 250 µl was placed in each well from the cells tube and 750 
µl (medium with stimulant) were added making a total volume per well of 1 µl. The 
following concentrations were used and added as shown below in Table 2.5 in each 
well.  
 
PMA 1 µl PMA in 749 µl culture medium 
Zymosan 20 µl zymosan with 730 µl culture medium   
polyI:C 50 µl  polyI:C with 700 µl culture medium  
LPS 5 µl LPS with 745 µl culture medium 
Grass  4 µl grass with 746 µl culture medium. 
IL-17A 1µl IL-17 + 2.5µl culture medium mixed 
and 1 µl taken and placed in well  
TNFα/IL-1β 25  l TNFα and 1  l IL-1β, with 724 culture 
medium  
 
                   Table 2.5: Recombinant cytokine preparation technique  
 
 
 
2.2.3 Pilot experiments using IOBA-NHC cells with single and multiple 
treatments 
The initial pilot experiments involved comparing a range of potential stimuli: IL-1β 
and TNFα, IL-17A, PMA, LPS, Zymozan, grass pollen extract, poly-IC or culture 
medium alone as a negative control were used to treat the cells and supernatants 
were harvested at 24, 48, 72, 98 hours. Cells were treat only once at time point 0. 
The samples were assayed by ELISA to quantitate secretion levels of EGFR, VEGF, 
CD44, TGFα, and p21.  
Additionally, a combination of treatments was used and sCD44 secretion was 
assessed by means of ELISA at 24, 48, 72, 96 hours. A greater variety of 
combinations of treatments was also performed and supernatants harvested at 144 
and 192 hours were processed to assess expression of sCD44 and by means of 
ELISA. Supernatants were harvested by sampling from the same well from every 
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time point. Additionally, epithelial cell viability and evidence of apoptosis was 
performed using YoPro staining and flow cytometric analysis. 
 
2.2.4 Single cytokine treatments of IOBA-NHC cells 
Preliminary data suggested treatment dependent and time dependent responses by 
the lines. The next study focuses on single treatment using IL-1β and TNFα, IL-17A, 
PMA or culture medium alone as a negative control and supernatants were 
harvested at 24, 48, 72, 96 hours. EGFR, TGFα and sCD44 levels were assessed by 
ELISA. p21 detection was also assessed at 144 and 192 hours. Means of duplicate 
wells were produced for EGFR and p21 and triplicate wells for TGFα and sCD44.  
 
2.2.5 Multiple cytokine treatments of IOBA-NHC cells 
PMA, IL-1β and TNFα, IL-17A or no treatment were used to treat cells at time points: 
0, 24, 72 and 144 hours. Before treatment supernatants were harvested and 
samples processed by means of ELISA for assessment of baseline detection of 
sCD44, EGFR and VEGF. Harvesting was performed at 24 hours, 72 hours, 144 
hours and 192 hours. Means of triplicate wells were developed for VEGF and sCD44 
and duplicate wells for EGFR analysis. 
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2.2.6 Steroid pre-treatment of IOBA-NHC cells and effect of IL-17E (IL-25)  
No treatment, or PMA, IL-17A, TNFα/IL-1β were added to cells at time point 0. 
Dexamethasone (0.1 µM, 1.0 µM, 0.1 µM, 0.01 µM, 0.001 µM) was added 30 
minutes prior to cytokine treatment and supernatants harvested at 48 hours. 
Samples were processed by means of ELISA for EGFR and VEGF.  
Further studies were performed with no treatment, IL-25 (1000ng/ml, 100 ng/ml, 10 
ng/ml,1.0 ng/ml), PMA, TNFα and IL-1β to treat cells and divided in a group without 
steroid treatment and one group with treatment of 1µM dexamethasone. 
Supernatants harvested at 48 hours were processed by means of ELISA for EGFR 
and VEGF. 
 
2.2.7 Multiple cytokine treatments of ChWK cells  
PMA, IL-1β and TNFα, IL-17A and no antigen were used to treat cells at time points: 
0, 24, 72, and 144 hours. Before treatment supernatants were harvested and 
samples processed by means of ELISA for assessment of expression of sCD44 and 
EGFR. Harvesting was performed at 24 hours, 72 hours, 144 hours and 192 hours.  
(means of duplicates for EGFR and triplicates for sCD44). Additionally lysates were 
prepared from samples at 144 and 192 hours for p21 expression from duplicate wells 
that received a single initial cytokine treatment.  
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2.3 Enzyme-linked immunosorbent assay (ELISA) technique  
 
This quantitative laboratory method was used to detect the specified analytes in 
vitro. The manufacturers’ instructions were used for preparation of reagents, test 
protocol and calculation of results (BenderMedsystems for detecting EGFR, sCD44, 
VEGF; TGFα, p21 by R&D systems).  
A 96-well plate (Immunolon microplate; Nunc,UK) was coated with capture antibody 
as shown in Table below 2.6 and incubated overnight at room temperature. The 
medium was aspirated and wells washed 3 times with wash buffer (0.05 % Tween 
20, Sigma-Aldrich) in phosphate buffered saline (PBS; Sigma- Aldrich). Plates were 
then blocked by reagent diluent (1% bovine serum albumin BSA; Sigma-Aldrich) and 
incubated in room temperature for 1 hour.  
The seven point standard curve was made and the highest standard concentrations 
are shown in the table below. Furthermore wells were aspirated, washed and the 
detection antibody (as shown in the Table 2.6 overleaf) was added for 2 hours in 
room temperature. Wells were then aspirated again and washed and Streptavidin-
horseradish Peroxidase (HRP) was added to each well and incubated for 20 minutes 
at room temperature. The wash step was repeated and substrate solution was added 
to each well and then incubated at room temperature for 30 minutes away from light.  
The coloured product is formed in proportion to the amount of the specific protein 
present in the sample or standard. This reaction was terminated with an acidic stop 
solution (2N H2SO4) and absorbance was measured at given wavelengths 
depending on manufacturer’s instructions (450nm), using an ELISA plate reader 
(Safire, Tecan). This process is outlined in Figure 2.5 in the next page and may vary 
for each marker.   
For assaying levels of intracellular human total p21, cell lysates were prepared to 
allow access for the antibodies. According to the manufacturer’s instructions for the 
production of lysates: cells were rinsed with PBS and solubilized at 10,000 cells/ml in 
Lysis Buffer and after 15 minutes centrifuged at 4000g for 5 minutes. The 
supernatant was transferred in to a clean test tube and assayed according to the 
manufacturer’s ELISA protocol.  
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Figure 2.5: Diagram illustrating the principles of the ELISA method (adapted by the 
product information and manual by Bender Medsystems). 
 
Protein Conjugate antibody Standard 
antibody 
Highest 
standard 
Source 
p21 180 µg/ml 9 µg/ml 4000 pg/ml RD systems  
TGFα 200 µl from reagent provided 10 ng/ml 1000 pg/ml RD systems 
sCD44 50 µl (1:50 of  10µl provided) 8 ng/ml 4000 pg/ml Bender medsystems  
VEGF-A 50µl(1:100 of 100µl provided) 4 ng/ml 2000 pg/ml Bender medsystems 
EGFR 100 µl as per manufacturer 50 ng/ml 3000 pg/ml Bender medsystems 
 
Table 2.6: Proteins of interest targeted for detection of ELISA  
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A standard curve was established for each run since the OD values of the standard 
curves may vary according to the conditions of the assay performance e.g. operator 
dependence, washing technique, temperature variations, pipetting technique. 
Bacterial or fungal contaminations of samples or reagents may cause inaccuracies. 
Random microscopy of samples in every ELISA assay did not reveal the presence of 
micro-organisms. Disposable sterile pipettes tips, flasks or sterilised glassware were 
used and all reusable equipment was rinsed thoroughly to prevent false positive or 
false negative results. Wells were emptied completely before dispensing fresh wash 
solution, filled with wash buffer for each wash cycle and did not remain uncovered or 
dry for extended periods. Frozen samples were thawed once and not reused to 
prevent loss of the bioactive human analytes under investigation. Stop solution was 
added uniformly and quickly throughout the microwells to completely inactivate the 
enzyme according to the manufacturer’s instructions for each assay.  
 
2.3.1 Calculation of standard curves 
 
The means of duplicate readings were then calculated for each standard and sample 
and the mean zero standard optical density (OD) reading was subtracted. The mean 
OD absorbance readings for the standard concentrations versus the concentration of 
the human analyte were plotted and a best-fitting curve was drawn. A seven point 
standard curve was made using a 2-fold serial dilution in duplicate wells in reagent 
diluent.  A standard curve was run for each group of microwell strips assayed.  
The equation used was in the format of y=mx+c with an R value close to 1.000. To 
determine the concentration of the analyte detected in each sample, the absorbance 
value on the y-axis was found and a horizontal line was extended to the standard 
curve. At the point of intersection the vertical line was extended to the x-axis and the 
corresponding concentration read. The equation was applied to convert each reading 
and then calculate the means of duplicate or triplicate wells.  
2.3.2 Statistical analysis 
Secretion levels of the markers assessed were evaluated by a paired Student’s t-test 
with a p value taken at <0.05 to be statistically significant and p <0.01 as highly 
significant. If more than three samples were obtained statistical analysis was 
performed with inclusion of SD bars.  
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2.4 Yopro-PI Epithelial cell viability studies 
Apoptosis is a highly regulated process of cell death and is distinguished from 
necrosis by specific morphological and biochemical changes. Apoptosis is followed 
by activation of Mg2+Ca2+ dependent endonuclease and DNA fragmentation as well 
as cytoplasmic shrinkage and loss of cell membrane asymmetry.  
 In the early apoptotic state there is a modification of membrane permeability that 
selectively permits entry of some DNA-binding molecules. (240). YO-PRO is a 
nuclear dye used to label cells in apoptotic state with compromised cell membranes. 
It is a fluorochrome that when fluorescing during flow cytometry emits in the green 
region and carries two positive charges and exhibits high fluorescence enhancement 
when bound to nucleic acid and does not label living cells (239). YOPRO can enter 
apoptotic cells whereas other dyes such as propidium iodide (PI) cannot (as shown 
below in Figure 2.6) (238). 
                    
Figure 2.6: Illustration of the YoPro method: PI enters through small pores of oncotic 
or necrotic cells, resulting in red fluorescing nuclei (6a), whereas YO-PRO-1 enters 
apoptotic cells that have intact membranes, resulting in green fluorescing nuclei (6b) 
(238).  
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Cell death by disruption of cell membranes can be detected by their inability to 
exclude dyes such as PI. On the other hand cells incubated with sufficient cytotoxic 
agent to render them incapable of reproducing may exclude PI for hours or even 
days (239). PI is a commonly used dye to detect dead cells by flow cytometry. PI 
carries two positive charges which prevents it entering intact cells. When coupled 
with DNA it is excited by 488nm light to give a bright signal. The binding of PI is 
reversible and therefore it must be maintained in the extracellular medium during 
analysis (239). Cells in early apoptosis are unable to pump out YO-PRO but are still 
not permeable to other dead cells discriminatory dyes. Live cells are not fluorescent 
or double negative, apoptotic cells are green (YO-PRO +ve) and dead cells are 
double positive PI+ve /YO-PRO+ve. The cell population should separate in three 
groups: live cells (green fluorescence), apoptotic cells (increasingly higher level of 
green fluorescence) and dead cells showing both red and green.  
Suspended cells are surrounded by a narrow fluid stream and pass one at a time 
through a focused laser beam. The light is either scattered or absorbed when it 
strikes a cell. Absorbed light of the appropriate wavelength may be re-emitted as 
fluorescence if the cell contains a naturally fluorescent substance or one or more 
fluorochrome-labelled antibodies are attached to surface or internal cell structures. 
Light scatter is dependent on the internal structure of the cell and its size and shape. 
Fluorescent substances absorb light of an appropriate wavelength and remit light of 
a different wavelength. Light and/or fluorescence scatter signals are detected by a 
series of photodiodes and amplified. Optical filters are essential to block unwanted 
light and permit light of the desired wavelength to reach the photodetector.  
The resulting electrical pulses are digitalised and the data stored analysed, and 
displayed through a computer system. The end result is quantitative information 
about every cell analysed. Since large numbers of cells are analysed in a short 
period of time (>1000/sec), statistically valid information about cell populations is 
quickly obtained. The cells scatter a fraction of the light which is detected by 
photomultiplier light detectors. A measurement for the diffraction of light horizontally 
is the forward scatter (FCS) and it depends on the cell volume. A measurement of 
the diffraction of light in a right angle is the sideways scatter (SSC) which depends 
on the granularity, the size of the cell, the structure of the nucleus, and the amount of 
the cytoplasmic contents. The characterisation of the unstained cells using light 
108 
 
scatter is represented using appropriate software in a graph form (Dot Plot) 
(241,242).  
 
2.4.1 Apoptosis Assay 
 The experimental protocol for apoptosis assay was followed. Harvested epithelial 
cells from confluent monolayers were enzymatically dissociated, pooled with non-
adherent cells in the culture supernatants, pelleted and washed in cold PBS and cell 
density adjusted to 1 x106cells/mL. For each assay 1 mL assay volume was used.  
Re-suspended single cells were stained with 0.5µM YOPRO-1 (by Molecular Probes) 
and 4 µg/mL propidium iodide (by Sigma- Aldrich) were added to the cells and 
incubated on ice for 20-30 minutes.  
After incubation the stained cells were washed in PBS prior to being acquired for 
flow cytometry (FacsCalibur by Becton-Dickinson, B-D) using 488nm excitation with 
green fluorescence emission for YO-PRO (530/30 bandpass) and red fluorescence 
emission for PI (610/30 bandpass). At least 10,000 events were acquired per sample 
and all flow cytometric data was analysed using CellQuest (B-D). Regions indicating 
the live cell population were drawn and the mean fluorescence intensity or 
percentage expression was measured.  
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CHAPTER 3 
 
 
 
RESULTS: IMMUNOHISTOCHEMISTRY STUDIES 
 
 
Conjunctival epithelial remodelling in CAED and OCP: Expression of epithelial-
mesenchymal communication associated molecules. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
3.1. Introduction  
 
To determine whether there is epithelial cell remodelling during CAED, a range of 
molecules associated with remodelling were investigated for their expression in 
conjunctival biopsies obtained from donors, comparing controls, CAED and OCP. 
The EMTU related remodelling epithelial molecules selected were EGFR, TGFα and 
CD44. In the first part of this chapter the antibody concentrations were optimized on 
a select few biopsies and then, in the second part, the optimal concentrations for 
each were applied for staining the remaining biopsies.  
 
3.2 Preliminary antibody optimisation immunohistochemistry results 
  
In a CAED biopsy anti-TGFα mAb (1:200 dilution) produced a mild staining pattern of 
the epithelium with patchy non -specific uptake in the stroma. On the contrary a 
higher concentration (1:50) produced too intense staining that was not possible to 
use for evaluating the CK18 expression. The dilution that produced acceptable 
staining of the expression yet allowing the assessment of the CK18 in the same slide 
was 1:100. Additionally in a GPC biopsy, anti-TGFα mAb (1:100) produced uniform 
and milder staining of the epithelium. The grading of the immunostaining with various 
antibody dilutions is shown in the Tables 3.1 and 3.2 for CK18, EGFR, TGFα, CD44, 
and IgG. 
In a CAED biopsy anti-EGFR mAb (1:200) showed significant uniform expression in 
the epithelium and diffuse non-specific uptake in the stroma and allowed for 
assessment of the CK18 expression. However in another biopsy of the same patient, 
using anti-EGFR mAb at a higher concentration (1:50) produced a too intense 
staining, whilst anti-EGFR mAb at 1:100 dilution showed brighter and more uniform 
intensity of staining in the same CAED patient biopsy. In a biopsy of GPC there was 
no EGFR expression detected for 1:100 dilution, yet the same dilution in a CAED 
biopsy showed mild positive epithelial detection. The detection of antibodies in the 
CAED biopsies showed 0 expression for the IgG. Indicative photomicrographs 
showing CD44 expression at various dilutions in CAED conjunctival sections are 
shown in Figures 3.1 (A-C).  
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The remodelling epithelial markers showed co-expression in the epithelium with 
CK18 and minimal CK18 was detected in the stroma where epithelial cells are 
absent as expected. Furthermore random CAED biopsies processed for double (3-
hour) antibody incubation (as above) showed 0 antibody expression for all 
antibodies. Based on the data above the final antibody dilutions were determined to 
be most suitable for the conjunctival biopsies of our Local Tissue Bank.  
CK18 epithelial expression 
Antibody dilution Fields scored x4 Overall score 
1:200 1+, 0,1+,1+ 1+ (uniform) 
1:100 2+,1+,2+,2+ 2+  
1:50 3+,3+,3+,3+ 3+ (uniform) 
 
EGFR epithelial expression 
Antibody dilution Fields scored x4 Overall score 
1:200 3+, 2+,2+,2+ 2+ (diffuse uptake) 
1:100 3+,3+,2+,2+ >2+ (patchy) 
1:50 >3+,3+,3+,3+ >3+ (very intense) 
 
TGFα epithelial expression 
Antibody dilution Fields scored x4 Overall Score 
1:200 1+, 0, 1+, 1+ 1+ (patchy,pale) 
1:100 3+, 3+, 3+, 3+ 3+ 
1:50 Non specific >3+ (too intense) 
 
CD44 epithelial expression 
Antibody dilution Fields scored x4 Overall score 
1:200 3+,2+,2+,2+ >2+ (uniform) 
1:100 3+, 3+, 3+, 3+ 3+ 
1:50 >3+, 3+, 3+, 3+ >3+ (very intense) 
 
 
 
Table 3.1: Preliminary optimization antibody data showing the epithelial grading for    
various antibody dilutions of randomly selected conjunctival biopsies 
  
 
 
 
IgG epithelial expression 
1:200 0  
1:100 0  
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EGFR stromal expression 
Antibody dilution Fields scored x4 Overall score 
1:200 1+,1+,1+,1+ 1+ (diffuse, uniform) 
1:100 3+,2+,2+,2+ 2+  
1:50 3+,3+,3+3+ >3+ (diffuse ,uniform) 
 
TGFα stromal expression 
Antibody dilution Fields scored x4 Overall Score 
1:200 0,0,0,1+ 0 
1:100 1+,1+,2+,2+ <2+ uniform  
1:50 Non specific >3+ (too intense) 
 
CD44 stromal expression 
Antibody dilution Fields scored x4 Overall score 
1:200 1+,1+,1+,1+ 1+ 
1:100 2+2+3+,3+ >2+ 
1:50 3+,3+,3+,3+ >3+ (too intense) 
 
 
 
 
Table 3.2: Optimization antibody data showing the stromal grading scores for 
various antibody dilutions of randomly selected biopsies. 
 
 
 
 
 
 
 
 
 
 
CK18 stromal expression 
Antibody dilution Fields scored x4 Overall score 
1:200 0,0,0,1+ 0 
1:100 1+,0,0,0 0 
1:50 0,0,0,0 0 
IgG stromal expression 
1:200 0  
1:100 0  
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Figure 3.1 (A-C): Example photomicrographs of conjunctival tissue (CAED) from the 
same donor biopsy specimen used for the CD44 antibody optimisation study at 
various dilutions (A) 1:200, (B) 1:100, (C) 1:50. In all sections there is intense 
epithelial staining and stromal antibody uptake. Anti-CD44 mAb (1:200) produced a 
better staining pattern than the other dilutions enabling improved epithelial 
expression assessment; Bar shown 250 µm. 
(a) epithelium, (b) stroma and (c) intrastromal epithelial ingrowths indicating papillae 
formation in CAED.  
 
 
 
 
B 
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3.3 Antibody staining 
 
The staining patterns are presented below for each antibody with descriptive 
analysis of the results in the remaining sections of the chapter. The 
photomicrographs show the differences in epithelial and stromal expression for each 
antibody relative to IgG controls, and various conjunctival sections of ocular allergy. 
Dot plot graphs were used to compare the antibody expression scores and Mann-
Whitney statistical analysis performed.  
 
3.3.1 EGFR Immunostaining (1:200) 
 
    
   
Figure 3.2(A-D): Photomicrographs of sections of conjunctival epithelial 
demonstrating that the epithelia have different levels of expression for EGFR in 
normal controls and CAED biopsies. (A) IgG control, (B) No epithelial expression (C) 
mild (1+) epithelial expression and (D) moderate (2+) epithelial expression with mild 
stromal staining. Note epithelial cell loss at C and D. Bars shown 50 µm. 
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3.3.2 TGFα Immunostaining (1:100)  
  
   
  
                                                  
Figure 3.3 (A-E): Photomicrographs of sections of conjunctival tissues showing 
different levels of TGFα expression in controls and biopsies of CAED. (A) IgG 
control, (B) 0 expression, (C) (1+) mild expression seen in basal epithelial area, (D) 
moderate (2+) expression of the intrastromal epithelial areas differentiating them 
from the surrounding stroma,  (E) intense (3+) epithelial expression with stromal 
staining. Bars shown 50µm.  
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3.3.3 CD44 Immunostaining (1:200) 
 
 
 
Figure 3.4 (A-D): Photomicrographs of sections of conjunctival epithelia showing 
different levels of CD44 expression in normal controls and various types allergic 
conjunctivitis. (A) IgG control, (B) 0 expression, (C) (1+) mild patchy epithelial 
expression, (D) intense (3+) epithelial CD44 expression and uniform mild (1+) 
stromal staining. Note epithelial cell loss at photomicrographs C and D (CAED). Bars 
shown 50µm.  
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3.3.4 Summary of immunostaining data  
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Figure 3.5: Dot plots showing the individual epithelial grading scores for each biopsy 
of EGFR, TGFα, CD44 expression with median values shown by red lines for each 
group. p values were calculated using Mann-Whitney analysis.  
p< 0.001 
p< 0.001 
p< 0.001 
p< 0.001 
p< 0.01 
p< 0.001 
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Figure 3.6: Dot plots showing the individual stromal grading scores for each biopsy 
of EGFR, TGFα, CD44 with median values shown by red lines for each group. p 
values were calculated using Mann-Whitney analysis.  
 
p< 0.01 
p< 0.001 p< 0.05 
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Figure 3.7: Dot plots summarizing the epithelial grading scores of EGFR, TGFα, 
CD44 with median values shown by red line for each group.  
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Figure 3.8: Dot plots summarizing the stromal grading scores of EGFR, TGFα, 
CD44 with median values shown by red line for each group.  
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Figure 3.9: Dot plots summarizing the epithelial and stromal grading scores of 
EGFR, TGFα, CD44 of the CAED group with median values shown by red line for 
each group.  
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3.3.5 OCP Immunohistochemistry Results  
 
There was no expression of EGFR and TGFα in all normal biopsies similar to that 
seen in biopsies from normal conjunctiva and seasonal allergic conjunctivitis in the 
control group in the previous ocular allergy immunohistochemistry study. Additionally 
both active and chronic OCP groups showed a lack of expression of EGFR and 
TGFα. 
 
Mild epithelial expression (1+) of CD44 was observed in both groups (chronic and 
active OCP). In the active OCP group there was positive expression in 7 out of 9 
slides expressing the antibody. In the chronic treated OCP group there was positive 
CD44 expression in the epithelium in 2 out of 6 biopsies. In both groups CD44 
expression was uniform and mild, localized in the epithelial layer. There was no 
expression in the control group. p21 expression was not detected in the chronic OCP 
group (four biopsies). Table 3.4 below shows the grading results of the OPC biopsies 
and the normal conjunctival tissues.  
 
Active OCP  
Antibody Epithelial expression Stromal expression Number of biopsies 
EGFR 0 0 9 
TGFα 0 0 9 
CD44 1+ in 7/9; 0 in 2/9 0 9 
 
Chronic Treated OCP 
Antibody Epithelial expression Stromal expression Number of biopsies 
EGFR 0 0 6 
TGFα 0 0 5 
CD44 1+ in 2/6; 0 in 4/6 0 6 
p 21 0 0 4 
 
Normal Conjunctiva 
Antibody Epithelial expression Stromal expression Number of biopsies 
EGFR 0 0 7 
TGFα 0 0 7 
CD44 0 0 7 
 
Table 3.3: Overall mean grading scores of EGFR, TGFα, CD44, p21 expression in 
OCP biopsies.  
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3.4 Discussion of results  
 
3.4.1 Expression of epithelial remodelling markers in the controls group  
 
All biopsies of normal conjunctival tissue showed a lack of expression of EGFR and 
TGFα at the epithelium and the stroma without intracellular or extracellular antibody 
expression. Two of the four normal biopsies showed mild 1+ expression of CD44 in 
the epithelium and the stroma. This could be due to the fact that during the process 
of taking the biopsy there was an induced tissue response to injury resulting in 
secondary expression. These two biopsies showed no expression at the epithelium 
and the stroma for TGFα or EGFR and the remaining biopsies had no expression. All 
the other biopsies had undetectable levels of expression. There was mild (1+) 
expression in two of the three GPC biopsies in the epithelium and much less in the 
stroma. One of the GPC biopsies showed no EGFR expression but there was some 
mild expression of TGFα and CD44. The two biopsies of SAC did not show any 
positivity of any of the antibodies in the epithelium and the stroma.  
 
Two of the three GPC biopsies showed mild (1+) TGFα expression. One showed no 
expression of the molecule in the epithelium and there was only scanty positivity in 
the stroma. On the contrary the same biopsy showed positive detection for EGFR 
and CD44. Possible explanations could include that the amount of tissue TGF-α was 
not significant enough to be detected or its production had not occurred at the time of 
biopsy. There was mild (1+) expression of CD44 in the epithelium in all three GPC 
biopsies. One slide showed equal expression in both the epithelium and the stroma. 
 
Overall, there was mild cytoplasmic and membranous expression of all molecules 
included in this study in the epithelium and much less in the stroma. The expression 
was diffuse, less than 1+ and mainly seen in the GPC biopsies. There was no EGFR 
or TGFα expression in the normal uninflamed subjects.  
 
 
 
 
123 
 
 
3.4.2 Expression of epithelial remodelling markers in VKC and AKC (CAED 
group)  
 
In VKC there was a moderate (2+) EGFR expression (in all four biopsies) in the 
epithelium and, in two a mild uptake in the stroma. The increased level of expression 
of the epithelium was statistically significant compared to controls (p < 0.01) but not 
for the stromal expression. Three out of four biopsies showed a mild (1+) TGFα 
epithelial expression of the antibody. Although this expression was not strong it was 
statistical significant compared to controls (p< 0.001). There was not stromal 
expression noted. Two out the three VKC biopsies showed strong CD44 expression 
in the epithelium. The biopsy that failed to express TGFα also did not express CD44 
but did show a moderate expression in the epithelium for EGFR and a mild 
expression in the stroma. CD44 expression in the epithelium was statistically 
significant compared to controls. Overall there was positive uniform epithelial 
expression of all three markers EGFR, TGFα and CD44 which was statistically 
significant compared to the controls group.  
 
One of the four AKC biopsies had no EGFR expression and this could suggest that 
there are inconsistencies in the pattern of EGFR expression in CAED. The remaining 
three were EGFR positive. Two were strongly positive and one biopsy showed a 
weak expression. Expression was mainly epithelial with some patchy stromal uptake. 
There was statistically significant (p<0.001) expression compared to the epithelial 
EGFR expression of the controls group but not statistically significant compared to 
the stroma. There was no statistical significance of the epithelial and stromal EGFR 
expression between VKC and AKC.  
 
There was positive TGFα expression in all four AKC biopsies. Two showed (3+) 
strong expression, one biopsy very mild (mean value 0.75+) and the remaining 1+ 
expression. There was a statistical significance (p< 0.001) in epithelial expression 
compared to the control group but not for the stroma. There was no statistical 
significance of epithelial and stromal TGFα detection between VKC and AKC. One 
biopsy was strongly positive for TGFα but showed no detection for EGFR and CD44. 
Two biopsies showed similar expression scores for both EGFR and TGFα.  
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There was strong CD44 cytoplasmic and extracellular expression in three out of the 
four AKC biopsies throughout all fields graded. One of the biopsies showed no 
detection; the same biopsy specimen which did not express EGFR, was strongly 
positive (3+) for TGFα. Similar reasons could be attributed for this as described 
above. However this expression was not statistical significant compared to controls. 
The same applies for the stromal expression. Three out of the four biopsies 
expressed significant levels of CD44 in the stroma.  
 
Overall, TGFα, EGFR and CD44 were strongly and uniformly expressed in the 
epithelium with some stromal expression in the VKC and AKC biopsies despite a few 
negative fields scoring for some biopsies and this was statistical significant between 
the control and the CAED group for all markers.  
 
The precise mechanisms by which remodeling is promoted in chronic allergic 
conjunctivitis are not clear. With the exception of VKC, little is known about the role 
of growth factors and remodelling in the pathogenesis of chronic allergic eye 
disease.  This is the first study to investigate and compare, by means of 
immunohistochemistry,  the expression of epithelial remodelling markers (EGFR, its 
ligand TGFα and CD44), in reversible and irreversible forms of allergic conjunctivitis 
and attempt to explore the possible application of the EMTU hypothesis in asthma to 
ocular allergy. It is possible that the intense EGFR, TGFα, CD44 expressions in the 
conjunctival epithelium in CAED may reflect the repair of damage induced by the 
chronic inflammation. However, an abnormal overhealing response to attempt repair 
of the damage may be a potential explanation for conjunctival epithelial remodelling.  
 
Initially, a series of immunohistochemistry studies were undertaken to determine the 
optimal antibody concentrations of epithelial EMTU-associated remodelling 
biomarkers: EGFR, its ligand TGFα and CD44 acting as a positive control. A control 
group of conjunctival biopsies (including normal tissue, SAC, GPC) was compared to 
a clinically severe disease group (AKC and VKC) and by means of 
immunohistochemistry the epithelial expression of the markers above was graded 
and analysed. Furthermore immunohistochemistry studies were performed with 
conjunctival biopsy specimens from patients with acute or chronic OCP aiming to 
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assess the expression patterns of EGFR, TGFα and CD44. There was a statistically 
significant difference in epithelial expression of EGFR, TGFα and CD44  between 
the controls and CAED groups and all ocular allergy patients had active disease at 
time of biopsying. The OCP biopsies showed no expression of the TGFα and EGFR 
and minimal CD44 expression in only two biopsies. This may suggest that the 
remodelling seen in severe ocular allergic disease with corneal involvement, is 
driven by the epithelium and is not of “autoimmune” origin as in OCP where the 
fibroblast is known to play a more central role. The figures below show the 
comparison of EGFR expression in biopsies from SAC, VKC and OCP.  
 
 
Figure 3.10: Photomicrographs of sections of conjunctival epithelia showing different 
epithelial EGFR expression in (A) seasonal allergic conjunctivitis, (B) vernal 
keratoconjunctivitis, (C) ocular cicatricial pemphigoid. Bar shown 50 µm. 
 
      
Figure 3.11: Photomicrographs of sections of conjunctival epithelia showing different 
epithelial TGFα expression in (A) seasonal allergic conjunctivitis, (B) giant papillary 
conjunctivitis, (C) ocular cicatricial pemphigoid. Bar shown 50 µm. 
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Limitations of the optimisation immunohistochemistry studies include the small 
number of biopsy specimens available for use in this study and the relatively long-
term storage at -70oC since they were obtained previously, for studies of our group, 
which may have influenced the quality of the tissue. GMA embedded conjunctival 
biopsies with significant tissue destruction were not included. GMA was the preferred 
technique in this study for fixation since it is known to preserve the tissues for longer 
and it allows more antibodies to be used. To prevent non-specific staining in positive 
controls excess washing buffer was carefully removed and freshly prepared reagents 
were used throughout the process. Incubation times were determined and it was 
concluded that for the given specimens an overnight single antibody staining was 
more appropriate to prevent difficulty with the interpretation of the expression of each 
antibody since in some tissues, strong positivity was anticipated.  
The cytokine microenvironment of the inflamed tissue may influence EGFR 
expression leading to differential and selective upregulation on some cells able to 
express the receptor. Other reasons that may explain the variable levels of EGFR 
expression include the degree of clinical severity, the type of inflammation, the cell 
types involved and the location of the tissue. The expression intensity and pattern 
may not be consistent across all three areas of the conjunctiva. Variations in the 
expression patterns could exist between the tarsal, bulbar and limbal areas at 
different time points of disease progression.  
Factors that may influence the variable immunostaining results are presence of a 
flare-up or a stable chronic not acutely inflamed state and the time of year the biopsy 
was taken. So far VKC has been the only form of persistent allergic conjunctivitis 
studied by means of immunohistochemistry to investigate the expression of 
remodelling markers in the epithelium or stroma. EGFR, VEGF, Collagens I, III, VII 
and fibronectin in VKC were highly expressed in the sub-epithelial area with collagen 
I being the major element in VKC compared to controls (123). There is increased 
diffused epithelial expression of fibrogenic growth factors TGFβ, PDGF, FGF in 
association with increased deposition of collagen in the giant papillae of VKC (127).  
Geographic variations may also influence the biomarkers’ epithelial expression since 
the disease has been found to be more severe in warmer climates. A lack of EGFR 
expression has been also reported in VKC where 8 in 16 conjunctival biopsies 
showed no positive expression of the epithelial receptor (123).  
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The results of the immunohistochemistry studies described in this thesis add new 
evidence on the description and comparison of the variable detection patterns of 
epithelial remodelling markers at different forms of allergic conjunctivitis. The results 
of this study demonstrate that expression levels of EGFR and TGFα were 
upregulated in the conjunctiva of patients with corneal involvement and active 
persistent/chronic allergic ocular disease (AKC/VKC) compared to controls. CD44 
not only acted as a positive control but is also known to enhance EGFR signalling 
and was also found to be overexpressed in the CAED group compared to the 
controls.  
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3.5 Summary  
 
EGFR expression was undetected in the epithelium of normal conjunctival biopsies. 
The overall weak positive expression of EGFR in the controls is accounted for by the 
mild expression in GPC biopsies. There is no published data to date regarding 
EGFR, TGFα and CD44 expression in AKC or GPC or the expression of epithelial 
remodelling markers in reversible compared with chronic forms of ocular allergic 
disease. The results show that the overall epithelial expression of the markers, 
EGFR and TGFα, was significantly increased in the CAED group of AKC and VKC in 
comparison with the controls group. The stromal expression was also increased but 
mainly in the AKC biopsies with some positivity in the VKC subgroup and it was 
almost negative for the control group. CD44 and EGFR seem to have the strongest 
expression in the epithelium followed by TGFα. OCP biopsies showed no expression 
of the EMTU epithelial markers which supports the suggestion that the EMTU 
hypothesis may be applied in allergic rather than autoimmune mucosal inflammation 
involving the conjunctival epithelium.  
 
Although technical limitations may influence the interpretation of the expression of 
antibody markers in conjunctival biopsies, the results provide immunohistochemical 
evidence that a similar proposal to EMTU hypothesis may be applicable to AKC and 
VKC (CAED). However additional evidence is required to reinforce the present data. 
Immunohistochemistry studies enable the assessment of the detection and pattern of 
expression of the molecules under investigation and provide a “snap shot” of the 
tissue at the time when the biopsy was taken. In vitro experiments may provide 
additional data regarding the functions of the epithelial conjunctival cells under 
inflammatory conditions. Therefore, in the next chapter (Chapter 4) two immortalized 
human conjunctival epithelial cell lines well known for their properties and used 
before in ocular allergy research were selected and used as in vitro models of 
human conjunctival epithelial responses: The IOBA-NHC and Wong-Kilbourne 
derivative of the Chang conjunctiva (CHwk).  
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CHAPTER 4 
 
 
RESULTS: IN VITRO STUDIES 
 
Responses to inflammation-related molecules by conjunctival epithelial cells: 
An in vitro model of ocular inflammation and abnormal repair. 
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4.1 Introduction 
This part of the study, aims to develop an in vitro model to focus on remodelling 
markers of epithelial repair and to determine if the EMTU hypothesis can be applied 
to the conjunctiva, supporting the results shown in Chapter 3. By comparing human 
conjunctival epithelial cells that were treated with potential stimuli once, it was aimed 
to produce an acute model of epithelial inflammation. In order to develop a more 
severe epithelial cell model, cells received multiple treatments over prolonged times.  
 
Human conjunctival cell lines were chosen since it was intended to avoid species 
differences. The use of animal models was considered but there was no available 
mouse model of CAED at the time of doing these experiments.  There was no 
access to primary conjunctival epithelial cell lines. Even if such a line was available it 
would have required repeat biopsies from the same donor in order to carry out this 
screening of various treatments. Therefore to determine if conjunctival epithelial cells 
are capable of secreting the remodelling molecules, in vitro studies were designed 
and performed using IOBA-NHC and CHwK human conjunctival epithelial cell lines. 
A more detailed account of the morphological and functional properties of the 
selected cell lines is given in sections 4.2 and 4.3. A key aspect of the single and 
multiple cytokine treatments in vitro models was that the culture medium used for the 
epithelial cell lines was replaced regularly to assure an adequate level of nutrients 
were present to maintain viability over longer incubation periods. Furthermore, to 
ensure that the wells did not become overgrown, cells were placed out in each well 
at lower densities at the beginning of the assays.  
 
In the first portion of this study, preliminary experiments were carried out using the 
IOBA-NHC line to determine the ability of the cells to secrete a range of molecules 
associated with remodelling after treatment with various cytokine combinations. 
Furthermore, a second set of experiments using the IOBA-NHC line were performed 
in an attempt to assess reproducibility and consistency of the responses using the 
positive control sCD44. Cell viability studies were also performed to determine 
whether early apoptosis of the epithelial cells had occurred in response to the 
treatments.  
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Finally, three cytokine treatments were selected for the remaining experiments 
based on their immunological properties and the secretory response profiles 
obtained from the preliminary experiments. The purpose of this part of the study was 
to determine the profile of remodelling-associated growth factors and other soluble 
mediators secreted by conjunctival epithelial cells in vitro under the effect of 
proinflammatory (TNFα/IL-1β) and Th17-type (IL-17) cytokines to further understand 
the contribution of conjunctival epithelial cells to ocular surface inflammation and 
repair. Phorbol 12-myristate 13-acetate (PMA) is well known for exerting a wide 
range of effects to cells and tissues and is an activator of Protein kinase C and 
hence NF-κB. It was therefore selected as a positive control known to induce cellular 
stress.  
During the last few years several developments that enhance our understanding of 
the physiological and pathological properties of the VEGF family have taken place. 
VEGF-B, -C, -D members of the VEGF family have also been cloned but it is VEGF-
A transcription that is activated in tissue hypoxia, by oncogenes and transmembrane 
tyrosine kinases such as EGFR. Binding of the ligands to the EGFR leads to DNA 
reproduction and cell proliferation. The selected ELISA kit assay quantitates the 
levels of the phosphorylated EGF receptor. When the receptor engages the ligand its 
degradation is accelerated (approximately 5 hours). Upon binding to the extracellular 
part of the receptor, internalisation, pH change, enzyme activation, re-organisation of 
the actin filaments and oncogene protein induction occur. Despite the fact that the 
precise mechanism of signal transduction is still unclear it is assumed that ligand 
binding to the receptor initiates transduction via tyrosine autophosphorylation and 
phosphorylation of interacting proteins.  
TGFα is known to have a high affinity for EGFR, acts in both an autocrine and 
paracrine fashion and is involved in a number of processes including angiogenesis 
and wound healing. Its precursor has an extracellular, a transmembrane and 
cytoplasmic domain and shedding of the mature soluble TGFα from its integral 
domain is highly regulated. EGFR activation, calcium and MMPs are among those 
factors known to regulate its release. TNFα converting enzyme is known to cleave 
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mature TGFα from its precursor. The ELISA kit selected to assay TGFα is suitable 
for cell culture supernatants. 
ELISA measures soluble CD44 (sCD44) present in supernatant presumably secreted 
by the CD44-expressing cells as part of a turnover of the CD44 molecule. It is 
assumed that what is detected in supernatants in soluble form will positively 
correlate with secretion levels by the epithelial cells.  In this study a sCD44 standard 
was used since it detects all CD44 isoforms comprising the standard extracellular 
protein regions thus providing a useful insight into different pathological processes. 
For the assay of intracellular p21, a sandwich ELISA kit was chosen to measure this 
analyte within cell lysates. The manufacturer’s instructions were followed for the 
preparation of lysates using the provided lysis buffer and frozen until assayed.  
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4.2 IOBA-NHC and CHwK cell lines: properties and experimental use 
4.2.1 Morphological characterisation  
 
The IOBA-NHC conjunctival cell line is the only non-transfected spontaneously arose 
from a primary culture of human conjunctival epithelium with continuous proliferation 
(immortalised), established and characterised at the University Institute of Applied 
Ophthalmobiology (IOBA), University of Valladolid Spain (235). The cells exhibit 
typical epithelial morphology with high proliferative activity without contaminating cell 
types. Care was taken to avoid excessive passaging of cells, and possible change in 
phenotype. For this, cells were only grown up to passage 20, before new vials were 
defrosted.  
Chromosome analysis confirmed the human origin of the IOBA-NHC lines and there 
is an altered karyotype with marker chromosomes. Though the ability of genetic 
variation of a cell line is partially responsible for the establishment of a continuous 
cell line, not all genetically variable cell populations are immortal. Cells have a 
polygonal shape with abundant mitotic figures. IOBA-NHC cells have a high 
proliferative ability determined by quantification of Ki-67 positive cells. Epithelial 
conjunctival markers such as EGFR were not detected by means of 
immunofluorescence microscopy but were detected by Western Blot and by flow 
cytometric analyses.  
Several mucin genes were expressed in various passages and cells have the 
capabilities to produce glycoproteins. The cells are also known to respond to pro-
inflammatory stimuli. ICAM-1 was expressed in unstimulated cells and upregulated 
by IFNγ after 24 hours post stimulation for 72 hours detected by means of flow 
cytometry. HLA-DR was not detected in unstimulated cells but after IFN-γ treatment 
there was low but detectable levels. Treatment of cells with TNFα lead to an 
upregulation of ICAM-1 (but less compared to IFNγ) but did not induce HLA-DR 
expression.  
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4.2.2 Cytokine responses  
Using the IOBA-NHC cell line the profiles of cytokines secreted in response to 
exposure to IFNγ (Th1- type), TNFα (proinflammatory), IL-4 or IL-13 (Th2- type) were 
previously investigated (210). The most effective stimulatory cytokine was TNFα 
followed by IFN-γ. In contrast IL-4 and IL-13 did not induce significant epithelial 
cytokine production. Eotaxin-1 production was increased after Th2 type and 
proinflammatory cytokines treatment. Secretion of IP-10, IL-8 and RANTES were all 
increased following TNFα treatment. To conclude, under artificial inflammatory 
conditions the IOBA-NHC line secreted various cytokines which are thought to 
participate in immunodulation of ocular surface allergic eye diseases (194).  
4.2.3 Muscarinic and adrenergic receptors 
The presence of muscarinic and α, β- adrenergic receptors in IOBA-NHC cell line 
was previously investigated (242). The cell line maintained expression of 
neurotransmitter receptors but with unknown functional state. IFNγ upregulated M2-
muscurinic receptor expression but TNFα did not alter expression levels of any 
receptors. A combination of cytokines (IFNγ and TNFα) induced increased 
expression of α2 adrenoceptors. This evidence makes the line of particular 
experimental use especially when investigating inflammatory immune ocular surface 
disease (e.g. dry eye, ocular allergy) since neural alterations are implicated in their 
immunopathogenesis (242).  
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4.2.4 CHwK cell lines: Morphological and functional characterisation  
The Wong-Kilbourne derivative of Chang cell line (ChWK) is spontaneously 
immortalised from human conjunctival epithelial cells. The cells have a fibroblastic 
appearance, do not express cytokeratin 4 (a marker of stratified non-keratinised 
epithelium), but do express EGF, vimentin and Fas (212). Additionally this cell line is 
phenotypically similar to primary human conjunctival cells lines, expressing ICAM-1, 
CD44, CD63, HLA-DR under basal conditions. The ChWK cell line characteristics 
were compared to primary human conjunctival cell line cells and it was reported that 
the ChWK line shares morphological characteristics with the mesenchymal cells with 
a dedifferentiated phenotype (212). CD44, which is known to have anti-apoptotic 
properties, is similarly expressed in both ChWK cells and primary conjunctival cell 
line cells. HLA-DR was reported to be upregulated after IFNγ treatment. ICAM-1 was 
detected at basal conditions and upregulated in a dose-response manner after IFNγ 
or TNFα treatment but IFNγ was more effective (212).  
 
4.2.5 Immunostimulatory properties of ChWK lines 
The immunomodulatory role of human conjunctival cells was previously investigated 
by means of the in vitro model of ChWK line (213). There was an upregulation of 
HLADR and ICAM-1 after IFNγ treatment. IL-4 treatment did not have any effect on 
HLA-DR or ICAM-1. The ChWK cell line cells are shown to behave in similar manner 
in terms of their ability to exhibit a proinflammatory role (213).  
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4.3 Examples of standard curves of analytes  
As described in Chapter 2, standard curves where obtained for every ELISA for each 
experiment. Example curves are shown below for each protein.  
                             
                                                                     
                                                       
       Figure 4.1: Examples of Standard curves produced for all proteins assayed by ELISA.  
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4.4 Results of in vitro pilot study with IOBA-NHC line after a single initial 
treatment and supernatant harvest at 24, 48, 76, 92 hours 
4.4.1. EGFR secretion  
In the untreated cells, EGFR was minimally secreted at 24 hours increasing 
gradually with time, reaching above 0.5 ng/ml at 96 hours. Maximal EGFR secretion 
occurred in response to exposure to grass pollen [2.0 ng/ml] at 96 hours and was 
minimal at 24 hours [1.5 ng/ml] level. There was a small gradual increase in its levels 
for all treatments with increasing time with the lowest levels for the untreated group 
and maximal for grass. The Figures 4.2 and 4.3 illustrate the EGFR secretion 
patterns.  
 
   
Figure 4.2: Pilot in vitro IOBA-NHC study: EGFR expression at 24, 48, 72, 96 hours 
after various treatment (mean values from duplicate wells)
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Figure 4.3: Data shown for each treatment indicating maximal EGFR secretion in 
response to grass antigen. Data is shown as means of duplicate wells.  
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4.4.2. VEGF secretion   
There was minimal VEGF expression at 24 hours for all treatments and an 
impressive increase at 48 hours which was further increased progressively at 72 and 
96 hours. Maximal levels for all groups were detected at 96 hours after treatment. 
Maximal expression occurred at 96 hours for TNFα/IL-1β [2450pg/ml] and PMA 
[2400 pg/ml] as well IL-17A [2100 pg/ml]. The secretion pattern and levels were 
different than those of EGFR. VEGF levels peaked at later timepoints and 
demonstrated a greater time-dependent progressive increase than for EGFR. 
Instead EGFR’s levels were more dependent on the type of treatment and had a 
slower rate of increase in levels. EGFR’s secretion appeared to be increasing in a 
stepwise manner with time for all stimulants. This is not the case of VEGF where 
there is an abrupt increase at 48 hours increasing until 96 hours for all treatments. 
Grass pollen appeared to be a more potent inducer of EGFR secretion but not for 
VEGF production. These variations are shown in Figures 4.4 and 4.5.  
  
Figure 4.4: Pilot in vitro study using IOBA-NHC cells showing VEGF secretion in 
response to a single exposure with various treatments at 24, 48, 72, 96 hours (based 
on mean values of duplicate wells).  
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Figure 4.5: Maximal VEGF secretion occurring after a single treatment with TNFα/IL-
1β, IL-17 and PMA. Data is shown as means of duplicate wells.  
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4.4.3. sCD44  
There was secretion of sCD44 even in the untreated wells at levels similar to the 
other treatments at 24 hours suggesting cellular turnover at normal culture 
conditions. There was no specific pattern of increased detection but the highest 
levels were found for PMA (7.9ng/ml) at 96 hours. The maximal levels for all groups 
occurred at 96 hours post-treatment except for the untreated group where maximal 
secretion occurred at 48 hours. Maximal levels at 96 hours were also detected for IL-
17A, TNFα/IL-1β and grass pollen extract. There was no specific pattern dependent 
on time or specific stimulants. There was an increase in sCD44 levels at all times for 
all groups. These changes are shown in Figures 4.6 and 4.7 below.  
 
  
Figure 4.6: Pilot in vitro study of IOBA-NHC cells showing levels of sCD44 after 
treatment with various treatments (based on the mean values of duplicate wells).  
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Figure 4.7: Maximal sCD44 secretion occurred at 96 hrs and there was significant 
turnover of untreated cells even at 24 hours. Data is shown as means of duplicate 
wells.   
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4.4.4  
TGFα: There was no secretion detected in response to any treatment at any time 
point. Standard curves were obtained for each assay. This suggested either that 
secretion was below the level of detection in this ELISA, or that the cells failed to 
secrete this molecule. Cell death was not observed microscopically. There was no 
infection noted (data not shown).  
 
4.4.5  
p21waf: There was only minimal detection (pg/ml) with large variations for all groups. 
This minimal positivity could be due to the small cytoplasmic p21waf concentrations 
(data not shown) and variability could be due to lysate failure. Standard curves were 
obtained for each assay well.  
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4.5 Pilot in vitro studies: sCD44 secretion by IOBA-NHC cells  
4.5.1 sCD44 levels at 24, 48, 72, 96, 144, 192 hours in response to a single 
cytokine treatment.  
In an attempt to determine reproducibility of the sCD44 secretion over longer time 
periods by IOBA-NHC cells a series of pilot in vitro studies using duplicate wells 
were performed. Production of sCD44 was monitored as a marker of epithelial 
response regardless the nature of the response profile. The results are shown below 
in ng/ml. Prior to cytokine exposure the culture medium was replaced to prevent cell 
loss due to deprivation of nutrients. The secretion levels obtained were overall higher 
compared to the first study and seemed to follow a similar pattern for each treatment 
at the various time points. Furthermore maximal secretion was noted at prolonged 
time points 144 and 192 hours for PMA. IL-17A, PMA and TNFα/IL-1β induced the 
highest levels of sCD44. The untreated group also secreted the molecule (Figure 
4.8).  
  
Figure 4.8: sCD44 levels after a single initial treatment by IOBA-NHC cells using 
various recombinant cytokines at 24, 48, 72, 96, 144, 192 hours based on mean 
values of two samples.  
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Furthermore, each treated group was compared to the untreated group and the 
variability of the production levels of sCD44 is shown (Figures 4.9 and 4.10) during 
various time points. PMA and TNFα/IL-1β exposure clearly increased levels of 
sCD44 at all timepoints. Others have a more variable pattern. The figures for each 
treatment are shown below. There is a distinct and separate progressive increase in 
the levels of sCD44 after treatment with PMA or TNFα/IL-1β compared to the 
untreated group.  
In the untreated group there is also a progressive increase in sCD44 production over 
time. This reflects cellular turnover increased with time. Zymozan appears to induce 
similar levels and at some time points equal levels of sCD44, which decrease below 
the unstimulated levels at 192 hours. Similar patterns are observed by LPS, poly I:C 
(TLR ligands) and grass pollen extract as shown below.  
These cell lines continuously grow and, over longer time periods, could potentially 
deplete the medium of its nutrients leading to cell death. In these prolonged assays, 
spent culture medium was replaced with fresh culture medium containing cytokines 
in each well after each treatment to provide more nutrients and continuous exposure 
to stimuli in relevant wells. One reason to explain reduction in secretion levels could 
be overgrowth of cells or cell death. To test this, apoptosis markers were applied and 
the results are shown in the next section.  
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Figure 4.9: (A) sCD44 production after TNFα/IL-1β treatment compared to untreated 
cells. The secretion pattern follows that of the untreated cells but at a higher level 
both reaching a plateau at the final time points. (B) sCD44 production after PMA 
treatment compared to untreated cells. (C) sCD44 production after IL-17A treatment 
compared to untreated cells. IL-17A also increased sCD44 levels but was minimally 
greater than the untreated cells and gradually increased with time. 
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Figure 4.10: (A) sCD44 production after poly I:C (TLR3 ligand) treatment compared 
to untreated cells. (B) sCD44 production with time after treatment with LPS (TLR4 
ligand) compared to untreated cells. (C) Comparison of sCD44 production after 
grass pollen extract treatment and untreated cells. (D) sCD44 production after 
zymosan (TLR2 ligand) treatment compared to untreated cells. All data is shown as 
means of duplicate wells.  
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4.5.2 Pilot in vitro studies to investigate sCD44 secretion at 144 and 192 hours 
by IOBA-NHC cells after the use of combination of treatments  
 
Further pilot in vitro studies were performed to investigate the effect of combination 
of treatments to the sCD44 production at prolonged time points (144 and 192 hours). 
It was intended to investigate whether combination of treatments would induce 
greater secretion levels and supernatants were harvested at prolonged time periods. 
The results shown below (Figures 4.11 and 4.12) did not reveal significant variations 
to the previously described results obtained after a single initial treatment. The 
untreated group showed significant levels of sCD44 indicating cellular turnover at 
prolonged time points despite the absence of treatments. PMA induced the highest 
sCD44 secretion levels at both time points and it was maximal at 192 hours. 
TNFα/IL-1β treatment also induced significant secretion but less compared to PMA. 
Prior to cytokine exposure the culture medium was replaced with fresh medium 
before treating the cells at 24, 48, 72 and 144 hours.  
 
 Figure 4.11: sCD44 production by IOBA-NHC cells using various combinations of 
treatments at 144 hours after treatment (based on mean values of duplicate wells).  
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Figure 4.12: sCD44 production by IOBA-NHC cells using various combinations of 
treatments 192 hours after treatment (based on mean values of duplicate wells).  
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4.6   Yo-pro epithelial cell viability studies: apoptosis assay results  
 
Epithelial cell viability studies were performed in parallel to the studies described in 
the previous section. The aim was to assess the viability state of the cell population 
and determine the proportion of cells that are undergoing apoptosis or are not viable. 
Samples were obtained from the last set of experiments presented above. Each 
sample was processed to determine the percentages of the cells in each of the 
following states: (a) live, (b) dead, (c) in early apoptosis and (d) in late apoptosis. 
Below the dot plot diagrams show the analysis of results and the percentages of cell 
populations in each state for the unstimulated group. Similarly the percentages are 
shown in the remaining diagrams.  
Figure 4.13 illustrates the percentages of cell population in the various stages of the 
cell cycle for the untreated cells. The PMA treated cells were 60% live and 26% in 
the early apoptotic state. Only 8% were dead. Figures 4.14 show a selection of the 
cell viability dot plot diagrams. Cells in late apoptosis are of similar percentages 
(15% and 13% respectively) in both treatment conditions with IL-17A and IL-
17A+Grass. Similarly for the cells in early apoptosis (9% and 5% respectively) and 
cells found dead (35% and 34% respectively).  
Furthermore in cells treated with combinations TNFα/IL-1β and TNFα/IL-1β+Grass 
pollen antigen the percentages of the cells in the 4 different stages of the cell cycle 
appear to be similar: 34% and 30% dead, 13% and 21% in late apoptosis, 5% and 
8% in late apoptosis respectively. The results are not indifferent for Zymosan and 
Zymosan+Grass pollen antigen. This also applies for polyI:C and PolyI:C+Grass 
pollen antigen, as well as LPS and LPS+ Grass antigen Additionally, doubling or 
tripling the Grass pollen concentration did not significantly affect the results.  
Therefore in the untreated group, 11  were found in late apoptosis and TNFα/IL-
1β+Grass had the highest percentage (21 ).  On the contrary PMA-treated cells 
were found to have the lowest percentages (6%) in late apoptosis and 8% were 
dead. PMA treated cells showed the highest percentage (26%) of cells in early 
apoptosis. The addition of grass did not cause a significant change in the 
percentages of the concentrations. The treatments did not induce early apoptosis at 
significant levels compared to the untreated group.  
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Overall, best responses were observed for PMA, TNFα/IL-1β and IL-17A and 
combination of treatments with grass extract did not show marked variability. Cell 
viability studies suggested that the treatments did not induce early apoptosis. 
Cellular activation was observed even in the untreated group and prolonged 
harvesting in 144 and 192 hours did not show marked variability on the secretion 
levels of sCD44. The dot plot diagrams are shown below (Fig 4.14). 
 
                                        
Figure 4.13: Epithelial cell viability assessment for the untreated cells. The 
annotations show the percentages of the cells in each state of the cell cycle. 
 
Furthermore the remaining experiments were performed and are described in the 
following sections, where sCD44, VEGF, EGFR, TGFα, p21 secretion levels were 
assayed by ELISA using two epithelial cell lines.  
 
 
 
 
 
 
10 1 10 2 10 3 10 4
YoPro
10
1
10
2
10
3
10
4
P
ro
p
id
iu
m
 Io
d
id
e
R2 R3
R4 R5
R2
  33% dead 
5%  in early apoptosis   
11% in 
late 
apoptosis  
51% live 
152 
 
                 
                  
                    
Figure 4.14:   Flow cytometric analysis YoPro-PI staining in conjunctival epithelial 
cells after 192 hours of cytokine stimulation. Examples of dot plots of PI and YoPro 
were generated from (A) PMA treated IOBA-NHC cells, (B) TNFα/IL-1β+Grass 
extract treated IOBA-NHC cells, (C) IL-17A treated IOBA-NHC cells, (D) TNFα/IL-1β 
treated IOBA-NHC cells, (E) Zymozan+Grass treated IOBA-NHC cells, (F) Grass 
extract (triplicated concentration) treated IOBA-NHC cells. The percentages of 
staining are shown for both markers.  
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4.7. In vitro studies using a single treatment in IOBA-NHC cell lines 
Based on the pilot data the experiments were repeated with one initial cytokine 
treatment (PMA, TNFα/IL-1β, IL-17A and untreated group) using IOBA-NHC cells 
and secretion of EGFR, CD44,TGFα was assayed by means of ELISA. Triplicate 
wells were used for each treatment to allow for a statistical analysis of the 
responses.  
4.7.1. sCD44 secretion  
Cells were treated once at time point 0 minutes and supernatants were harvested at 
24, 48, 72, 96 hours. sCD44 levels progressively increased with time. This includes 
the untreated group suggesting cellular turnover. Maximal production occurred after 
PMA treatment at all time points even in the untreated group (minimal level at 
2.5ng/ml in the untreated group and maximal at 96 hours at 13 ng/ml). A similar 
effect was observed for IL-17A but at much lower levels. TNFα/IL-1β induced sCD44 
secretion peaking at 72 hours just above 6ng/ml and then reducing at 96 hours (6.0 
ng/ml). The results are shown in Figure 4.15 below. 
 
Figure 4.15: sCD44 levels at 24, 48, 72, 96 hours after treatment at time 0 with 
PMA, TNFα/IL-1β and IL-17A and untreated group (Data is shown as means ±SD 
from triplicate wells).   
 t test 24hrs t test 48 hrs t test 72 hrs t test 96 hrs  
Untreated vs PMA  p<0.01 p<0.01 p<0.05 p<0.05 
Untreated  
Vs TNFα/IL-1β  
p<0.01 p<0.01 
 
NS 
 
NS 
 
Table 4.1: t-tests shown for sCD44 levels. IL-17A treated groups were not 
statistically significant to unstimulated - not shown.  
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4.7.2. EGFR secretion   
In the untreated group EGFR secretion was present at 24 hours and slowly 
increased with time at 96 hours (8ng/ml). It is noteworthy that there was a stepwise 
slow increase in EGFR secretion in the untreated group. Maximal secretion occurred 
once again with PMA treatment at 96 hours (>20ng/ml). This pattern is similar to the 
sCD44 secretion pattern. IL-17A induced EGFR secretion that remained at almost 
constant levels around 10ng/ml throughout all times. TNFα/IL-1β treatment also 
induced EGFR production which increases from 10ng/ml at 24 hours to 14ng/ml at 
96 hours. EGFR epithelial secretion increased with time as a response to the 
cytokine treatments as well as in the untreated group indicating cellular turnover. 
 
Figure 4.16: EGFR levels at 24, 48, 72, 96 hours after one treatment with PMA, 
TNFα/IL-1β, IL-17A and untreated group (based on mean values of duplicate wells).  
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4.7.3. TGFα secretion 
 As shown in Figure 4.17, TGFα secretion was detected from 24 hours with a 
stepwise progression. It declined for all treatment groups at 96 hours. Its maximal 
secretion occurred at 72 hours after treatment with IL-17A. All groups had maximal 
TGFα levels at 72 hours. There was no significant variation in the baseline, untreated 
group, for all time points and there was increased secretion for all groups at most 
timepoints after treatment as summarised in Table 4.2.  
 
Figure 4.17: TGFα secretion after treatment with PMA, IL-17A, TNFα/IL-1β at 24, 
48, 72 and 96 hours (Data is shown as means ± SD from triplicate wells except 
levels at 96 hours for which duplicate samples were used; hence error bars for levels 
at 96 hours are not included).  
t test 24hours 48 hours 72 hours 
Untreated vs PMA  p<0.01 NS NS 
Untreated  
vs TNFα/IL-1β  
p<0.01 p<0.05 
 
p<0.05 
 
Untreated vs IL-17A p<0.05 p<0.01 NS 
 
Table 4.2: t-test analysis for TGFα secretion levels compared to untreated cells. No 
statistical analysis was performed for the levels at 96 hours since data were obtained 
for two samples.  
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4.7.4 Summary of findings  
The following table summarises the responses by the IOBA-NHC cells after a single 
cytokine treatment. There was increased secretion for all remodelling markers 
assayed in response to treatment with all cytokines.  
 
Effect on secretion after a single cytokine 
treatment over 96 hours by IOBA-NHC cells  
cytokine EGFR VEGF sCD44 TGFα 
PMA ↑ ↑ ↑ ↑ 
IL-17A ↑ ↑ ↑⃰ ↑ 
TNFα/IL-1β ↑ ↑ ↑ ↑ 
     
Table 4.3: Summary of responses of the remodelling markers after a single cytokine 
treatment. ⃰ IL-17A induced increased sCD44 secretion until 48 hours but was found 
to be reduced at 72 and 96 hours compared to the untreated group. 
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4.8 In vitro studies using multiple treatments in IOBA-NHC cell lines 
In this part of the in vitro studies, the cells were treated three times with the same 
treatment and the secretion of EGFR, CD44 and VEGF was assayed by means of 
ELISA. Supernatants were harvested at 24, 72, 144 and 192 hours and culture 
medium containing stimuli replaced.  
4.8.1. EGFR production   
Similarly there was a progressive increase in EGFR secretion with time and repeated 
treatments. Interestingly, EGFR levels were lower than the ones observed in the 
once-only treatment studies described in the earlier section. TNFα/IL-1β induced 
maximal levels at 192 hours after 3 treatments (0.35 ng/ml). PMA followed and then 
IL-17A showed a stepwise increase in the EGFR secretion including the untreated 
cells. 
 
 
Figure 4.18: EGFR secretion after three treatments at various time points (based on 
the mean values of duplicate wells).  
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4.8.2. sCD44 secretion  
There was a progressive increase of the sCD44 levels from the first 24 hours for all 
groups with maximal secretion after two PMA treatments at 144 hours. Furthermore 
the sCD44 levels decreased at 192 hours after a third treatment as shown in Figure 
4.19 below. The reduction in sCD44 levels could be due to toxicity induced by the 
treatments after prolonged culture periods and therefore a reduction in epithelial cell 
function.  Secondly epithelial repair could have taken place resulting in a reduction of 
sCD44. EGFR secretion pattern correlates with sCD44 levels except for the final 192 
hours sample. There are also similarities with the secretion pattern of VEGF.  
  
Figure 4.19: sCD44 secretion based on triplicate wells at various timepoints. Data is 
shown as means ± SD from triplicate wells.  
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4.8.3 VEGF secretion 
The production pattern is similar to the one observed by the IOBA-NHC line after one 
treatment in the pilot set of in vitro studies. There was a stepwise pattern with 
minimal levels from the first 24 hours and maximal at 192 hours. Maximal production 
occurred after three TNFα/IL-1β treatments at 192 hours [12.0pg/ml]. The stepwise 
increase applied for all groups with increasing time after treatment including the 
untreated group. The production pattern of EGFR correlates well with VEGF with 
progressive stepwise increase with time. Both markers appeared to be present in the 
first 24 hours but in the pilot in vitro study after one treatment EGFR appeared at 
greater levels earlier than VEGF.  
 
Figure 4.20: VEGF production after three treatments over a period of 192 hours. 
Data is shown as means ± SD from triplicate wells.  
t test 24 + 48 hrs 24+120hrs 24+120+48 
Untreated Vs PMA  p<0.01 p<0.05 p<0.05 
Untreated  vs 
TNFα/IL-1β  
NS NS p<0.05 
 
Table 4.4: t-tests for VEGF production of untreated vs PMA and TNFα/IL-1β groups. 
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4.8.4 Summary of responses  
The following table shows a summary of the responses observed by the IOBA-NHC 
cells after multiple cytokine treatments.  
Effect on secretion after multiple 
cytokine treatments over 192  hours 
by IOBA-NHC cells  
cytokine EGFR VEGF sCD44 
PMA ↑ ↑ ↑ 
IL-17A ↑⃰ ↑ ↑⃰ ⃰ 
TNFα/IL-1β ↑ ↑ ↑ 
 
Table 4.5: Summary of the secretion of remodelling molecules in response to 
multiple cytokine treatments by IOBA-NHC cells.  
⃰ IL-17 induced increased EGFR secretion compared to the untreated group but at 
the final time point at 192 hours was shown to be reduced.  
⃰ ⃰ IL-17 induced increased sCD44 levels for the first 72 hours but the levels were 
reduced compared to the untreated group until the final time point.  
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4.9 In vitro studies using IOBA-NHC cells to investigate p21waf levels after a 
single treatment with PMA, IL-17A and TNFα/IL-1β at 144 and 192 hours.   
There was increased expression for all treatments above baseline and greatest 
levels were noted after IL-17A. However the levels produced are at very low 
concentrations (pg/ml). Levels decreased at 192 hours and were higher at 144 hours 
after one treatment (0.95 pg/ml with IL-17A treatment and 0.30 pg/ml after TNFα/IL-
1β or PMA. The results are shown below in Figure 4.21. Given the small 
concentrations of the duplicate samples, statistical analysis could not be performed.  
             
Figure 4.21: Increased p21waf expression after treatment with PMA, TNFα/IL-1β and 
IL-17A at 144 and 192 hours (based on means of duplicate wells)  
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4.10 ChWK cell line: EGFR and sCD44 levels after multiple treatments and 
comparison with IOBA-NHC line.  
4.10.1 sCD44:  
There was a stepwise increase in sCD44 production in response to all treatments as 
relative to baseline for all timepoints. The levels were much higher than those 
obtained from the IOBA-NHC line indicating that the ChWK line may have different 
capabilities in its response to injury since the confluence levels were similar for both 
lines. The production pattern is shown below in Figure 4.22 and the IOBA-NHC data 
are included for comparison purposes. Maximal production occurred in response to 
PMA (15ng/ml) at 192 hours and minimal after IL-17A treatment at 24 hours 
(5.0ng/ml). Despite different levels, the secretion profiles obtained by the two lines 
were remarkably similar, suggesting a common response to injury based on their 
morphological and functional variability. Statistical analysis was not performed given 
the fact the levels under comparison were produced by different cell lines under 
different conditions on different days.  
 
Figure 4.22: sCD44 levels in ChWK and IOBA-NHC lines after three treatments over 
192 hours. Data is shown as means ± SD from triplicate wells  
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4.10.2 EGFR secretion  
Once again there was increased EGFR secretion with higher levels than for IOBA-
NHC. Maximal production occurred at 192 hours after three treatments with TNFα/IL-
1β (0.5 ng/ml). The production pattern increased with time whereas in the IOBA-NHC 
line there was a stepwise increase. The results are shown below in Figure 4.23 with 
the IOBA-NHC line data included for comparison purposes.  
 
Figure 4.23: Mean EGFR secretion levels by ChWK and IOBA-NHC cells after three 
treatments based on duplicate wells.  
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4.10.3 p21waf expression 
All levels were increased with increasing time with maximal expression at 192 hours 
after PMA treatment. The untreated group also showed increased p21 expression 
indicating cell turnover in culture medium. All treatments induced higher levels at 192 
hours compared to samples at 144 hours. The results are shown in Figure 4.24 
below based on means duplicate wells.  
         
Figure 4.24: p21 levels by ChWK epithelial cells at 144 and 192 hours by duplicate 
wells.   
The following table shows a summary of the different responses observed in p21 
secretion by the two different cell lines.  All treatments induced increased production 
of p21 by IOBA-NHC cells but not CHwK cells. This could be explained by the 
differences in the gene expression profiles compared to primary conjunctival 
epithelial cells.  
Effect on p21 expression after a single 
cytokine treatment over 192 hours by IOBA-
NHC  and CHwK cells  
cytokine IOBA-NHC 
cells 
CHwK cells 
PMA ↑ ↑ 
IL-17A ↑ − 
TNFα/IL-1β ↑ ↓ 
  
Table 4.6: Summary of the effects of different cytokines to p21 expression by two 
conjunctival epithelial cell lines.  
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4.11 Effects of steroid dexamethasone pre-treatment and IL-25 to the secretion 
of EGFR and VEGF by IOBA-NHC cells.   
Based on the previous results obtained, further studies were conducted to 
investigate the effect of pre-treatment with the topically administered steroid drug 
dexamethasone, frequently used in the management of CAED, on the secretion of 
EGFR and VEGF.  Initially, various concentrations of dexamethasone were used and 
production of VEGF and EGFR assayed by means of ELISA in supernatants 
harvested at 48 hours. Furthermore a dose response effect to EGFR and VEGF 
secretion was investigated using IL-25 (or IL-17E) with and without dexamethasone 
pre-treatment. All sets included an untreated group of cells. Triplicate wells were 
used and repeated twice. The cells were treated with PMA, IL-17A, TNFα/IL-1β and 
IL-25 (1 ng/ml, 10 ng/ml, 100ng/ml, 1000 ng/ml).  The results are shown in Figures 
4.25 and 4.26. Standard curves for all studies were obtained.  
In the first set of in vitro studies investigating a possible dose response effect for 
dexamethasone EGFR was not secreted. This could be for a number of reasons: an 
option is that EGFR was not secreted by the untreated cells and dexamethasone 
influenced its secretion in the remaining groups of cells treated with cytokines and 
inhibited its secretion. Another explanation could be that EGFR levels were too low 
to detect in this instance. On the other hand, VEGF secretion was increased in all 
wells with all treatments and the addition of dexamethasone did not induce a 
reduction of levels compared to the wells without steroid pre-treatment. There was 
no VEGF production for the untreated cells and maximal VEGF secretion was noted 
after TNFα/IL-1β treatment with 0.1 M dexamethasone. The production of VEGF by 
IOBA-NHC cells is shown in Figure 4.25.  
A further set of in vitro studies was performed in an attempt to investigate the 
secretion profile of EGFR and VEGF after treatment with various concentrations of 
IL-25 as shown in Figure 4.26 with and without dexamethasone pre-treatment. A 
group of untreated cells was included as well. Supernatants were harvested at 48 
hours from 4 wells for each molecule and it was repeated twice. In the analysis 
shown in Figure 4.26 the EGFR outlier values were not included. There was 
increased production for VEGF with only a small reduction in response to 
dexamethasone pre-treatment. The results are summarised in Table 4.7. There were 
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similarities in the production levels induced by the various concentrations of IL-25 in 
both groups and maximal secretion occurred when treated with TNFα/IL-1β without 
dexamethasone (1000 pg/ml).  EGFR was minimally secreted in most groups in the 
set without dexamethasone but maximal secretion occurred in the untreated cells 
(380 pg/ml). However EGFR production in the set with dexamethasone pre-
treatment appeared to be reduced in the group treated with PMA, IL-25 (1.0nm/ml), 
IL-17A, but increased by the untreated cells. The cells treated with TNFα/IL-1β 
showed minimal secretion when dexamethasone was added. When dexamethasone 
was added to cells prior to exposure to IL-17A, and TNFα/IL-1β, VEGF secretion 
was shown to be slightly reduced or similar to levels from untreated cells suggesting 
that response to IL-17A and pro-inflammatory cytokines TNFα/IL-1β may be inhibited 
by a steroid sensitive pattern but only to a limited degree. Given the variable 
secretion patterns and nature of cytokine microenvironment it is suggested that 
further in vitro experiments are performed to investigate the immunomodulatory role 
of dexamethasone over more time points rather than one which was used in this 
study.  
Effect on VEGF secretion after a single cytokine 
treatment at 48 hours by IOBA-NHC  cells  
cytokine Without 
Dexamethasone 
With 
dexamethasone 
PMA ↑ ↓ 
IL-17A − − 
TNFα/IL-1β ↑ − 
IL-25  
(1 ng/ml)  
↑ ↑ 
IL-25 
(10 ng/ml) 
↑ − 
IL-25 
(100 ng/ml) 
↑ − 
IL-25 
(1000 ng/ml) 
− − 
             
Table 4.7: Summary of the secretion of VEGF in response to various cytokine 
treatments with and without dexamethasone pre-treatment. IL-25 increased the 
production but there was not a dose response effect. Dexamethasone did not induce 
a significant reduction in VEFG secretion.  
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4.12 Discussion  
4.12.1 IOBA-NHC and ChWK conjunctival epithelial cell lines secrete EMTU 
associated molecules after treatment with pro-inflammatory cytokines and IL-
17. 
To date there is no published in vitro data on the production profiles of human 
VEGF-A, EGFR, sCD44, TGFα, p21waf by human conjunctival epithelial cells. This is 
the first study to provide data on their in vitro secretion patterns by two conjunctival 
epithelial cell lines under various inflammatory conditions in response to a variety of 
cytokines.  
Overall there is increased epithelial cell secretion for all remodelling markers after 
cytokine treatment which progressively increases with time in a stepwise manner. 
PMA and TNFα/IL-1β induced greater secretion levels. The untreated group also 
showed some secretion which increased with time, reflecting an increase in cell 
numbers per well during the experiment, but for sCD44 and p21waf there is a 
reduction at the final time point. The ChWK line showed increased p21 levels with 
increasing time. There are similar secretion patterns for EGFR and VEGF.  
Repeated treatments did not increase further the production levels. VEGF showed a 
similar secretion pattern in the single treatment pilot IOBA-NHC in vitro line and in 
the multiple treatments study. However repeated treatments did not show higher 
production levels. EGFR levels were lower than VEGF and similar in the two sets of 
experiments. Once again multiple treatments did not induce a greater increase in its 
levels. sCD44 acts as a positive control and an EGFR signalling enhancer and its 
levels also increased with time but did not show significant variations in all sets of in 
vitro experiments. Repeated cytokine/allergen treatments did not induce higher 
levels of secretion of the markers. All experiments demonstrated increased secretion 
of the remodelling markers without significant variations and no error bars were 
shown in levels of two experiments. The treatment with steroid dexamethasone did 
not alter the secretion of EGFR and VEGF in vitro. 
This is the first study to investigate and attempt to develop an in vitro model of 
epithelial remodelling markers in ocular allergic inflammation. The in vitro secretion 
patterns of the markers chosen, based on the EMTU hypothesis in asthma, reflect 
the capabilities of conjunctival epithelial cell lines to respond to injury and stress. 
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These properties can be used to assess further their potential in repair mechanisms 
and the immunomodulatory roles of anti-VEGF and anti-EGFR in ocular allergy.  The 
increased secretion levels of sCD44, EGFR, TGFα and VEGF are in agreement with 
the increased expression seen in the immunohistochemistry studies. So far, 
epithelial remodelling markers have been extensively studied in the respiratory 
mucosa and there is no published data to date about similar properties of 
conjunctival cells in vitro.  
EGFR and TGFα production have been investigated in cultured ozone or TNFα 
induced cellular stress primary human nasal epithelial cells. Ozone had no effect on 
EGFR expression but this was not the case for TNFα (5-50 ng/ml for up to 48 hours). 
There was increased EGFR expression (p <0.01) compared to controls in a dose-
dependent manner, with maximal expression between 12-24 hours (196). EGFR 
positivity detected in nasal polyp epithelium correlated with the TNFα positive 
immunoreactive cells (254).  
Primary bronchial epithelial cells and the NCI-H292 line cells were exposed to EGF 
and H2O2 aiming to achieve EGFR activation. TNFα (10ng/ml) stimulation of the line 
resulted in increased expression of IL-8 which correlated EGFR expression. In the 
same study, the authors examined the effect of dexamethasone (1.0µM) on EGF 
induced IL-8 release. Its inhibition was decreased as the dose of EGF was 
increased.  
When serial and parallel scrape wounds were inflicted in confluent monolayers of 
16HBE-14o bronchial epithelial cells, EGF addition enhanced healing and 
dexamethasone 0.1, 1.0, 10.0 µM did affect wound closure (82).  Additionally the 
involvement of EGFR activation was investigated in healing using the tyrosine kinase 
inhibitor tyrphostin AG1478 (a selective inhibitor of EGFR signal transduction) in 
H292 bronchial epithelial cell lines. It was reported that EGFR activation was an 
intrinsic mechanism of epithelial repair with release of an autocrine ligand. There 
was increased EGFR expression at epithelial sites of injury in asthmatic airways but 
not in control subjects. Similar evidence was provided by immunohistochemistry of 
airway biopsies in the same study as described in previous sections. In those 
asthmatic patients participating in the study using glucocorticoids there was no 
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significant correlation between any of the markers under investigation and steroid 
use (255).   
Further evidence to support abnormal epithelial repair and epithelial mediated 
remodelling, the role cyclin dependent kinase inhibitor p21waf was investigated using 
primary bronchial epithelial cells. Cells were exposed to H2O2 with or without TGFβ 
(10 ng/ml) and experiments with dexamethasone 1 µM were also performed. H2O2 
was found to be a potent inducer of p21waf expression. Similarly TGFβ increases 
p21waf expression but dexamethasone did not affect its levels (98). Additionally 
increased asthma severity was correlated with increasing p21waf expression 
regardless steroid use by the asthmatic subjects.  
 
4.12.2 Advantages and limitations of IOBA-NHC and ChWK lines in 
experimental use 
 
The IOBA-NHC epithelial cell line seems to exhibit features that resemble the 
primary human conjunctival cells in terms of morphology and function. More 
specifically the ChWK cells have been reported to be contaminated with HeLa cells 
and HeLa markers were expressed in their karyotype. Additionally they have the 
variant A of enzyme glucose-6-phosphate dehydrogenase which may interfere with 
result interpretation. However no functional similarities have been reported. Some 
studies have reported differences in the cytokine profiles expressed but this could be 
also secondary to the culture media and conditions used. These major problems 
associated with cell lines involving low level contamination with other cells (eg HeLa 
positive cells) and/or mycoplasma (although this was routinely tested for as part of 
our normal lab procedures), may persist undetected and cause alterations to cell 
behavior and gene expressions. 
Both cell lines have been used before for experimental in vitro studies. Some 
researchers justify use of IOBA-NHC because it retains most of the structural and 
functional features of the human conjunctival epithelium. Cell lines are considered a 
satisfactory addition to animal studies to investigate specific cellular responses which 
may add to our understanding of the pathophysiological aspects of disease in 
humans. They permit easy and fast cell growth with small variations in experimental 
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conditions. Both lines have been used before by our group and others to study the 
role of conjunctival epithelium in allergic disease.  
Cell line popularity can be estimated by the numerous publications and the American 
Type Culture Collection (ATCC) which includes over 3,600 cell lines from over 150 
different species. Immortalized cell lines are often used in research instead of 
primary cell cultures since they are cost-effective, provide an unlimited supply of 
material and offer no concern regarding ethical issues associated to human and 
animal tissue experiments. However a significant drawback is that in vitro cell 
cultures are studied in the absence of their local natural environment which includes 
interactions with other cell types that may be important to the hypothesis being 
tested.  
 
In this thesis the EMTU hypothesis of asthma is tested to conjunctival tissue and 
involves the interaction of epithelial cells with mesenchymal cells. Therefore a 
drawback of the in vitro experiments of this thesis is the study of EMTU markers in 
epithelial cells only. Co-cultures of conjunctival epithelial cells with mesenchymal 
cells and/or fibroblasts are suggested for further studies. Additionally, cell lines do 
not completely mimic primary cells. Therefore caution has been taken when 
designing the experiments by choosing two, rather than one, immortalized 
conjunctival epithelial cell lines, under conditions that other groups and our group 
have already tested. Further studies as key control experiments to confirm and 
replicate the expression patterns and properties of these markers could include the 
use of primary conjunctival cell lines.  
 
The pathogenesis of chronic/persistent ocular allergy is multifactorial and despite 
that our understanding has increased about the role of the epithelium there are still 
mechanisms and functions not yet known. Therefore this adds as an additional 
limitation to the conclusions that can be safely drawn from the in vitro studies of this 
thesis given the artificial nature of cell lines and the fact that the markers under 
investigation are analysed in isolation from other factors that may also occur at the 
same time and not assayed.  
 
173 
 
Cell viability studies were performed to ensure that the remodelling markers’ 
secretion was not affected by apoptosis/death. Results showed that exposure to any 
of the cytokines did not induce early apoptosis in comparison to untreated cells. 
However further studies could be carried out to ensure that production was not 
affected by cell density differences by means of total protein content determination 
(spectrophotometrical analysis of the cell lysates using the BCA assay). Alternative 
more sensitive way of determining total cell counts per well at the end of the 
experiment would be to use Trucount beads and processed by FACS to obtain an 
accurate live cell number per well.  
Both cell lines secrete the remodelling markers assessed but the stepwise increasing 
secretion pattern with time and cytokine treatments by the IOBA-NHC line cells show 
differences in their behavior under stress conditions. In addition it is known that the 
gene signature expression patterns of the two lines when compared to primary 
conjunctival epithelial cell lines differ and that the IOBA-NHC pattern was closer to 
primary cultures than the CHwK (256). The results of the in vitro experiments provide 
useful information for the choice of the conjunctival cell line that is more appropriate 
in future experiments to increase validity of extrapolation to clinical scenarios.  
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CHAPTER 5 
 
 
GENERAL DISCUSSION 
 
 
 Conjunctival epithelial remodelling and the application of the EMTU 
hypothesis in CAED. 
 
 Th-17 T cell-derived cytokines may have roles in epithelial conjunctival 
remodelling in CAED.  
 
 
 Re-classifying Ocular allergic disease and novel treatment strategies 
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5.1 Conjunctival epithelial remodelling and the application of the EMTU 
hypothesis in CAED.  
 
5.1.1. EGFR and TGFα expression parallels disease severity in CAED  
 
The data in the present study, and from previous studies utilising VKC biopsies, 
supports a similar TGFβ and EGFR-ligand mediated remodelling mechanism in the 
severe forms of disease of ocular allergy (AKC and VKC). The current study showed 
an overexpression in AKC and VKC of the EGFR, its ligand TGFα and CD44, known 
to act as the receptor enhancer, leading to its activation. The expression was mainly 
epithelial and was not detected in normal conjunctival biopsies. Mild cytoplasmic 
epithelial expression was also observed in GPC. GPC biopsies in the current study 
showed minimal expression of EGFR and TGFα in 2 out of 3 biopsies. There is no 
study to date reporting the expression levels and distribution of TGFα in the 
conjunctiva in chronic allergic eye disease. In CAED the EGFR expression profile 
from this study is in agreement with the data reported by a previous 
immunohistochemistry study with VKC tissue biopsies (126). In that study the 
investigators used an anti-EGFR mAb (1:10; Amersham) and observed expression in 
8 out of 16 VKC biopsies in the deeper epithelial layers. The data from both studies 
may suggest epithelial mesenchymal communication and therefore may support the 
application of the EMTU hypothesis in CAED.  
 
EGFR activation was investigated in corneal wound healing by means of 
immunoprecipitation and immunoblot analysis in an in vivo rat corneal model and it 
was concluded that EGFR was activated during corneal wound healing in vivo (255). 
It was suggested that the epithelium can produce several EGFR ligands enhancing 
the healing response. More specifically the level of EGFR phosphorylation was 
increased within 15-30 minutes after wounding and remained elevated for several 
hours. This timing is consistent with the initiation of the re-epithelialization stage and 
the data are also consistent with EFGR’s role in stimulating cell proliferation in the 
limbus and distal to the original wound. Based on previous evidence (257-259,123) 
and taking into account the data of this study we may conclude that EGFR activation 
and its ligands’ expression may indicate a possible role in the regulation of epithelial 
cell maintenance and repair on ocular surface epithelia. Therefore it is suggested 
176 
 
that in the conjunctival mucosal environment, the epithelial EGFR activation in 
combination with the mesenchyme may be responsible for the enhanced repair 
response leading to remodelling and altered tissue functions with growth factors and 
cytokine involvement.  
 
TGFβ epithelial expression was reported previously to be increased in VKC biopsies 
but was absent or very weakly expressed in control subjects (130,126). TGFβ 
promotes fibroblast proliferation and collagen expression and has been proposed to 
have a role in remodelling in chronic asthma (260). The balance between TGFβ 
mediated fibroblast differentiation and EGFR-ligand mediated cell proliferation is of 
particular importance in remodelling and chronic asthma pathogenesis.  
 
The results are in agreement with other data based on immunohistochemistry 
studies and in vitro experiments involving nasal epithelial cells where increased 
expression of TGFα and EGF as well as EGFR in the epithelium was reported in 
response to exposure to ozone by means of immunohistochemistry (123). EGFR 
was upregulated in this acute stress model indirectly and due to the proinflammatory 
effects of ozone. Ten nasal biopsies after exposure to ozone showed significant 
epithelial EGFR expression compared to air exposure (p= 0.007) and 6 showed 
increased expression for TGFα and EGF (p = 0.028) (123). The data in the present 
study revealed higher levels of statistical significance of all markers in the severe 
disease ocular allergy group compared to controls despite the mild positivity 
observed in the GPC subjects. Furthermore treatment of human nasal epithelial cells 
with TNFα in vitro, resulted in significant EGFR secretion.  
 
Previously, immunostaining of  biopsies of asthmatic subjects exhibited strong EGFR 
expression.  Ten normal bronchial biopsies, 13 mild and 5 severe asthmatics and 
anti-EGFR antibody 25µm/ml were used and a  uniform expression of epithelial 
EGFR was observed and increased with disease severity (82). There was no effect 
of corticosteroid treatment on EGFR expression. EGFR expression patterns are in 
agreement with the present study but steroid drops treatment was stopped 4 weeks 
prior to biopsy. Given the chronicity of the disease and the need for long-term 
treatment it could be suggested that 4 weeks off treatment would not be long enough 
to influence the expression profile of EGFR and its ligands. It is therefore proposed 
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that in AKC and VKC, steroid treatment may not alter significantly EGFR expression 
patterns. The results of the in vitro exposure to dexamethasone which had no effect 
on soluble EGFR and VEGF levels would support the hypothesis that 
dexamethasone does not alter their cellular secretion.  
 
 
5.1.2 Pro-inflammatory cytokines TNFα/IL-1β promote in vitro EGFR and its 
ligand TGFα secretion by conjunctival epithelial cells.  
The in vitro studies of the thesis showed increased secretion of EGFR by all groups 
including the untreated cells but at lower levels. Increased secretion levels were 
observed after treatment with PMA, then TNFα/IL-1β and IL-17A. There was a 
stepwise increase in its levels with time after exposure to the recombinant cytokines 
but multiple treatment combinations did not produce greater secretion levels.  
TNFα/IL-1β induced increased EGFR secretion, indicating a possible role for this 
proinflammatory cytokine in this epithelial inflammation and repair in vitro model. 
This observation is in agreement with other reports on human epithelial cell lines. 
EGFR expression in human nasal epithelial cell lines (HNECs) was increased after 
exposure to TNFα and after exposure to ozone, and it was suggested that the later 
may induce an indirect effect to EGFR expression. Maximal secretion occurred at 24 
hours in a dose response manner increasing gradually from12.5 ng/ml to 200 ng/ml 
of TNFα (123). In this study the expression profile of EGFR was investigated over 
shorter and longer time periods using single or multiple cytokine treatments.  
Additionally further in vitro studies have also reported similar responses to TNFα 
stimulation in EGFR expression (261-263). The role of this pro-inflammatory cytokine 
in ocular allergy is well documented from previous studies. Immunostaining and in 
vitro results showed increased EGFR expression and secretion. PMA and IL-17A 
also induced EGFR expression in a stepwise manner. PMA seems to be more potent 
in inducing EGFR secretion than the other cytokines in the present study.  
Interestingly activated neutrophils, the most prominent cell type infiltrating the 
airways, were reported to release TNFα in large quantities in ozone exposed human 
nasal mucosa (123). The results in Chapter 4 of this study have shown increased 
EGFR secretion by conjunctival epithelial cells in response to TNFα treatment. The 
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data from the current study are in agreement with previous studies conducted in 
nasal mucosa. It is noteworthy that the TNFα levels produced by the cell lines itself 
may have not been high  enough to induce EGFR expression and other cell types 
with well-known proinflammatory roles (e.g. eosinophils, mast cells and 
macrophages) can also contribute. In addition it was observed that the positive 
staining for EGFR in nasal polyp epithelium correlated with the number of TNFα 
positive immunoreactive cells (264).   
EGFR signalling is proposed to be an intrinsic part of the response to injury and not 
dependent on an exogenous ligand (82). Human bronchial epithelial cell lines were 
used (16HBE14o) and demonstrated in vitro increased secretion of TGFα, 
amphiregulin and HB-EGF which resulted in EGFR activation after scrape wounding 
of cell monolayers. Additionally it was showed that EGF promotes bronchial epithelial 
repair in vitro and EGFR expression was significantly increased in the areas of 
epithelial damage in bronchial biopsies of asthmatics but not normal subjects (82). 
TGFα secretion was also increased after exposure of human nasal mucosa to ozone 
and assessed by means of immunohistochemistry compared to nasal mucosa 
exposed to air (123).  
 
5.1.3 EGFR and TGFα levels correlate with eosinophilic activation and 
neutrophilia  
 
Notably in the severe of forms of disease AKC and VKC it was reported that there is 
upregulated eosinophilic activation and different cytokine profiles (159). It has been 
found that in VKC there was eosinophil co-expression of proinflammatory cytokines 
IL-3, IL-5, IL-6, GM-CSF whereas in AKC the profile changed with increased 
eosinophilic expression of IL-4, IL-8 and GM-CSF (18). IL-4 is known to be produced 
by Th2 T cells, mast cells (267) and eosinophils (154) and participates in the Th2 
type response. In chronic asthmatics EGF significantly stimulated IL-8 production in 
a dose dependent manner (254) which is a potent neutrophil chemoattractant (265). 
EGF-stimulated IL-8 production was found not to be affected by steroid treatment 
(266). Neutrophilic infiltration is a feature of increasing severity in chronic forms of 
ocular allergy with highest neutrophil cell counts in AKC (154). Therefore the 
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epithelial damage could lead to neutrophilia via an EGFR dependent increase in IL-8 
production by the conjunctival epithelium.  
 
5.1.4 Increased CD44 levels in CAED parallel disease severity.  
 
Previous studies have reported that CD44 production is associated with epithelial 
injury, can be regulated by cytokines (103) and has a physiological role in epithelial 
repair (104). The increased expression of CD44 in inflammatory diseases acts as a 
positive control confirming the degree of tissue response to injury in chronic forms of 
disease (AKC and VKC). However, some CD44 expression was also observed in the 
milder inflammatory condition GPC in the control group as well as in two normal 
controls hence  it failed to reach significance (taking statistical significance at 
p<0.05). The expression pattern follows that of EGFR and its ligand TGFα and is 
mainly epithelial with milder patchy or diffuse stromal uptake. Increased expression 
of CD44 reflects a response to injury of the layer involved; hence its role as a 
positive control reflecting tissue damage.  
 
Both cell lines showed increased production of the positive control marker, 
hyaluronate receptor, CD44 in all groups, in response to pro-inflammatory cytokines, 
indicating a baseline degree of cell turnover, probably reflecting the culture tissue 
conditions. The increased levels paralleled the EGFR and VEGF secretion profiles in 
vitro which have been also shown to be overexpressed in VKC and AKC biopsies.  
CD44 expression was investigated by means of antibody-staining and confocal 
microscopy using cultured differentiated human bronchial epithelial cells (268). CD44 
was expressed in normal bronchial airway biopsies in the areas of epithelial damage, 
18 hours after scraping (268). Some but not all cells co-expressed the proliferation 
marker Ki-67 in addition to CD44. A similar response of increased CD44 expression 
was found in two of the healthy conjunctival tissues included in the control group of 
the thesis. Overall CD44 expression levels were also shown to be increased in the 
bronchial epithelium of asthmatics (102).  
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5.1.5 Increased p21waf secretion in vitro in IOBA-NHC conjunctival epithelial 
cell line parallels EGFR and CD44 profiles.  
From the results of the in vitro studies there was increased p21waf secretion after 
treatment with all cytokines. This observation is in agreement with other studies 
which suggested that the expression of this cyclin-dependent kinase inhibitor is 
increased in epithelial injury. p21waf overexpression in asthmatic mucosa affects cell 
proliferation and survival leading to abnormal epithelial repair and remodelling (78).  
The increased production of EGFR does not seem to be associated with increased 
proliferation as part of a cellular response to injury and is not associated with an 
increased expression of proliferating cell nuclear antigen (PCNA) (269). It is known 
that p21waf interacts with PCNA to prevent its activation of DNA polymerase δ (269). 
CDK inhibitor p21waf interacts with cyclins D and E to inhibit transition from G1 to S 
phase via inhibition of the phosphorylation of the retinoblastoma protein (269). Cell 
division is a highly regulated process and transition through the restriction point and 
entry into the S phase is regulated by CDKs that are in turn regulated by cyclins D, E 
and A. CDK activity is modulated by phosphorylation and requires cyclin binding and 
may be inhibited by the CDK inhibitory proteins (270).  
Cellular population homeostasis depends on the balance between cell proliferation, 
growth arrest and apoptosis. Cell differentiation, growth inhibition, DNA damage are 
known to affect the levels of p21waf which in turn affects all the processes described 
above (271). After treatment of primary bronchial epithelial cell in vitro with TGF-β, 
p21waf expression and localisation was observed to be in the nucleus as also 
observed in tissue sections (98). Expression of p21waf after tissue response to injury 
is important since it is involved in cell apoptosis and survival processes. Its anti-
apoptotic role correlates with its cytoplasmic distribution in oxidant treated bronchial 
epithelial cells (98).  
By means of immunohistochemistry the distribution and expression of p21waf, 
proliferation marker Ki67 and EGFR was investigated in bronchial biopsies from 
asthmatic children. Immunostaining for Ki67 was localised only in the basal cells and 
its expression was significantly reduced in the asthmatic epithelium compared to 
normal subjects. There was a positive correlation in the increased levels of EGFR 
and p21waf expression but there was no positive correlation between eosinophils and 
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p21waf or Ki67 (272). Based on in vitro studies, epithelial injury induces expression of 
various growth factors (e.g. TGFβ, FGF, PDGF, ET-1) and these in turn promote 
fibroblast proliferation (50,272). This effect can be further enhanced by inhibition of 
EGFR mediated epithelial repair (82). These results support the suggestion that 
abnormal epithelial mesenchymal communication in the injured mucosal membrane 
mediate remodelling processes and disease perpetuation (97).  
Therefore increased p21waf expression in conjunctival epithelial cells may suggest 
that in chronic ocular allergic disease there is an abnormal epithelial response to 
injury leading to reduced cellular proliferation and replacement of injured cells. 
Furthermore this suggests an imbalance in the relationship between cellular 
apoptosis and survival affecting the regulation of conjunctival epithelial cell 
population and homeostasis. These results are in agreement with the observations 
made in chronic asthma and may contribute to disease perpetuation and epithelial 
mediated remodelling in AKC and VKC.  
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5.1.6 TNFα/IL-1β and IL-17A induce VEGF secretion by conjunctival epithelial 
cells in vitro.  
 
It has been demonstrated that fibroblasts and monocytes stimulated in vitro with IL-
17A produce VEGF-A (273,274) and in vivo cornea after HSV infection via induction 
of IL-6 expression (305). Additionally IL-6 was shown to be a regulator of IL-17A 
production by T cells (275,276). Increased ocular surface IL-6 production has been 
documented in human dry eye disease (277,278) and there was also a correlation 
with disease activity (279). VEGF has a well-established role in angiogenesis and is 
also known to participate in remodelling amplifying the continuation of the chronic 
inflammatory process (38,280). Its role in epithelial mediated remodelling in mucosal 
inflammatory disease has been suggested with specific reference to chronic asthma 
(260) and vernal keratoconjunctivitis (281,126).  
The in vitro results of the current study on VEGF secretion profile  are in agreement 
with the findings by  other studies utilising VKC biopsies (281,126) suggesting that 
conjunctival epithelial mediated remodelling plays an important role in the 
immunopathogenesis of CAED. However it is not yet known if VEGF production 
occurs secondary to EGFR upregulation or is indirectly mediated via cytokines acting 
as intermediate mediators. The roles of the pro-inflammatory cytokines TNFα and IL-
17A may suggest that intermediate factors participate in disease perpetuation via 
growth factor expression.  
Growth factors are well known to regulate production of the components of 
extracellular matrix, integrins and collagens. The epithelium in the present study 
seems to be the source of VEGF and similar studies have documented that TGFβ, 
bFGF and PDGF are derived from the conjunctival epithelium in VKC (126,130) as 
well as fibroblasts and other inflammatory cells participating in the cell mediated 
immune mechanisms in VKC (282,283).  
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5.1.7 Epithelial mediated remodelling in asthma and chronic allergic ocular 
disease 
EGFR overexpression has been documented in asthmatic epithelia at both the 
mRNA and protein levels (82,83,284). Additionally in vitro studies reported that 
EGFR and its ligands play an important role in epithelial repair in asthmatic airways 
(82). More specifically the in vitro studies performed in bronchial epithelial cell 
cultures suggest that EGFR plays an important role in bronchial epithelial repair and 
remodelling in asthma (82). The significant upregulation of EGFR expression 
observed in the current study in VKC and AKC biopsies is in agreement with the 
findings from other studies in airway mucosa and VKC as described above.  This 
suggests that abnormal epithelial repair is participating in conjunctival epithelial 
remodelling in the chronic forms of ocular allergic disease as proposed by the EMTU 
hypothesis in chronic asthma.   
VEGF is also overexpressed by the conjunctival epithelium as documented by 
immunohistochemistry in VKC biopsies (126), flow cytometry in tears of VKC 
patients (281) and in vitro in the current study as described previously. In asthmatic 
airways there is increased VEGF expression  which is also produced by eosinophils 
and macrophages (285). This observation was associated to the increased 
vascularity observed of the bronchial mucosa and the numbers of VEGF-positive 
cells (285). In a murine model of asthma there was increased VEGF expression and 
furthermore an increased VEGF expression in asthmatic airways was detected after 
antigenic stimulation (286,55).  
The factors described above seem to have a central role in epithelial remodelling in 
chronic asthmatic mucosa and in severe forms of ocular allergic inflammation. 
Additionally fibrogenic growth factors PDFG, bFGF, TGF-β1 which are known to 
participate in remodelling were all found to be increased in the epithelium in VKC 
compared to normal subjects (126,130) and they have been reported to promote 
fibroblast proliferation and increased extracellular matrix production and deposition in 
the pulmonary mucosa in pulmonary fibrosis (59). It has been suggested that binding 
of all of these factors to the extracellular matrix glycosaminoglycans may induce 
prolonged activity of the factors at the fibrotic areas (130). The conjunctival epithelial 
cells communicate via cytokines and growth factors with the fibroblasts and regulate 
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cellular processes, wound healing and angiogenesis (51,52).  Overexpression of 
PDGF, bFGF and TGF-β1 has been demonstrated by bronchial epithelial cells in a 
three-dimensional in vitro model and promote fibroblast proliferation (50).  
Conjunctival remodelling is known to affect VKC and results from this thesis suggest 
that remodelling markers are upregulated in CAED. However no studies to date have 
demonstrated the histological changes associated with remodelling in the 
conjunctiva. Therefore this is a limitation of the current study and it is suggested that 
if more biopsies were available, more histopathological features could be 
investigated in AKC and VKC compared to controls. More specifically, using 
conjunctival sections stained with haematoxylin and eosin, measurements of 
basement membrane thickening or fragmentation and areas of destruction of 
conjunctival epithelium could be assessed as in previous studies in asthmatic 
airways (287-289) and an attempt to relate the findings with the epithelial 
conjunctival expression of EGFR and TGFα.  
In the asthmatic lung there is growing evidence over the last few years that the 
epithelium plays a crucial role in the immunopathogenesis of airways remodelling. 
An emerging theory proposed an inability of the airways epithelium to properly repair 
leading to EMTU activation and remodelling. More specifically it proposed that Th2 
cytokines co-participate with the epithelial damage leading to inappropriate 
reactivation of the EMTU, inflammation and remodelling in chronic asthma. This 
thesis investigated the possibility of applying the EMTU hypothesis of asthma to 
CAED.  
Key EMTU molecules are found to be upregulated by conjunctival epithelial cells but 
these findings are mainly in vitro investigations in isolated epithelial cells. The 
immunostaining data, although they provide evidence that EMTU molecules are 
overexpressed in CAED, on their own are not sufficient to support fully the 
application of the EMTU hypothesis in CAED. Although this is the first study to look 
for evidence on the EMTU hypothesis in the conjunctiva and CAED, the interactions 
between the different cell populations forming the EMTU have not been studied 
either in vitro or in vivo. Therefore future challenges include the development of 
systems that will enable this hypothesis to be fully tested and the hypothesis that 
inherited susceptibility genes e.g. ADAM33, influence the EMTU reactivation and 
185 
 
upregulation of molecules and mediators indicative of the remodelling processes in 
CAED.  
This study focused on in vitro experiments with isolated conjunctival epithelial cells 
treated with recombinant proteins. One mouse model has been recently developed 
in severe AED (324) but there have been no developments on an animal model for 
CAED. Therefore fibroblast-epithelial co-cultures of primary conjunctival cells with 
cell junction formation and plated on collagen/matrix membranes to develop three-
dimensional cultures or interaction of cells, are suggested for future laboratory work. 
These models may retain the advantages of isolated cell cultures but also allow 
investigations of long-term events and studies of the pharmacological targets of 
intercellular processes involved in CAED. A CAED mouse model has been recently 
developed which will hopefully enable many of the in vitro experiments to be 
performed in vivo to investigate further the application of the EMTU hypothesis and 
future treatment strategies. Briefly, murine dendritic cells are pulsed with short 
ragweed pollen (SRW) and then injected subconjunctivally into SRW-sensitised mice 
which are then topically challenged daily with SRW for 5-7 days. Signs and 
symptoms of a clinically severe form of allergic conjunctivitis were observed (338).   
Compared to airway remodelling, where there is growing interest and amount of 
investigations behind the mechanisms involved, conjunctival remodelling and CAED 
pathogenesis have not been extensively investigated. Questions remain not fully 
answered and it is hoped that the results of this thesis will support future work 
towards understanding better the following elements:  
1) Is conjunctival epithelial remodelling the cause of CAED or a product of 
chronic inflammation?  
2) Is inflammation essential for the development of conjunctival epithelial 
remodelling or they are both parallel events contributing to disease 
pathogenesis?  
3) Is conjunctival epithelial remodelling in CAED reversible?  
4) Is conjunctival epithelial remodelling genetically determined?  
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Although conjunctival remodelling is considered to occur as a consequence of 
chronic inflammation, the idea that the EMTU reactivation in chronic asthma 
induces remodelling has led to the suggestion that inflammation and remodelling 
are parallel than sequential events. The results of this thesis have shown for the 
first time that there is upregulation of remodelling associated molecules and 
mediators related to the EMTU in CAED. This hypothesis may explain in part why 
the prolonged use of steroids may have a limited effect on limiting disease 
progression in CAED.  
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5.1.8 EGFR and associated epithelial remodelling mediators in CAED are not 
expressed in OCP 
 
In the present study there was no expression of EGFR and its ligand in active and 
chronic OCP. This may suggest separate T cell driven responses in fibroblast-
mediated remodelling mechanisms in OCP differentiating this conjunctival 
inflammatory disease from an epithelial-mesenchymal mediated remodelling 
mechanism with EGFR activation in chronic allergic disease. Data reporting 
overexpression of collagens (130), metalloproteinases (130,281), growth factors 
(TGF-β, FGF, PDGF, VEGF) (130,131,126,281) in VKC as opposed to controls, 
contribute to remodelling. This evidence taken together with the overexpression of 
EGFR and its ligand may support the role of epithelial-mesenchymal mediated 
communication leading to remodelling, disease perpetuation and chronicity.  
 
Given the absence of EGFR expression and it ligand in active and chronic OCP it is 
likely that EGFR mediated remodelling of the conjunctiva is not a feature of 
autoimmune disease. Hence the immunostaining data of this thesis suggest that 
there is no evidence to support the application of the EMTU hypothesis to OCP. This 
re-enforces the fact that OCP is a different disease process where cicatrizing 
autoimmunity against the basement membrane is the key mechanism rather than 
remodelling mediated by epithelial injury. The cicatrizing component of the disease 
leads to blindness due to surface failure, corneal vascularization and opacification. 
EMTU activation instead is a feature of epithelial-mesenchymal driven response in 
chronic forms of mucosal inflammatory disease with an allergic component in its 
immunopathogenesis. Therefore, cellular and cytokine responses together with 
EGFR mediated interactions may suggest that there are several self-propagating 
vicious cycles contributing to disease perpetuation and chronicity.  
 
In OCP, progression of sub-epithelial conjunctival fibrosis due to continuous 
excessive matrix deposition leads to conjunctival contraction, forniceal shortening, 
symblepharon, meibomian gland dysfunction. Various molecules participate in the 
fibrotic process and so far most research reports investigated the role of conjunctival 
fibroblasts. T cells are increased in the subepithelial infiltrate at all phases of ocular 
pemphigoid disease. TNFα expression is increased by a large number of stromal 
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infiltrating cells in active OCP. TNFα induces increased MMP-9 expression and 
decreased TIMP-2 as well as increased ICAM. TNFα seems to have a profibrotic, 
chemoattraction and pro-inflammatory roles in human conjunctival fibroblasts (337). 
However the results of this thesis suggest that a concomitant EGFR upregulation is 
not observed suggesting that if TNFα is responsible it may be acting indirectly via 
activation of another pathway.  
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5.1.9 EGFR expression is not affected by steroids in severe asthmatic mucosa.  
It has been reported that EGFR expression and neutrophilia in severe asthma are 
refractory to corticosteroid treatment (82,293). More specifically the synthetic 
corticosteroid dexamethasone (1 µM) did not affect basal or EGF-stimulated wound 
closure (82). The same applies when used at 0.1, 1.0 or 10.0 µM concentrations but 
not for 100µM for which there was significant inhibition. It was suggested that the 
result regarding the 100 µM dose may reflect a non-specific effect on wound closure 
given this very high steroid dose. In the current study it is also observed that there is 
no significant effect of the steroid dose on levels of EGFR secretion after cytokine 
treatment. Steroids induce increased p21waf expression (294) but here was no 
obvious relation between corticosteroid dose used by severe asthmatic subjects and 
the levels of bronchial epithelial p21waf expression (98).  
A repeat wound model has been described using mucociliated human bronchial 
epithelial cells to investigate the effect of therapeutic agents in epithelial repair in a 
chronic state. It was reported that epithelial repair is dependent on autocrine EGF-
mediated migration. Dexamethasone induced an inhibitory effect in repair and 
cellular proliferation at the short-term but showed increased long-term potential.  
However the mechanism to explain this effect remains unclear (295).  
All the above indicate that steroids used in the treatment of chronic forms of asthma 
and severe ocular allergy, do affect the expression of mediators involved in 
remodelling which are accountable for disease irreversibility and progression. 
Additionally steroids have no effect on cellular homeostasis which is regulated by cell 
proliferation, growth arrest and apoptosis. Taken all together it can be concluded that 
the cellular changes in the mucosal epithelium of the bronchial airway and 
conjunctiva in severe inflammatory disease are not regulated by steroids. This may 
explain why steroids are ineffective in achieving disease control in the severe forms 
of these inflammatory diseases of the mucosal membrane such as asthma and 
CAED.  
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5.1.10   Epithelial-mesenchymal transition (EMT): repair and fibrosis 
The roles of mesenchymal cells in tissue repair, fibrosis as well as tumour 
metastasis are not fully understood. It is suggested that epithelial-mesenchymal 
transition (EMT) is an important source of these cells and is a biologic process that 
enables a polarised epithelial cell to transform into a mesenchymal cell with ECM 
production and migratory properties, invasiveness as well as resistance to apoptosis 
(296). There are three types of EMT representing distinct biological processes: Type 
1 occurs in embryogenesis and mesenchymal cells generate secondary epithelia but 
do not cause fibrosis; type 2 EMTs that occur with wound healing; type 3 EMTs that 
occur in neoplasia. Type 2 EMTs are associated with inflammation, wound healing 
and regeneration generating fibroblasts in an attempt to repair tissues after trauma 
or inflammatory injury (297).  
EMTs are found to occur in fibrosis in the kidney, liver, lung and intestine (298-301). 
Markers of fibrosis secreted by mesechymal cells in EMTs include, fibroblast specific 
protein 1 (FSP1) which is a cytoskeletal protein, α-SMA (α- smooth muscle actin), 
collagen I, vimentin and desmin (302, 294). TGFβ is shown to induce EMT-mediated 
fibrosis (302, 303). Recombinant BMP-7 is known to act as an endogenous inhibitor 
or TGFβ induced EMT (302, 10) and was shown to reverse EMT with repopulation of 
healthy epithelial cells in mice with fibrosis when administered systemically (303). 
EMT evidence was reported in kidney biopsies with fibrosis in humans using 
labelling of vimentin, cytokeratin and α-SMA (304) with similar observation made in 
intestinal biopsies in patients with Crohn’s disease (305).  
Based on in vitro experiments, EMT occurs in the repair of the lacrimal gland and is 
responsible for the generation of mesenchymal cells as suggested by the expression 
of EMT markers vimentin and snail1, at the peak phase of the lacrimal gland repair 
process and in mesenchymal cells isolated from injured lacrimal glands. The authors 
suggested that by reinforcing our understanding of the EMT molecular processes it 
would enable researchers to propose novel therapeutic strategies that target lacrimal 
gland healing and repair and promote production of the aqueous layer of the tear film 
(306). All the above may suggest that new treatment strategies by inhibiting the EMT 
processes may have a role in the management of the severe chronic forms of 
inflammatory disease.  
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5.1.11 Summary 
In summary there is immunohistochemical and in vitro evidence that epithelial 
remodelling markers are overexpressed in the conjunctival in allergic conditions. 
Combining the EMTU hypothesis for the pathogenesis of severe asthma and the 
results presented in this thesis it is suggested that a similar paradigm to asthma 
EMTU occurs in chronic and persistent forms of ocular allergy which may account for 
disease progression and severity. Figure 5.1 below (modified by 260) attempts to 
summarise the events in AKC and VKC and present a conjunctival EMTU paradigm 
to account for the severity and chronicity of these forms of disease. 
 
  
 
 
 
 
Figure 5.1: A proposal of the application of EMTU hypothesis in CAED based on the 
results of this thesis (modified by 260).  
 
 
 
 
Chronic  inflammation  
   Growth factors   & CYTOKINES  
 EGFR ligands, CD44, TGF-β, VEGF 
   Conjunctival Remodelling     AKC, VKC   
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Based on evidence from previous studies on remodelling mediators in VKC 
(126,130) and the results of this study on the role of Growth factors and epithelial 
remodelling is suggested that conjunctival epithelial remodelling co-participates in 
disease pathogenesis and perpetuation. In addition to the mediators, cytokines and 
cellular aspects as shown in Table 5.1 below (modified from 136), growth factors 
participating to tissue remodelling have been added in an attempt to update the 
already known evidence so far.  An updated table summarising together all cellular 
and molecular participants is shown below.  
 
 
OCULAR ALLERGY  
IgE mediated (SAC/ 
PAC) 
IgE and non-IgE 
mediated (VKC/AKC) 
Non-IgE mediated 
(GPC) 
Mediators Histamine 
Prostaglandine D2 
Leukotrienes 
PAF 
ICAM 
Histamine 
Prostaglandins 
Leukotrienes 
PAF 
ICAM, VCAM,  
MMPs, proteases  
Prostaglandins 
Leukotrienes 
ICAM 
Remodelling Factors  TGFβ, TGFα, 
PDGF,EGF, EGFR, 
VEGF, CD44 
CD44, EGFR, TGFα 
Cytokines/chemokines IL-1, IL-4, IL-8, 
TNFα, IFNγ 
IL-1, IL-4, IL-6, IL-8, IL-
10, IL-13, IL-17, TNFα, 
IFNγ, Eotaxin, MCP, 
RANTES 
IL-1,IL-6,IL-8,TNFα, 
IFNγ, RANTES, MCP 
Cells Mast cells 
Neutrophils 
Eosinophils 
Mast cells, T cells, NKT 
Neutrophils  
Basophils, Macrophages 
 
T cells 
Neutrophils 
Macrophages  
 
Table 5.1: A summary of the cellular and cytokine participation in ocular allergy 
including the results of this Thesis.  
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5.2 Th-17 T cell-derived cytokines may have roles in epithelial conjunctival 
remodelling in CAED.  
5.2.1 IL-17A induces EGFR secretion in vitro by human conjunctival epithelial 
cells 
T cell cytokine profiles differ in CAED with a Th2 type pattern (IL-3, IL-4, IL-5) in VKC 
and Th1 type (IL-2, IFNγ) in AKC (159). It may be uncertain whether further T cell 
variations may be implicated in chronic allergic disease forms. The presence of Th17 
cells in ocular allergic disease was recently investigated in CAED (244). More 
specifically there were increases in epithelial and subepithelial Th17 (IL-17 producing 
CD4+ T cells) cells in AKC and VKC conjunctival biopsies compared to controls 
(normal biopsies and SAC). Together with the detection of increased levels of IL-17E 
in tears specimens from VKC subjects, the data suggest a pro-inflammatory role for 
Th17 cells. IL-17 expressing cells have also been reported in autoimmune dry eye in 
man and in a mouse model (291) and in OCP (292). It is likely that IL-17 may have 
different roles in various forms of ocular surface inflammatory diseases. Further 
studies are required to investigate the role of IL-17 in the pathogenesis of tissue 
remodelling. 
 
Six members of the IL-17 cytokine family are secreted by activated memory T cells. 
IL-17 has been shown to induce reduced expression of β-defensin which has 
antimicrobial properties indicating a role of IL-17 in antimicrobial defence (287). IL-17 
which is known to have a pro-inflammatory role is shown to induce IL-8 production in 
human bronchial epithelial cells which in turn promotes neutrophil migration (32). IL-
17A induced neutrophil infiltration is also observed in cornea after HSV infection 
(287).  
Additionally the increase in neutrophils was positively correlated to increased EGFR 
expression in the nasal epithelium after exposure to ozone (123). The same study 
showed that exposure of nasal epithelial cells to ozone induced IL-8 production. 
Increased IL-8 production in vitro occurred after treatment of bronchial epithelial cell 
lines (H292) with H2O2 and EGF (254). More specifically EGF induced a dose-
dependent IL-8 release. In the same study there was positive correlation of IL-8 and 
EGFR expression with neutrophil numbers (264).  
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These events in addition to the cytokine effects from other cell types involved, 
participate in disease perpetuation re-enforced by abnormal epithelial mediated 
remodelling in chronic mucosal inflammatory disease and continuous response to 
injury.   
Exposure of human conjunctival epithelial cells to IL-17A induced IL-8 and CD44 
expression as well as MMP2 and MMP-9 (244,287). Additionally, it was shown that 
treatment of human corneal epithelial cells with IL-17A was shown to induce 
increased expression levels of MMPs mRNA and impaired barrier function (167). 
Similar observation supported that IL-17A promotes MMP-2, -7, -9 and in addition it 
affects VEGF-A bioavailability (307). In this current study it was found that IL-17A 
induces increased EGFR secretion by conjunctival epithelial cells in vitro after a 
single or multiple treatments but it is not clear if this effect is direct. It is also shown 
that this effect is not sustained and was reduced after 48 hours. It is therefore 
suggested that other factors and cytokines may participate as intermediaries. It is 
proposed that IL-17 via its proinflammatory and regulatory actions may have roles in 
promoting conjunctival epithelial remodelling in ocular allergy.  
 
5.2.2 IL-25 (IL-17E) induces VEGF secretion in vitro by conjunctival epithelial 
cells with and without dexamethasone pre-treatment. 
It has been reported that IL-25 (or IL-17E) amplifies the Th2 cell-mediated 
inflammation in asthma (256-260) but its role in conjunctival allergic response 
remains unclear.  IL-25 with TSLP (Thymic Stromal lymphopoietin) promotes Th2 
differentiation and proliferation resulting to enhanced Th2 functions with increased 
expression of IL-5 and IL-13. IL-25 enhances Th2 expansion and sustains Th2 cell 
activation (308). TSLP is an IL-7-like cytokine that can activate dendritic cells (DCs) 
which, in turn, can re-enforce the allergy-inducing properties of Th2 cells by 
upregulating the expression of pro-allergic genes (309).  
Th2 cytokines are known to participate in VKC (36,218,310) and more specifically 
Th2 cytokines IL-4, IL-5 were found to be significantly elevated (311-313,151,281). 
Given also that in VKC, there is increased expression of growth factors VEGF, 
TGFβ, PDGF, EGFR (130,126,281) it may be suggested that IL-25 may have a role 
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in influencing their overexpression indirectly. Hence it is likely that IL-25 may have a 
role in augmenting the inflammatory response in the severe forms of ocular allergy 
leading to disease perpetuation and epithelial mediated remodelling as suggested by 
the EMTU hypothesis.  
However in the current study there was not a dose response effect in VEGF and 
EGFR levels after treatment with increasing concentrations of IL-25. Additionally at 
48 hours the EGFR expression is minimal (at pg/ml) and hence with possible little 
clinical relevance. On the contrary VEGF secretion was elevated but there was no 
significant difference in its levels with increasing IL-25 concentrations. The EGFR 
levels at 48 hours after IL-25 treatment in the current study were lower, in both 
groups (with and without dexamethasone) including the untreated cells. Given from 
the results of other in vitro experiments in the current study, EGFR levels increased 
with increasing time. For the IL-25 treated cells, sampling took place once at 48 
hours and this could provide a possible explanation for the low levels observed. On 
the contrary VEGF expression is greater. This may be explained by the fact that 
epithelial VEGF production may be influenced directly by other factors. On the 
contrary, EGFR’s secretion may be indirectly influenced by intermediate cytokines 
interfering with the epithelial responses to inflammation in the cytokine 
microenvironment.  
VEGF levels appeared to be greater than EGFR’s and steroid pre-treatment did not 
cause significant reduction in its levels. This observation is in agreement with the 
reports from other studies which investigated the effect of steroids to EGFR 
expression. EGFR’s levels paralleled IL-8 expression and neutrophil numbers in the 
submucosa in asthmatic bronchial biopsies. In the patients using corticosteroids 
there was no reported correlation between any of the measured parameters and 
steroid dose (254). These findings provided evidence to support that EGF stimulates 
IL-8 mRNA production from bronchial epithelial cells linking EGFR upregulation and 
neutrophil response. In conjunctival epithelial cell lines PMA, TNFα/IL-1β and polyI:C 
(TLR3) induced IL-8 expression (244). Figure 5.2 below summarises the findings of 
the thesis and presents a proposal for the possible role of proinflammatory and Th17 
cytokines along with EMTU mediated remodelling in CAED.  
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Figure 5.2: A proposal for the interactions between Th2/Th17 mediated inflammation 
and the EMTU in CAED pathogenesis (Modified by reference 84).  
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5.2.3 Toll Like receptors (TLR) and conjunctival epithelial cells  
Toll pattern recognition receptors play an important role in the innate immune system 
and are believed to function as dimers. They recognize ligands of microbial origin 
and are present on various cell types including dendritic cells and provide a link 
between adaptive and innate immunity. After binding to the ligands the pathogen 
may be phagocytosed and digestion products can be presented to CD4+ T cells. 
Immune cells may produce cytokine mediating inflammatory responses. Recent 
evidence regarding the roles of TLRs expressed by epithelial conjunctival cells 
indicates potential new immunomodulatory roles of the epithelium in inflammatory 
responses of allergic origin. LPS is TLR4 ligand and zymosan binds TLR2.  
In contact dermatitis, nickel (Ni2+) triggered an inflammatory response by directly 
activating human Toll-like receptor 4 (TLR4) (314). Furthermore TLRs have been 
expressed in healthy and allergic conjunctiva in VKC patients (315,316) and TLRs 
are also expressed in vitro by conjunctival epithelial cell cultures (317). TLR2 
expression was up-regulated on conjunctival epithelial cells by IFNγ and 
Staphylococcus aureus which is a common pathogen colonising the conjunctiva in 
AKC (317). It has been investigated by means of immunohistochemistry and relative 
real-time polymerase chain reaction the expression of TLRs in VKC tissues 
compared to control tissues. TLR2, TLR4, and TLR9 were expressed in the 
conjunctival epithelium and stroma of normal and VKC subjects.  In VKC tissues, 
TLR4 was upregulated, TLR9 was downregulated, and TLR2 was slightly decreased 
compared to control tissues. Both showed a more intense immunoreactivity in the 
stroma. TLR4 was localized on CD4+ lymphocytes, eosinophils, and mast cells. 
Lymphocytes and eosinophils, but not mast cells, expressed TLR9. The upregulation 
and downregulation of TLR expression in healthy conjunctiva and VKC suggest that 
there may be a role for TLRs in VKC (315). TLR3 ligand polyI:C induces TSLP 
expression in vitro by primary conjunctival cell cultures (318). Similar responses 
were also observed in bronchial epithelial cell cultures (319). Corneal epithelial cells 
treated with TLR3, -5, -6 ligands (TNFα/IL-1β) secreted TSLP mRNA (320).  
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In the in vitro pilot data of this thesis, single IOBA-NHC cell treatments with polyI:C, 
zymosan and LPS induced production of all markers (EGFR, VGFR, CD44) but at 
lower levels compared to pro-inflammatory cytokines and PMA. Taken all the facts 
described above together it may be suggested that in VKC and AKC additional 
pathogen immune mediated mechanisms may run in parallel accounting for disease 
severity.  
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5.3 Classification of ocular allergic disease and novel therapeutic strategies 
5.3.1 Re-classifying Ocular allergic disease  
Both proposals for the grading of AKC and VKC recognised the absence of a helpful 
classification system based on symptomatology, clinical signs and requirement for 
decisions to treat these conditions. Further advances have been made since then 
that enhance our understanding about the immunopathology and pathogenesis 
which could assist in re-classifying the forms of the full spectrum of ocular allergy. An 
updated classification system could focus on proactive management suggestions 
based on available therapies.  Therefore re-enforcing our understanding of the 
immunopathological processes could help to find a common consensus between 
ophthalmologists, allergologists and immunopathologists.  
In 2011 ten Latin American ocular allergy experts participated in a 4-round Delphi 
panel approach aiming to define, classify, stage and provide diagnosis and treatment 
recommendations. It was concluded that the task of creating guidelines in ocular 
allergy was very complex and many controversial topics still remain unsolved. The 
Ocular Allergy Latin American consensus proposed that the term “ocular allergy” is 
the general term to describe ocular allergic diseases but a consensus on its 
classification and the role of systemic steroids was not reached. The panellists 
agreed on the need of a staging system based on disease severity and the need of a 
larger consensus with international groups of experts to improve recommendations 
on treatment (321).  
A general consensus is required for Allergic conjunctivitis’ classification and staging, 
based on clinical signs and decisions for therapy and there are significant difficulties 
to overcome when one attempts to classify ocular allergic diseases. AKC and VKC 
on some occasions may overlap yet AKC has no age limitation and involves the 
conjunctiva, the cornea and the lids. On the other hand if VKC is not “vernal” is 
frequently chronic. Many ophthalmologists recommend that if overlapping, the worse 
component must lead the management plan. The term “allergic conjunctivitis” may 
not sufficiently describe all forms of allergic eye disease, thus a new classification 
system is desirable, preferably derived from the varied pathophysiological 
mechanisms operating in the different forms of ocular allergy (322). 
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Finally, the recent Task Force report from the EAACI ocular allergy interest group on 
diagnosis and management of ocular allergy unifies the nomenclature and 
classification of ocular allergy, describes current methods to diagnosis and 
summarises the therapeutic options and management. The new classification 
proposed is shown below in Figure 5.3. The new classification is based on 
pathophysiology and hypersensitivity nomenclature and both IgE- and T cell 
mechanisms have been shown in VKC and AKC (323).  
 
            
Figure 5.3: The New classification for ocular allergy proposed by the EAACI Task 
Force in 2012. 
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The IgE level of involvement has been used as the major feature when classifying 
ocular allergic diseases. Epithelial remodelling of the conjunctiva irreversibly alters 
the tissue function and structure.  The results of this thesis suggest that epithelial 
remodelling co-participates in disease progression and perpetuation in CAED. It is 
not seen in reversible forms of disease without corneal involvement. Therefore it is 
suggested that it may be used as a pathologic feature to distinguish between the 
chronic and persistent (AKC, VKC) forms from the more acute and seasonal 
reversible types (SAC, PAC) (Table 5.2 below).  
GPC shares features from the reversible forms of disease and some mild expression 
of remodelling molecules featuring in the severe forms AKC and VKC without 
permanent changes in cytological architecture (fibrosis, epithelial hypertrophy etc). 
Removal of the biomaterial reverses the clinical signs but its persistence leads to 
epithelial injury and cell activation leading to EGFR expression. The following table is 
proposed to present a summary of the immunopathological features of various form 
of ocular allergy 
 
Table 5.2:  A proposal for the features used for the classification of ocular allergy 
(Modified by reference 135) 
 
 
 
 
 
 
OCULAR 
ALLERGY 
IgE 
Mediated 
IgE & non-
IgE 
mediated 
Non-IgE 
mediated 
Tissue 
Remodelling 
Corneal 
involvement 
Intermittent  SAC  
Persistent  PAC VKC GPC VKC VKC 
Chronic   AKC CDC AKC AKC 
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5.3.2 New treatments, strategies and further studies  
From a patient’s perspective, symptom relief of the acute flare up episodes is the 
most desired aim of treatment with long term disease control. So far the 
instantaneous relief is not easy to achieve because of the irreversible nature of the 
chronic forms of ocular allergic disease. Most therapeutic strategies are centred on 
the inhibition of the allergic response and suppression of the inflammation. The long 
term complications of steroids make way for the use of steroid-sparing T cell 
immunomodulatory agents. It is clear that AKC and VKC require T-cell targeted 
strategies to achieve long term control. Figure 5.4 below summarises the current 
knowledge of the agents that can regulate the immune function at various levels in 
allergic disease. Immunity and inflammation have numerous features that overlap at 
the cellular and cytokine profile levels. In allergic conjunctivitis blocking CCR7 
topically  is shown to impair he pathogenic contribution of dendritic antigen 
presenting cells based on work carried out using CCR7 knockout mice C57BL/6 
mice which is the only animal mouse model so far used in a study to investigate 
novel treatments in AED. CCR7 blockage leads to inhibition of Th2 reactivity and IgE 
synthesis as shown by this allergic conjunctivitis animal model (324).  
                
      Figure 5.4: Multiple targets of immunomodulation in allergic disease (325).  
 
203 
 
Combinations of anti-allergic agents aim to inhibit histamine effects and induce an 
anti-inflammatory response. Levocabastine has antihistamine actions and reduces 
adhesion molecule expression (326). Additionally it reduces eosinophilia via 
increased expression of integrins in the conjunctiva (327). The efficacy when 
combining levocabastine with pemirolast is increased improving the benefits in SAC 
and PAC (328). Systemic administration of cyclosporine A and tarcolimus lead to 
complete remission in 6 patients with AKC (329) Administration of probiotic eye 
drops with Lactobacillus acidophilus in patients with mild and moderate VKC showed 
significant improvement after 4 weeks of treatment in six out of the seven patients 
(330). 
The current treatments for asthma achieve little effect on the natural history of the 
disease and are based on disease severity and control rather than targeting the 
pathogenic mechanisms. The importance of subphenotyping asthma into different 
endotypes with different causal mechanisms has been described (331). Novel 
pathways causing disease that explain better the development and progression of 
asthma, may form a better basis for treatments that combat disease perpetuation 
rather than reduce an inflammatory response and temporarily induce symptom relief. 
It is important to identify those patients who would respond to biologic therapies 
targeting markers of Th2 dominant disease (331).  
The results of this study raised a number of questions: would primary cell cultures 
from normal and allergic conjunctival tissues share similar functional responses to 
cytokines? In the future to address these issues, conjunctival biopsies need to be 
obtained from patients with different conjunctival inflammatory disease. Secondly, 
are the treatments currently available, have an effect on EMTU? It would be 
important to know if patients who have received early immunosuppression treatment 
develop evidence of EMTU activation and disease progression. Furthermore, based 
on the roles of EGFR and VEGF described in this study, what would be the effect of 
anti-VEGF and anti-EGFR agents on EMTU development and the cytokine profiles in 
the forms of ocular allergy?  
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5.3.3 EGFR inhibition as a possible new therapeutic strategy to control 
inflammation in chronic asthma and chronic allergic eye disease 
 
Currently there are both in vitro and in vivo studies in animal regarding tyrosine 
kinase inhibitors and airways remodelling in asthma. EGFR inhibition has been 
shown to reduce epithelial cell proliferation, decrease collagen deposition and goblet 
cell proliferation in the airways (333). However the clinical application of these 
findings has not been translated so far due to the complex nature of the disease 
especially in severe cases. The role of anticancer drug gefinitib, an EGFR inhibitor 
was investigated, for the control of allergic airway inflammatory disease. More 
specifically, pre-treatment with gefitinib reduced IL-4 and IL-13 concentrations in 
bronchoalveolar lavage fluid as well as eosinophil recruitment in the lung in a dose 
dependent manner (332). This effect was associated with reduced EGFR expression 
and activation in mice. Therefore a similar role may be applicable in chronic allergic 
disease forms.  
 
In fact EGFR expression was reported to be increased in an animal model of colitis 
(334) and EGF pr administration was beneficial in left sided ulcerative colitis (335) in 
which it was reported that there is serum EGF downregulation (336). This is of 
particular interest since it demonstrates the physiological mitogenic properties of 
EGFR ligands which promote epithelialisation and wound healing. On the contrary in 
chronic asthma and chronic allergic eye disease the EGFR expression and its 
ligands demonstrate abnormal epithelial repair and remodelling which are suggested 
to be accountable for the disease severity and steroid non-responsiveness. 
Therefore it could be hypothesised that EGFR inhibition in chronic mucosal 
inflammatory disease of allergic origin may be beneficial. It is therefore proposed that 
similar studies are desinged to investigate the immunomodulatory role and effects on 
cytokine profiles and remodelling  in vitro of anti-EGFR and anti-VEGF agents and in 
vivo in CAED.  
 
This thesis showed by means of immunostaining using  GPC biopsies from 
symptomatic patients that the EMTU remodelling epithelial molecules are lightly 
expressed. GPC as described in previous sections can be seen in contact lens 
wearers due to the biomaterials used. It is therefore proposed that when designing 
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contact lens matterials, the EMTU molecules may be used as a screeing tool to 
investigate wheather the biomatterial used is capable of inducing their upregulation 
in vivo using a CAED animal model as described above.  
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